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Underactive bladder (UAB) is a health issue which is receiving increasing attention in the 
urological literature. The most recent symptomatic definition approved by the International 
Continence Society steering committee in 2016 states: “Underactive bladder is characterised 
by a slow urinary stream, hesitancy and straining to void, with or without a feeling of 
incomplete bladder emptying and dribbling, often with storage symptoms”. UAB is considered 
a symptom syndrome suggestive of the urodynamic observation of detrusor underactivity 
(DU). The symptomatic burden of lower urinary tract symptoms (LUTS) associated with DU and 
known impact of LUTS on quality of life highlight the requirement to understand how the 
patient with UAB feels and functions for clinical outcome assessment purposes. Currently, no 
fully validated patient reported outcome (PRO) measures exist for the assessment of UAB. The 
thesis describes the development of the ICIQ-UAB, a new PRO measure for the assessment of 
the symptoms of UAB, and their associated bother and impact. Qualitative methodology was 
employed to understand how the clinical diagnosis of DU manifests as symptoms, by a 
thorough exploration of the lived experience of patients. Decisions on the inclusion of draft 
questionnaire items, including their content, language and response items, were made on the 
basis of the qualitative evidence and consultation with an expert clinical panel. Draft items 
were refined by cognitive interviews which confirmed the items to be understood and 
interpreted as intended by patients. Validity and test-retest reliability of the ICIQ-UAB was 
supported by a European pilot study, and the wider cultural applicability by additional patient 
interviews in the US and Japan. The developmental ICIQ-UAB is now ready for further large-
scale validation in future clinical trials and is envisaged as an important tool for the monitoring 
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Chapter 1 The pathophysiology and epidemiology of underactive 
bladder 
1.1 Introduction 
The statement “the bladder is an unreliable witness” was first made by Bates in 1970, and 
refers to the complex problems urologists have when trying to interpret the symptoms 
presented by patients 1. This introductory chapter presents a symptom syndrome that is 
increasingly recognised as being associated with bothersome symptoms of the lower urinary 
tract; the underactive bladder. The current status of the terminology surrounding underactive 
bladder is examined, and the known epidemiology, pathophysiology, diagnosis and treatment 
are discussed. Some content of this chapter was published in the Investigative and Clinical 
Urology as an invited review article entitled ‘Definition and Symptoms of Underactive Bladder’ 
in September, 2017 2. 
1.2 Lower urinary tract symptoms 
The term lower urinary tract symptoms (LUTS) was introduced in 1994 3, and relates to the 
symptoms experienced by individuals with pathology of the bladder, prostate (in men), and 
the urethra. LUTS are broadly divided in to three groups: storage, voiding and postmicturition 
symptoms  4. Storage symptoms are experienced when there is a dysfunction in the ability of 
the bladder to store urine, such as increased urinary frequency, urgency, urinary incontinence, 
and nocturia. Voiding symptoms relate to problems with the flow of urine and include 
symptoms such as a slow/reduced stream, hesitancy and intermittency. Postmicturition 
symptoms encompass problems encountered immediately after voiding, such as the sensation 
of incomplete emptying or postmicturition dribble. There is a high prevalence of LUTS in the 
community. In a large population-based survey, the prevalence of at least one storage LUTS 
was found to be 51.3% in men and 59.2% in women. The prevalence of at least one voiding 
LUTS was less (16.9% in men and 14.2% in women) 5. The prevalence of LUTS also increases 
with age 6, with 80% of men having benign prostate hyperplasia (BPH) and associated LUTS 
when over 80 years of age 7. The known impact of LUTS on day to day life, such as the 
associated embarrassment or inconvenience of incontinence and increased urinary frequency 
on social, physical activities, and lifestyle, highlights the importance of meaningful treatment 




A reliable method of evaluating bladder function is by urodynamic study 10. The simplest of 
urodynamic techniques is non-invasive uroflowmetry, where urine flow is studied using 
relatively simple equipment to measure parameters such as the urinary flow rate per unit time 
expressed in millilitres per second (ml/s), maximum flow rate Qmax (ml/s), total voided volume 
VV (ml) and average flow rate Qave (ml/s). Abnormal flow rates, and flow patterns such as an 
intermittent stream can be interpreted and classified by different urological diagnoses. Further 
investigation is by cystometry, which is the method by which both the voiding and storage 
phases of micturition may be evaluated. During standard cystometry, the (intravesical) 
pressure pves in the bladder is measured along with the pressure in the abdominal cavity pabd 
(usually in the rectum) during bladder filling and voiding 10. The detrusor pressure pdet can then 
be calculated electronically (pdet= pves-pabd) and other parameters such as the detrusor pressure 
at maximum flow pdetQmax,. When the results of these investigations are related to the 
symptomatic complaints of the patient, urodynamic diagnoses can be made and treatment 
strategies planned accordingly.  
1.4 Symptom syndromes for LUTS 
There are common linkages of LUTS which can be used to derive symptom syndromes. The 
most widely recognised of these is the overactive bladder (OAB), defined as “urgency, with or 
without urge urinary incontinence, usually with increased daytime frequency and nocturia” 4,11. 
The use of a symptom syndrome enables wider clinical recognition of the presenting 
symptoms, and identifies individuals who will potentially incur benefit from a specific 
intervention. Terminology such as ‘overactive bladder’ also facilitates patient understanding of 
their symptoms, as their understanding intuitively fits with how they perceive their own 
symptoms. When investigated further by healthcare professionals, patients with OAB are 
sometimes identified as having detrusor overactivity (DO). This is a urodynamic observation of 
bladder contraction during filling, which may be spontaneous or provoked 12. Alternatively, 
there may be findings of inflammation in the lower urinary tract, or some other factor which 
sensitises the sensory nerves from the lower urinary tract. Thus, storage LUTS are largely 
encompassed by a symptom syndrome (OAB) and urodynamic observation (DO). These two 
terms are not interchangeable, since OAB patients may not have DO on filling cystometry; 
likewise DO may occur with no associated urgency 13. A similar approach based on a symptom 
syndrome and urodynamic observation, has been proposed in further developing the field for 
voiding LUTS. Detrusor underactivity (DU), an increasingly recognised cause of troublesome 
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voiding, is considered the analogous urodynamic observation to the proposed underactive 
bladder (UAB) symptom complex 14,15. Although overactive bladder syndrome is comparatively 
well understood, underactive bladder syndrome is relatively under-researched.   
1.5 Terminology of underactive bladder 
The International Continence Society (ICS) derived the terminology of lower urinary tract 
function 4 and is the main basis for the wordings and definitions used most widely in clinical 
practice. There has been much interest generated in this topic in recent years and efforts 
made to reach professional consensus on symptomatic definitions.  
The definition of urodynamically diagnosed DU is given by the ICS in 2002 as “a contraction of 
reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to 
achieve complete bladder emptying in a normal time span” 4. DU is generally understood to be 
either the impairment of detrusor muscle contraction resulting from neuronal damage, or 
changes to the detrusor resulting in impaired contractile function 16. This loss of detrusor 
functionality is also referred to in the literature as impaired detrusor contractility (IDC). This 
has been described as having two fundamental characteristics; the strength of the contractile 
force and the ability to adequately maintain these contractions 17. IDC  and DU are sometimes 
used interchangeably but should not be considered as synonymous, as DU describes a clinical 
syndrome, whereas IDC describes an attribute of detrusor function 18. Other terms which 
describe loss of detrusor muscle functionality include detrusor areflexia, hypotonic bladder, 
detrusor failure and bladder failure. These all have their limitations and reflect the past 
ambiguity of terminology 15. Even the ICS definition of DU does not define reduced strength or 
duration, prolonged bladder emptying, completeness of bladder emptying, or a ‘normal’ time 
span. This lack of consensus of terminology and complex aetiologies that result in DU are some 
of the barriers to having standardised parameters that define urodynamic DU 18–20. However, 
studies which patients with LUTS referred for further urodynamic investigation, have used 
various criteria for urodynamic DU which may be considered. Most recently, Gammie et al. 21 
and Uren et al. 22 use a bladder contractility index (BCI) of <100 and a bladder outlet 
obstruction index (BOOI) of <20 in men. This combination of BCI with BOOI thresholds restricts 
the acceptable degree of BOO, resulting in the exclusion of patients with probable co-existing 
DU with BOO (those with a low BCI yet relatively high BOOI). Women were required to have a 
detrusor pressure at maximum flow (PdetQmax) of <20 cmH2O and a maximum flow rate (Qmax) 
of <15ml/s. These thresholds were later endorsed by Fode and Sønksen 23. However, these 
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parameters are not likely to be definitive, given the ongoing research efforts of many, and 
further complications introduced through the proposed classification by aetiology 24. 
Going forward from this non-specific definition of urodynamic DU, a working symptomatic 
definition for UAB was derived by a consensus group at the 2014 International Consultation on 
Incontinence – Research Society as follows; “The underactive bladder is a symptom complex 
suggestive of detrusor underactivity and is usually characterised by prolonged urination time 
with or without sensation of incomplete bladder emptying, usually with hesitancy, reduced 
sensation on filling, and a slow stream” 14. This definition of UAB raises some important points 
for discussion. Firstly, the underactive bladder is the symptom complex suggestive of detrusor 
underactivity, so UAB is not considered synonymous with DU. The implication is that that a 
diagnosis of DU on urodynamics is not essential for a patient to have UAB, just that the 
symptoms in the definition are presented. The underlying aetiology and pathophysiology are 
also not specified, so UAB could also be comprised of a highly heterogeneous group. For 
example, patients may have impaired contractility with other urological conditions such as DO, 
BOO or urodynamic stress incontinence, and still be classified as having UAB. Furthermore, the 
overlap of LUTS associated with these conditions, such as a slow flow, high urinary frequency 
and incontinence 14,15,25, presents a further challenge to deriving a symptomatic definition. The 
need for further qualitative and quantitative research to elucidate the patient reported 
symptoms on which a symptomatic definition may be based is increasingly recognised 14,26. 
The latest symptomatic definition proposed by a Working Group set up by the ICS in 2016 is: 
“Underactive bladder is characterised by a slow urinary stream, hesitancy and straining to void, 
with or without a feeling of incomplete bladder emptying and dribbling, often with storage 
symptoms” 27. The ICS Working Group gives some explanatory notes. Firstly, that UAB “occurs 
in association with diverse pathologies and based on current knowledge there is no single 
distinguishing symptom”. This is in contrast to OAB, for which urgency is the central defining 
symptom. Secondly, that “storage symptoms in UAB are varied and may be highly prevalent, 
including nocturia, increased daytime frequency, reduced sensation of filling, and 
incontinence”. Finally, “underlying mechanisms of storage symptoms are diverse and are often 
related to a significant post voiding residual urine volume”. Other latterly proposed definitions 
recognise the overlap of possible co-existing bladder outlet obstruction. Fode and Sønksen 
give theirs as: “Underactive bladder is the subjective feeling of prolonged urination time, slow 
stream, and hesitancy, which may or may not be associated with poor bladder emptying and 
subsequent storage symptoms in men and women without evidence of any outlet obstruction” 
23. Dewulf et al 24 supplement the original definition by Chapple et al. (2015) using symptoms 
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shown to be more common in patients with DU than in patients with BOO 21: “Underactive 
bladder is a symptom complex suggestive of DU and is usually characterized by prolonged 
urination time with or without a sensation of incomplete bladder emptying, usually with 
hesitancy, reduced sensation on filling, slow stream, palpable bladder, always straining to void, 
enuresis, and/or stress incontinence.” . Here, the concept of UAB is therefore a term which 
encompasses LUTS related to impaired bladder emptying, which cannot be primarily attributed 
to the presence of BOO.  
Crucially, the terminology used must meet the needs of both patients and healthcare 
professionals. It is a specific expectation that both professionals and their patients equally 
understand the descriptive terms used for their condition. Underactive bladder as a concept is 
a comparatively simple term, and one that is reasonably straightforward for patients to take 
on board 2. However, the complications of deriving a specific symptomatic definition are 
apparent.  Even for patients, as the terminology does not make the contrasting storage and 
voiding functions clear, the possibility of having both an underactive and an overactive bladder 
may be intuitively confusing. In conclusion, since there is no normative data or clear cut 
thresholds, the term for UAB is vague in its description, and rather discursive. Healthcare 
professionals can be rather dismissive of the term as a result. Nevertheless, conceptually, the 
term is considered useful for both clinical and research purposes, and it is absolutely certain 
some patients do manifest weakness of their bladder contractility when attempting to void 2. 
Whilst there are differences between proposed definitions, there is also a core consensus 
which intuitively fits with the concept of an underactive bladder.  
1.6 Epidemiology of underactive bladder 
The lack of consensus on definitions of urodynamic DU, the similarity of LUTS from often co-
existing urological conditions, and that DU is fundamentally a urodynamic observation, means 
the extent of the underlying contribution of DU to the prevalence of LUTS in the general 
population is difficult to determine 28. However, some studies have attempted to investigate 
the prevalence of underactive bladder using symptoms alone. Valente et al. (2014) evaluated 
responses to an 18-item survey, mailed to 5000 randomly selected community-dwelling 
residents aged 60 years and above in Detroit 29. Data was collected relating to clinical urinary 
symptoms and demographic characteristics. From a total of 633 respondents to the survey, 
23% reported difficulty emptying their bladder and 48% needing to strain to empty their 
bladder. The authors conclude on the basis of this evidence that DU is ‘common and morbid’. 
However, there is an inability to distinguish DU based on clinical symptoms from other (often 
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co-existing) disorders such as DO and BOO. Without a urodynamic diagnosis the contribution 
of DU to the symptoms reported within this study are impossible to establish. The low 
responder rate is also is also concerning due to the possible bias caused by those with 
symptoms being more likely to respond. Nevertheless, a relatively small number of studies 
have used urodynamics to estimate the prevalence of DU in patients who present with non-
neurogenic LUTS, albeit with variable definitions of urodynamic DU. Table 1 gives the details of 
the sample size, diagnostic criteria and prevalence of underactive detrusor found in these 
studies. These may be summarised as DU being present in 9-10% of men less than 50 years of 
age, and up to 48% of men older than 75 years of age. Prevalence is less in women at 12-19%. 
 
Table 1. Detrusor underactivity prevalence in men and women when presenting with LUTS. 
 
Abbreviations: Detrusor pressure at maximum flow (PdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=PdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 
calculated by BOOI=PdetQmax-2Qmax. Bladder Voiding Efficiency (BVE) = (voided volume/total bladder 
capacity)×100. 
 
Study Sample size 
with DU (n) 
Age (years) DU urodynamic 
diagnostic criteria  
Prevalence (%) 
Abarbanel et 
al. (2007) 30 
Male: 82 
Female: 99 
≥70 Q max<10ml/s 
PdetQmax <30 cmH20 
48 
12 




>65 Male: BCI<100 
Female: PdetQmax ≤10 
cmH20 and Qmax ≤12ml/s 
40.2 
13.3 
Hoag and Gani 
(2015) 32 
Male: 25  
Female: 54  
Mean: 59.2 
(range 19-90) 
BCI<100 and absence of 
identifiable BOO 
23 
Fusco et al. 
(2001) 33 





Groutz et al. 
(1999) 34 
Female 206 63 <12ml/s and PVR of 
>150ml 
19.4 
Valentini et al. 
(2011) 35 
Female 449 ≥55  “impaired detrusor 
contraction leading to 
prolonged voiding time 
and high residual 
volume” 
14 
Wang et al. 
(2003) 36 
Men 90 18-50 PdetQmax<30cmH2O and 
Qmax<15ml/s 
10 
Nitti et al. 
(2002) 37 





1.6.1 DU and other co-existing urological conditions 
Studies show the complexities of the underlying pathophysiology that urodynamics can reveal 
in patients that present with LUTS. Urodynamic diagnoses such as DU, DO, BOO, urodynamic 
stress incontinence, low bladder compliance, acontractile detrusor, bladder hyposensitivity or 
hypersensitivity may be present in isolation or as concomitant conditions 14,33,37. Joeng et al 
(2012) evaluated the urodynamic data of 1179 patients aged over 65 years who presented 
with LUTS 31. Half the men and three quarters of the women with DU also had other co-existing 
conditions such as DO, BOO, or urodynamic stress urinary incontinence. An investigation of 
community-dwelling elderly (≥70 years) men (n=82) and women (n=99) by Abarbanel and 
Marcus (2007) observed ‘impaired detrusor contractility’ (IDC) in 48% of men and 12% of 
women 30. Of those with ICD, 66% of the men, and 50% of the women also had involuntary 
detrusor contractions (DO). BOO was found in 40% of the men, and of those who had IDC, 10% 
also had co-existing BOO. They conclude that by using presenting LUTS alone, it is not possible 
to determine the underlying pathophysiology contributing to the symptoms.  
1.6.2 Gender 
Although the prevalence by gender is poorly understood, the studies using referred 
populations for urodynamics and by symptomatic presentation have found that DU tends to be 
less prevalent in women than in men 30,31,34,35. Of the studied patients in Jeong et al (2012), 
40.2% of men and 13.3% of women met their urodynamic inclusion criteria for DU 31. The 
authors give no explanation for why a higher prevalence was found in men, other than it is 
likely to be multifactorial. However, by using a referred sample any epidemiological 
conclusions are likely to be problematic. For, example, there is a greater necessity for 
diagnostic pressure flow studies performed prior to prostatectomy to differentiate BOO from 
DU in men 38. Patients with DU may have less improvement in post-operative outcomes after 
prostatectomy than those with BOO and no impaired detrusor function, so establishing DU 
preoperatively is valuable 39. Thus, males with suspected BOO or DU are recommended to be 
referred for pressure flow studies so the clinician and patient will have a fully informed choice 
on whether to proceed with corrective surgery. Referral may also bias the sample in favour of 
females, for example, in the study by Gammie et al. (2016), of the 437 patients who met their 
criteria for DU, 70% were women 21 and of the 28,282 patient records reviewed in their 




Although DU occurs in men and women of all ages, a relationship of reduced detrusor 
contractility 40 or increased prevalence of DU with age has been found by several studies 
15,20,21,30. In their study of 1179 patients aged over 65 years who presented with LUTS, Jeong et 
al. (2012) found the prevalence of DU increased with age in both men and women, suggesting 
that DU is an important factor in the pathophysiology of LUTS in the elderly 31. Valentini et al. 
stratified their study population of 449 women (>55 years) into three groups 55-64, 65-74 and 
75-93 years 35. Detrusor underactivity defined as ‘impaired detrusor contraction leading to 
prolonged voiding time and high residual volume’ predominated in the oldest group, and 
detrusor pressure decreased whilst post void residual increased with age. However, other 
studies have differing findings, particularly in relation to detrusor contractility and function 
41,42. In a study of 30 healthy female volunteers, Karam et al. (1997) reported that maximum 
detrusor pressor did not correlate with age 43. Madersbacher et al. (1998) had similar results, 
for both sexes (253 men and 183 women) in a referred population for urodynamics, there 
were no age-related correlation with maximum detrusor pressure 44. In vitro assessment of 
human detrusor smooth muscle found no evidence of a decline in contractility or excitability 
with age 45. Smith et al. (2010) concludes that it is as yet inconclusive whether impaired 
detrusor contractility is a cause the of age-related impaired bladder emptying 18. There are 
limitations with the cited studies, including variable definitions of impaired detrusor 
contractility and urodynamic DU. Nevertheless, these data suggest that it is not just the 
contractile potential of the detrusor muscle but the other aetiological factors of DU that may 
explain age-related trends. 
To summarise, despite the absence of reliable background population data, DU appears to be a 
relatively common urological condition in patients with LUTS. The prevalence of DU by gender, 
age, or relative to other urological conditions is unclear, and in the cited studies may be partly 
determined by the study population. Although the community prevalence of DU is not 
currently known, a proportion of patients with DU in the background population are 
asymptomatic and do not present for urologic assessment 46, so the prevalence may be 
underestimated. This is supported by qualitative evidence that suggests many patients with 
DU successfully manage their symptoms to minimise impact on their lives 22. Only by 
accurately measuring presenting symptoms will it be possible to achieve a more robust picture 
of their prevalence and impact on the population.  
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1.7 Symptoms of UAB 
There is a current lack of qualitative studies in the literature which explore the patient-
reported symptoms and impact of DU or UAB. Qualitative work is called for, in particular to 
inform the further development of the symptomatic definition of UAB 14,26. Hoag and Gani 
(2015) evaluated the presenting symptoms of 79 patients with DU, defined as a BCI<100 in the 
absence of BOO. It was not clear how the presenting symptoms were evaluated. However, the 
most common symptoms were urgency (63%), slow stream (61%), straining (57%) and nocturia 
(48%). The symptoms of UAB may reflect underlying DU, but the isolation of symptoms that 
may be attributed to DU may be complicated by the presence of additional lower urinary tract 
dysfunctions 32. For this reason, Hoag and Gani were not able to attribute the presenting 
symptoms entirely to DU, in particular as co-existing DO in patients was not excluded from the 
analysis. Furthermore, the underlying aetiology of some presenting symptoms may also be 
complex, so ascertaining the underlying mechanism and to what extent symptoms can be 
attributed to DU may be uncertain. For example, the aetiology of nocturia is complex and age-
related 47,48,  
 In a retrospective large scale analysis of a UK hospital database, Gammie and colleagues 
(2016) have recently made attempts to identify differences in relative occurrence of the signs 
and symptoms of patients with urodynamic DU, in comparison with patients with BOO and 
those with ‘normal’ pressure flow studies 21. Many symptoms and medical history factors 
showed a statistically significant difference in relative occurrence. In male patients, the 
symptoms of decreased urinary stream (56% in patients with DU, 82% of patients with BOO, 
and 30% in those with normal PFS) and hesitancy (51% in DU, 69% BOO, 26% with normal PFS 
26%) were in high frequency. In women, a decreased urinary stream was present in 29% of DU 
patients, 20% of BOO patients and 4% of those with normal PFS. However, as symptoms that 
were specific to a particular group were low in prevalence, and the relative differences in 
symptom occurrence generally indistinct; information that could be used to symptomatically 
differentiate DU from BOO still remains unclear 27. 
1.8 Impact of UAB 
Although there is no UAB-specific qualitative research, it is known that there can be a broad 
impact on patients’ lives through qualitative studies associated with LUTS 9,49,50. Disruption to 
sleep due to waking several times in the night and the lifestyle inconveniences caused by 
increased daytime urinary frequency can be particularly bothersome. The necessity to plan 
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ahead for awareness of the location of toilets, impairment of social life, embarrassment in 
particular situations and reduced self-esteem are a feature of qualitative studies in male 
patients with LUTS 50,51. However, overall, LUTS do appear to be often tolerated and well-
managed by patients 8,50. Many patients with UAB have a high post void residual and perhaps 
correspondingly, a high proportion of patients self-catheterise and experience UTIs 32. The 
consequences can be very bothersome, in particular the impact of nocturnal voiding, urinary 
tract infections, and the inconvenience of self-catheterisation on day-to-day life 9. 
1.9 Pathophysiology of the underactive bladder 
The control of micturition requires complex connections between areas of the central nervous-
system (CNS), and involve the sympathetic, parasympathetic and somatic systems 52,53. The 
neural pathways between the CNS, urinary bladder and urethral outlet are regulated by simple 
on-off switching circuits by which voiding and storage functions are achieved. Reflexes that 
control storage are organised in the spinal cord during bladder filling, whereas voiding reflexes 
are mediated by parts of the brain 53. During filling, the parasympathetic detrusor innervation 
is inhibited, and the urethral sphincter (striated muscle) is activated, which prevents the 
bladder emptying involuntarily. Voiding is initiated by the relaxation of the urethral smooth 
muscle and sphincter, followed by the contraction of detrusor smooth muscle a few seconds 
later, increasing the pressure inside the bladder and resulting in the flow of urine 53,54. 
Neurogenic dysfunctions in the efferent or afferent nerves involved in innervating the 
micturition reflex, in the brain/spinal cord, or myogenic detrusor muscle failure are some of 
the probable causes of UAB 55. Ageing, bladder outlet obstruction, neurological disease and 
autonomic denervation are other possible causes 46.  
1.9.1 Neurogenic disorders 
Neurogenic DU can be caused by the dysfunction of the central or peripheral nervous system 
24. DU may be observed in patients with neurological disease such as multiple sclerosis (MS), 
stroke, Parkinson’s disease, multiple system atrophy, or trauma such as spinal cord injury and 
spinal tumours 24,56,57. Following investigation of 106 ischemic stroke patients who underwent 
urodynamic studies, 15% had DU, and 14% had DO with impaired contractility 58. MS patients 
frequently present with both voiding and storage symptoms. Neurogenic DO is the most 
common urodynamic finding in patients with MS, but a combination of urological conditions 
often present 59. In a study of 65 patients who underwent urodynamic studies, Amarenco et al. 
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(2013) found DU in 6% of cases 60. The site of the neurologic lesion in the central nervous 
system may determine the type of bladder dysfunction and symptom presentation 61.  
1.9.2 Bladder outlet obstruction 
Studies have established that morphological changes in the bladder wall can be seen with BOO 
62,63, so long-term BOO may be considered as a potential risk-factor for DU 64. However, in a 
study of 196 male and female patients referred for urodynamics who underwent a repeat 
urodynamic assessment, 10 years after their original assessment, there was no evidence that 
bladder contractility decreased in those with long-term BOO 65. The bladder contractility in 
patients with underactive detrusors also did not change over time. In Abarbanel et al. (2007) 
10% of men with BOO had co-existing impaired detrusor contractility, so it is known that 
although not all men with BOO develop DU, some men with DU have co-existing BOO 30,66. The 
aetiology of BOO is different in women due to the lack of a prostate gland, and may be a 
consequence of complications post-incontinence surgery or conditions such as urethral 
stricture or prolapse. As BOO is more uncommon in women, it is possible that BOO may have 
an influence on the relative prevalence of DU in men and women 28 but the relationship 
between BOO and DU requires further research. 
1.9.3 Ischemic bladder disease and autonomic denervation 
A possible explanation for the increase in LUTS with age may be atherosclerosis and vascular 
endothelial dysfunction 67,68. This has also been shown in animal models, for example, vascular 
damage can eventually lead to bladder underactivity in rats 69. In rabbits it has been 
demonstrated that moderate bladder ischemia may cause DO, whereas severe bladder 
ischaemia can cause impaired bladder contraction 70. This has led to the suggestion that DO 
may progress to DU 71, although there is no convincing evidence of this hypothesis 28. 
Hyperglycaemia in diabetic patients is also known to be the main factor in causing the 
autonomic neuropathy that can cause diabetic voiding dysfunction, and may lead to DU/UAB 
72,73.  
To summarise, the aetiology of impaired bladder emptying is likely to be complex, and 
associated with diverse morbidities or pathophysiological mechanisms. For these reasons, the 




1.10 Non-invasive diagnosis 
There would be considerable advantage for patients and clinical practice if it was possible to 
diagnose DU by non-invasive techniques 2,74. Indeed, cystometry requires the insertion of a 
catheter, is time consuming, bothersome for patients, expensive, and has a risk of urinary tract 
infection, haematuria and urinary retention 75. The work of Gammie et al. (2016) discussed 
earlier presents several differences in relative occurrence of symptoms, and suggests that a 
specific patient reported outcome questionnaire used alongside other non-invasive tests may 
be useful for diagnosis 21. Ultrasonographic measurement of detrusor wall thickness may add 
additional diagnostic information and has been shown to diagnose DU and BOO non-invasively 
76. A recent pilot study of 123 men showed that an ultrasound measurement of the detrusor 
wall thickness of ≤1.23mm with a bladder capacity >445ml is diagnostic of DU 77. These 
parameters can be used to diagnose DU in 100% and exclude DU in 85% of patients. In 
addition, the use of penile cuff-urodynamics to measure isovolumetric contraction strength is 
promising 78, although neither this method or ultrasonic measurement have yet been tested in 
clinical trials 79. 
1.11 Treatment 
The treatment options for patients with DU are currently rather limited. However, there are a 
number of conservative measures that can be advised, before pharmaceutical options or 
possible surgical interventions may be considered. For those who suffer recurrent urinary tract 
infections as a result of incomplete bladder emptying, bladder drainage by catheter is the 
usual preferred treatment option. The teaching of intermittent self-catheterisation (ISC) is 
recommended for those patients with sufficient manual dexterity, visual acuity and cognition 
80. Long-term catheterisation by indwelling or suprapubic catheter is an option for those who 
are unwilling or unable to perform ISC. For some patients with DU who have a particularly slow 
stream, or bothersome high urinary frequency or nocturia ISC may also be appropriate 80.  
The use of outlet reduction surgical techniques such as Transurethral Resection of the Prostate 
(TURP) may be used to reduce outlet resistance to facilitate emptying of the bladder in men. 
However, it is widely accepted that patients with impaired contractility have poorer outcomes 
following surgery than those with confirmed BOO 81,82. In a study of 224 men with a diagnosis 
of DU who had undergone TURP, there were no symptomatic improvements after long-term 
follow-up (>10 years) 82. It is important that preoperative urodynamic assessment is carried 
out for those patients with suspected detrusor underactivity, so an informed decision can be 
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made whether to proceed with surgery. In women, the transurethral incision of the bladder 
might be effective in treating patients with DU 83. However, the risk of incontinence due to 
sphincter damage reduces its clinical appeal 84. 
The multifactorial pathophysiology of UAB and DU complicates the pharmacological treatment 
of underactive bladder. There are often multiple contributing factors to the symptoms 
presenting within an individual patient, so even when a component  on which an agent can act 
is identified (e.g. to improve contractility of the detrusor, or decrease urethral resistance), 
there may not be the desired outcome 85. In addition, voiding occupied only a small fraction of 
the time of the day whereas medication will be continuously active, making any side effects 
particularly problematic. Muscarinic receptor agonists such as bethanechol and carbachol 
work by activating the detrusor muscle. However, there is no evidence of beneficial effects for 
patients with DU/UAB, as it is likely that the lack of selectivity to target sites makes the action 
of the drug ineffective 86. The reduction of urethral resistance by α-adrenoceptor antagonists 
are widely used and are sometimes partly effective for the management of urinary retention 
caused by BOO 87. This may also improve bladder emptying in DU/UAB patients, and some 
positive results have been shown for neurogenic patients 88 but as yet the evidence for the 
efficacy is inconclusive 85. Other mechanisms of action on detrusor contraction and the 
simultaneous relaxation of the urethra by prostanoids may show promise 89, but clinical trials 
are required. There is a need to better understand the mechanisms of voiding difficulties and 
pathophysiology of those with DU, in order to tailor the drug development accordingly. 
There are several electrostimulation techniques which are used to treat UAB. 
Neurostimulation and neuromodulation techniques work by stimulating the bladder or the 
detrusor muscle by nerve root stimulation at the spinal cord, transurethral stimulation, 
pudendal nerve stimulation, or at the sacral nerve 90. However, these techniques may only be 
possible in certain patients and are still experimental in some cases. Nevertheless, sacral 
neuromodulation has had some positive results 91, has been FDA approved for the treatment 
of underactive bladder, and is clinically available.  
1.12 Conclusion 
Patients with LUTS referred for urodynamic tests are commonly found to have a weak and 
poorly sustained detrusor contraction, termed detrusor underactivity. When the presenting 
symptoms of these patients are reviewed, they encompass storage, voiding and 
postmicturition LUTS. The proposed symptom complex of UAB has been described by the ICS 
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Working Group as being characterised by “a slow urinary stream, hesitancy and straining to 
void, with or without a feeling of incomplete bladder emptying and dribbling, often with 
storage symptoms”. This definition is a good starting point; however, the differentiation of 
symptoms that may be attributed to DU in the context of other co-existing urological 
conditions is currently not possible to determine. There is a need for further qualitative and 
quantitative research to elucidate the symptoms that can be attributed to DU. Overall, the 
available treatments for underactive bladder are still unsatisfactory. There is scope for the 
further development of testing of pharmaceutical agents, but further clinical trials are required 
to test the efficacy of the existing treatments. In conclusion, there is increasing recognition 
that there is a requirement to understand better all aspects of epidemiology, aetiology and 
pathophysiology of the underactive bladder to enable further progress on developing effective 
treatment options to be made. Indeed, ultrasonic measurement of detrusor wall thickness or 
penile-cuff urodynamics when used alongside a condition-specific patient reported outcome 





Chapter 2 Questionnaire design and psychometric evaluation 
methodology 
2.1 Introduction 
The overlap of symptoms from different lower urinary tract and voiding disorders can present 
a challenge for clinicians to ascertain a clinical hypothesis by history taking alone. However, 
there are a number of ways which a clinician may objectively capture a patient’s experience in 
order to formulate treatment strategies. The urinary diary (includes the frequency volume 
chart and bladder diary), allows a patient to record and self-report their symptoms as they 
occur, and is accepted as an integral tool in the initial assessment of LUTS.  When completing a 
bladder diary the patient records information such as fluid intake, voided volume, the time of 
micturition and other symptoms for a few days before their visit to their clinician 92. Clinician 
completed questionnaires are available 93,94, however, these are not widely used as it has been 
shown that interviewer administration can introduce potential bias when assessing patient 
responses 95,96. Patient-centered questionnaires are increasingly recognised as the most 
important way of reviewing symptoms and their impact from the patient perspective 97,98. A 
patient reported outcome (PRO) is defined by the U.S. Food and Drug Administration (FDA) as 
‘any report of the status of a patient’s health condition that comes directly from the patient, 
without interpretation of the patient’s response by a clinician or anyone else’ 99.  Over the last 
twenty years, there has been a large growth in the number and scope of available PRO 
measures (PROMs) for the assessment of LUTS, and their impact on health-related quality of 
life (HRQL). PROMs are distinct from patient reported experience measures (PREMs) which are 
concerned with measuring a particular service or aspect of their care 100.  
The development of a new PROM is a detailed and lengthy process involving numerous sub 
studies 101–104. The following chapter will give an overview of the rigorous process involved in 
the design and validation of a new PROM. Chapter 3 goes on to review some the important 
instruments that are available for use in research and clinical practice for LUTS and evaluate 




2.2 Design and use of PRO measures 
Patient reported outcome measures enable the capture of the subjective patient experience in 
an objective and measureable way. They are recognised as providing valuable information of 
patient reported symptoms and impact on quality of life, and to allow assessment of change 
during ongoing clinical evaluation, research or as outcome measures in clinical trials. In clinical 
practice it is possible to monitor the ongoing progress of a patient, to formulate clinical 
hypotheses and manage treatment accordingly. PROs may be used for epidemiological 
research or the monitoring of health services 105. In clinical trials PROs are often used as 
primary outcome measures for the measurement of change in symptoms or HRQol aspects 
relating to the intervention in question 106,107. 
PRO measures tend to be structured as a series of simple questions (or items) with fixed 
responses which patients can understand and answer quickly and easily. The patient is asked 
to provide information about perceived severity of symptoms or impact on quality of life over 
a recent period of time known as a ‘recall period’. The questions include a series of possible 
answers (response options) which allow the patient to indicate the frequency or severity by 
which they experience a particular symptom or impact on quality of life. These response 
options are usually assigned points from low to high severity, which allows the calculation of 
an overall symptom score. Through multiple administrations of the measure it is therefore 
possible to monitor the ongoing progress of a patient, to formulate clinical hypotheses and 
manage treatment accordingly 103.  
There are three main measurement properties a questionnaire must demonstrate. The first 
two, validity and reliability are traditionally considered the fundamental characteristics that a 
PRO instrument must possess 103,105,106. The questionnaire must be shown to be able to 
measure the symptoms or health-related quality of life aspects in an accurate (valid) and 
stable (reliable) manner 101,103,104. The third property, responsiveness, is of importance if a 
questionnaire is to be used in clinical applications as an outcome measure to detect change in 
a patient’s condition. The concept of validity relates to whether the instrument actually 
measures the construct that it intends to measure 101–103.  Along with reliability, it is the degree 
of confidence that may be placed on interpretation of the instrument’s measurement or score 
104. One aspect of validity is content validity. This refers to whether the PRO instrument covers 
all relevant content, without omitting any important issues, but also excluding any irrelevant 
items 101,104,109. As PROMs are fundamentally reported by the patients, qualitative research 
methodology is essential to the establishment of content validity 111,112 
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The first section of this chapter will discuss in detail the qualitative methodology required to 
demonstrate content validity when developing a new PRO instrument. The chapter goes on to 
describe methodologies for the quantitative evaluation of an instrument’s psychometric 
measurement properties. In questionnaire development, psychometric evaluation provides 
further evidence of validity, reliability and responsiveness in order that users may have 
confidence in the measurements that are made 104,113.  
2.3 PRO measure development good practice guidelines 
The release of the United States FDA ‘Guidance for Industry: Patient Reported Outcome 
Measures: Use in Medical Product Development to Support Labeling Claims’ in 2009 99 and the 
subsequent guidance ‘Qualification Process for Drug Development Tools’ 114 document  reflects 
the increasing importance placed on the use of PROs in the drug development  process. These 
documents along with reports by Patrick et al. by the International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR) 112,115 provide direction to ensure the 
methodology used for the development of an outcome measure for use in clinical trials is 
rigorous and standardised. The following description of the qualitative methodology used in 
the development of a new PRO instrument is informed, in part, on the recommendations 
described by these sources. In particular, if a new PRO measure is intended to be used as an 
outcome measure in clinical trials (e.g. to support labelling claims), then adherence to these 
regulatory guidelines during development of the instrument is of particular necessity 99,114.  
2.4 Context of use 
When developing a new PRO measure the first decisions to be made surround the context of 
use. This is defined by the purpose for which the PRO measure is likely to be used, the disease 
which is to be measured, and the target patient population 112. It is helpful to develop an 
endpoint model which clearly sets out the intended context of use for the instrument. For 
instance, the endpoint for a PRO instrument with the intention for use in clinical trials should 
specify the condition or disease which is to be measured and the demands on the instrument 
in order for the trial objectives to be fulfilled (e.g. to provide symptom scores of treatment 
versus comparison groups, or to detect improvement due to an intervention). If an instrument 
is to be used as an outcome measure in a clinical trial, the endpoint is particularly important to 
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be considered in order that potential requirements for medical product labelling claims are 
met 99.  
The target population should be considered and the extent to which the condition may vary 
across ethnicities, cultures or countries. A diverse a sample as possible is required to ensure 
the eventual instrument represents demographic variations of the potential questionnaire 
respondents. If the PRO measure is likely to be used internationally then language is likely to 
be a significant factor for consideration during derivation of item wording. The content validity 
of the instrument in different countries is supported if concepts are elicited in the population 
in which they are intended to be used (e.g. by the consideration of concept elicitation 
interviews in simultaneous sub studies in different target patient populations).  
2.5 Literature review and expert clinical panel 
The review of existing qualitative literature gives insight into the known patient experience of 
the condition to inform the development of the conceptual framework. The review of the 
published properties of these existing questionnaires determines the necessity or justification 
for the development of a new questionnaire. In addition, it allows the identification of 
domains or concepts of interest that may relate to the condition of study. The literature review 
and consultation with clinical experts then inform the development of a conceptual framework 
or disease model. The conceptual framework sets out the concepts to be measured by the 
instrument in a diagram that presents a description of the relationships between items, 
domains (sub concepts), and concepts to be measured 99. This organises and documents 
hypothesised concepts that are likely to be considered for inclusion as items in the instrument. 
An expert clinical panel made up of multidisciplinary health professionals in the field is 
consulted on the clinical relevance of these hypothesised concepts. The collation of this 
information also contributes to the development of an exploratory interview guide for the 
initial qualitative interviews or focus groups 112,115.  
2.6 Qualitative interviews and/or focus groups 
The use of individual semi-structured interviews and/or focus groups are the qualitative data 
collection methods used in concept elicitation for PRO measure development 116. Focus groups 
are usually six to ten people who are encouraged to discuss around the topic, allowing the 
comparison and enrichment of individual experiences by the feedback and social interaction of 
a group dynamic 112,117. An experienced group facilitator is essential for focus groups to ensure 
the discussion is kept on the subject matter, or the tone is not unduly swayed by a particularly 
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assertive member of the group. The data generated by focus groups can be difficult to analyse 
due to multiple participants expressing their views, but this can also provide a rich source of 
data. Individual interviews are better suited to topics which are personal or sensitive in nature 
or when a discussion requires particularly detailed experiential information 112. Although data 
collection may take longer in one-to-one interviews, the process of transcript analysis can be 
less complex and scheduling of interviews is generally easier. Interviews must be conducted by 
a trained qualitative researcher with excellent personal communication skills to elicit the 
important issues.  
Leidy and Vernon (2008) describe three types of qualitative interviewing that are 
recommended in PRO measure development: exploratory, developmental and confirmatory  
117. Exploratory interviews are used to explore around the topic for which little may be 
understood. This provides better understanding of the condition and the concepts which are 
likely to be explored in later interviews and provide additional information surrounding the 
potential endpoint of the PRO measure. There can also be the incorporation of important 
concepts into the ongoing development of the interview guide. Developmental interviews 
build on this process by focussing specifically on the language, phrases and expressions that 
patients use to describe their experience to inform the item content. Here, the endpoint of the 
PRO instrument drives the objective of the interviews, for instance, if an instrument is 
intended to assess symptoms and their bother then the interview questions should be 
designed to elicit this from the patients. Finally, confirmatory interviews can be conducted to 
document content validity and identify specific concepts, words or phrases that can be 
mapped on to the new instrument.   
2.6.1 Conduct of interviews or focus groups 
Concept elicitation interviews or focus groups are audio recorded to allow the transcription of 
the content for later review and analysis. Audio recordings rather than video recordings are 
generally more acceptable for patients when talking about sensitive topics and aid with 
participant anonymity 112. The confidentiality of the recordings is assured to the patients and 
full written informed consent is taken for their use. It is important to quality check and clean 
the interview transcripts to ensure accuracy to the original source, as the dialogue provides 
essential context which shapes the analysis. 
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2.7 Interview guide 
The interview guide is generated following the literature review and input from the clinical 
experts. It represents a clear set of questions and probes that are intended to elicit open-
ended responses from the interviewees in a semi-structured manner. A well designed 
interview guide is important in order to help avoid possible interviewer bias, or unintentional 
influence of the researcher on the type of responses from the participant 118. Questions should 
be carefully worded to be open-ended, non-leading and include the concept of interest to 
ensure the question has the required specificity. If possible a timeframe which is appropriate 
can be included in questions to provide context and to reduce recall bias. For example, if the 
concept of interest was back pain a suitable question would be “How did your back feel over 
the last 24 hours?” Follow up probes may be included which serve to explore the concept in 
greater detail such as: “How about when you got up in the morning? Or when you went to 
bed?”. These probes should be used after a patient has been encouraged to speak 
spontaneously about their experiences. Ideally, a draft guide is tested in the target or similar 
population before the data collection to identify questions that require improvement or to 
improve the flow of the interview. Iterative revisions are also made to the schedule in ongoing 
interviews to follow-up of concepts of interest that may require further exploration. 
2.8 Sample size and qualitative data saturation 
There is no set number of interviews or sample size required for PRO measure development, 
as this is dependent on the number of measured concepts elicited, the complexity of how 
these concepts are experienced by patients and the heterogeneity of the patient population 
characteristics under study 111. The current guidance is that interviews are generally scheduled 
until the concept may be considered saturated 112,114. The simple definition of saturation in the 
context of qualitative research is the point at where no new information is obtained from 
additional qualitative data 119. More specifically in the PRO field, saturation has been defined 
as ‘the point in the data collection process when no concept-relevant information is being 
elicited from individual interviews, or focus groups, or no new information is deemed missing 
during cognitive interviewing’ 120. The purpose of demonstrating saturation in PRO research is 
to document that the condition under scrutiny has been adequately explored from the 
perspective of the patient population of interest. Once there are no new important concepts 
emerging from further interviews, concept saturation can be considered achieved.  
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Saturation may be documented and demonstrated by the construction of a saturation table, 
which supports the  content validity of the tool under development 99,121.  An example of a 
saturation table for a set of concepts elicited relating to stress urinary incontinence is shown in 
Table 2 (adapted from 111). There are no new concepts elicited by interview 3 so this set of 
concepts may be considered saturated.  
Table 2. Saturation table example for stress urinary incontinence.  
Stress urinary 
incontinence concepts 
Interview 1 Interview 2 Interview 3 
Leakage when 
sneezing 
X X X 
Leakage when 
exercising 
X   
Leakage when 
coughing 
 X X 
Leakage when laughing X  X 
 
Although the assessment of saturation is useful conceptually, it provides little guidance to 
accurately predict sample sizes before data collection. However, it is likely that in a relatively 
homogeneous study population saturation is likely to occur in the first twelve interviews 122. 
Within PRO research there is a move towards including a high diversity of populations within 
clinical trials, so the choice of sample and expected sample size should reflect this. Therefore 
some contingency should be planned for when predicting sample sizes, as a more diverse 
sample will mean that saturation may take longer to achieve 123. Typical sample sizes in recent 
PRO instrument development studies tend to be thirty or forty interviews 9,124,125. 
2.9 Analysis of qualitative data 
There are a number of approaches derived from different intellectual traditions which exist for 
interpretative qualitative analysis. It is beyond the scope of this thesis to explore these 
methods in detail. However, when selecting the approach to analysis of qualitative data, it is 
most important that the theoretical framework and methods should be appropriate to the 
research objectives 126,127. It also may be argued that there should be flexibility in the approach 
in order to answer a range of possible research questions 128. Smith and Firth 129 describe three 
general methods of approach to the analysis of qualitative data which are commonly used: 
 Sociolinguist methods (e.g. discourse and conversation analysis which look to 
understand the meaning of language 130). 
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 Methods which use inductive logic to develop theory (inspired by grounded theory 131). 
 Interpretive methods to describe participants’ experiences (e.g. content analysis 132 
and thematic analysis 126). 
In PRO measure development, there are no specific guidelines to the approach. This is often 
the case when employing qualitative research methodology, as there is considerable overlap 
of the techniques and methodologies used. However, methodology for qualitative analysis 
both in and outside PRO research are often inspired by grounded theory 133. Here, the 
development of concepts or theory evolve ‘through continuous interplay between analysis and 
data collection’ 131. Grounded theory incorporates three types of coding 130,133:  
 Open coding (where the data is examined, compared and categorised by concepts),  
 Axial coding (the data is re-categorised based on the relationships or connections 
between categories)  
 Selective coding (the core phenomenon is identified that represents the whole dataset 
and data is selectively coded that relates to this) 
The initial approach to coding interviews for PRO research recommended by Patrick et al. 
(2011) 112 lends itself well to general inductive coding 134. The ideas generated are not unduly 
influenced by prior knowledge and are wholly derived from the patient data. Resulting themes 
are developed ‘from the field upwards’ rather than having preconceived ideas 135. This type of 
analysis is suitable for topics where very little is known, and allows the documentation and 
naming of codes in the patient’s language. This is appropriate when devising items to maximise 
patient comprehension at a later stage. However, during PRO instrument development it is 
unrealistic to expect the researcher to restrict oneself to an entirely inductive theoretical 
commitment. It is acknowledged that the naming of codes may, and perhaps should, be 
influenced by current theory (e.g. recognised symptoms). Kerr et al. 121 cites the technique of 
thematic analysis 126 as a good balance between inductive and deductive logic which may be 
suitable for the specific objectives of analysis required by PRO research. In essence, within PRO 
measure development, the coding requires the organized cataloguing of the patient’s 
experience within specific context set by the population of interest and vision of the PRO to be 
developed. 
2.9.1 Coding process  
During familiarization of the transcripts, the data is read and assessed to define and name new 
codes. Newly collected data is compared with previous data according to the principles of the 
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constant comparison method (rooted in the principles of grounded theory 133). The accuracy of 
the codes are re-evaluated as the interviews progress, and modified according to the patient’s 
descriptions. Where possible, the names of the codes are based on the wording of the 
patients, as they represent not the researcher but the patient perspective. This process of 
collection of new data through interviewing followed by transcription, coding and evaluation 
and modification of existing codes is inherently iterative in nature. The eventual endpoint is a 
final coding dictionary, with each code defined and presented in a way which exhibits how 
each code interrelates within the context of the patient quotes. 
Qualitative data analysis programs such as Atlas.ti 136 or NVivo 137 can facilitate the process of 
categorising and organizing the data. These programs do not aid with the actual coding; the 
skill of assigning the right code to the patient expression is dependent on the decisions of the 
researcher.  
2.9.2 Rigour in qualitative analysis 
As with any qualitative research, when analyzing data there is an onus on the researcher to 
reflect on their own perspective and to recognise that their own decisions are influenced by 
their prior knowledge and experiences. This is known as the principle of reflexivity and is 
fundamental to the credibility of qualitative research 127(p20). Through continual reflexive critical 
analysis the researcher strives for ‘objectivity’ in order to maximise the overall credibility 138. 
In order to introduce further rigour to the coding process, good practice in the analyses of 
qualitative data recommends the use of multiple coders 112. A qualified qualitative researcher 
not affiliated with the project is given a selection of interviews for review and coding. An 
advantage of double coding is that an independent coder not immersed in the project may 
perceive different items of information that are worthy of scrutiny. This provides multiple 
perspectives to the analysis of the dataset, as it is acknowledged that there will be different 
ways of categorising the same data. Coders will independently complete the analysis of one or 
two transcripts at regular intervals throughout the data collection period. Meetings between 
the coders are arranged to evaluate and reconcile areas of inconsistency between the coding 
framework and dictionary. In addition, this process evaluates the interviewer consensus 
regarding the meaning of the concepts, determines whether the major concepts of the dataset 
have been coded, and that there are no significant omissions. 
The process of inter-rater agreement (IRA) may be used to illustrate the stability, accuracy and 
reproducibility of a coding scheme 139. Correlations of 0.80 or higher between raters 
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demonstrate good inter-rater reliability. This level of quantitative agreement evaluation is not 
usually necessary for self-administered questionnaires, but may be required for instruments 
using observer ratings or multiple interviewers 111. 
2.10 Comment on FDA guidance to qualitative approach 
As already mentioned in this chapter, there is a considerable importance placed on the FDA 
guidance by PRO researchers and pharmaceutical sponsors, due to the significance of being 
able to support a labelling claim based on the eventual PRO measurements. However, there is 
little detail on the type of sampling and no recommendations on the approach to qualitative 
analysis. The FDA guidance states that documentation must be provided to demonstrate that 
saturation has been reached. In addition, it recognises that a sample size cannot be 
recommended but the sample should reflect ‘variations in severity and in population 
characteristics such as age, sex, ethnicity, and language groups in accordance with the 
anticipated clinical trial design’. Arguably, this is advantageous as it allows the PRO 
researcher greater flexibility. However, Kerr et al. (2010) 121 argue that there is a conflict here; 
whilst there is an attempt to increase rigour by demonstrating concept saturation, the 
sampling strategy is at theoretical odds with this. The advised sampling strategy would suggest 
a quota or maximum diversity sampling should be used to maximise the generalisability or 
representativeness to the intended clinical trial population. However, the concept of 
interviewing to saturation implies an approach linked with grounded theory, and thus a 
theoretical sampling approach.  
Kerr and colleagues also question whether data saturation tables are meaningful. Effectively, 
the researcher makes a choice whether to assess saturation at the level of broad themes or at 
a high level of detail. It is easier to demonstrate saturation if only the broad themes are listed 
as opposed to one which details a higher level of analysis. The attempt at demonstration of 
rigour must not be at the expense of the ‘subjectivity and creativity necessary to develop a 
meaningful understanding through qualitative inquiry’ 121,140.  
Three recommendations are made for the study protocol 121. Firstly, to incorporate an element 
of iterative data collection and analysis which allows the saturation of the data to be assessed 
whilst data collection is ongoing. Secondly to have an existing planned procedure to assess 
saturation, and finally, to allow flexibility to have further interviews to achieve saturation if 
required.   
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2.11 Generation of draft PRO instrument 
2.11.1 Item generation 
The selection of items to include in the PRO instrument is mainly related to whether a concept 
is mentioned frequently by patients in the concept elicitation interviews. However, an item 
may also be considered for inclusion even if mentioned infrequently, for example, if it was 
mentioned by only 5% of patients but was described as a particularly bothersome and 
important symptom by this minority. Whether or not the concept was mentioned 
spontaneously (without prompting) in the interviews can also add weight to the decision to 
include a particular item 141. Expert clinical input can be useful to provide insight into the 
diagnostic value of including an item, or mechanisms which contribute to an illness 101,142. The 
published literature should also be used to determine which concepts to include as items. 
Using this information, the instrument developer makes decisions on the criteria which are 
suitable to evaluate the specific condition within the context of measurement. The overall 
consideration is to include items that capture the range of important concepts that represent 
the experience of the condition which is to be measured 115 
The wording of items will be dependent on intent of the item, expert clinical input and the 
qualitative data obtained in the concept elicitation interviews. The PRO instrument should use 
terminology that is familiar to the patients who will be reading the questionnaire. For example, 
the use of the term ‘somnolence’ in an item may be appropriate and valid in a clinical setting 
but may not be understood by the patient population. The use of ‘sleepiness’ or ‘drowsiness’ 
in the item stem may be more appropriate. The way the concepts are described by patients in 
the concept elicitation interviews is a guide to the words which are used in the developing 
instrument.  
2.11.2 Recall period 
The period of time over which the patient is asked to recall their symptoms is an important 
consideration. A recall period that is too long may run the risk of introducing recall bias, where 
the respondent is not able to accurately remember their symptoms, but too short, and the 
necessary information may not be captured. Multiple administrations may also be required 
which increase the burden on the patient. The FDA recommends a recall period which is as 
short as possible in order to minimise recall bias, whilst also taking into account potential 
respondent burden 99. The selection of an appropriate recall period will depend on the purpose 
of the instrument, the frequency of assessment and length of time over which the condition of 
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interest provides a stable measurement 143. Patients will also describe the length of time they 
observe symptom or impact fluctuations which can influence the sensible choice of recall 
period.  
2.11.3 Response scale 
The selection of a response scale is an important aspect of the item design that should occur in 
conjunction with development of the question items. Firstly, the developer must choose 
whether to measure severity, frequency, or length of time in relation to a concept. For 
example, an item measuring pain could evaluate how severe that pain was, the number of 
times the pain was experienced, or the duration for which the pain has been experienced. 
There are also a number of different types of scales to choose from, as described in Table 3 144. 
The advantages or disadvantages of using a particular response scale will depend on the type 




Table 3 Examples of response scales. Adapted from (Hambleton et al., 1991) 
Example 1. Numerical rating scale (average severity) 
Please rate your pain by circling the number that best describes your pain on average in the 
past 24 hours 
 








Example 2. Visual analog scale (peak severity) 
Please mark a (/) to indicate how you have felt over the last 24 hours 
 
Not at all ---------------------------------------------------------------------------------------------------- 
Extremely 
 
Example 3. Likert-type scale (patient impression of change) 
Since starting the medication, my knee pain is: 
 






Very much worse 
 
Example 4. Categorical scale (occurrence of waking) 
Did you wake up in the night due to shortness of breath?  
 
YES       NO 
 
Example 5. Numeric scale (frequency of headaches) 
How many headaches did you have in the last week? 
 
Enter number _________ headaches 
 
Example 6. Amount of time (duration) 
 
Thinking about the migraine headache that you had today. How long did it last? 
 
Enter amount of time________ hours(s) and ________ minute(s) 
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2.11.4 Order, formatting and layout 
Following item generation, the presentation, order and organisation of the instrument must be 
considered. Often, items which cover similar concepts are grouped together in ‘domains’ to 
facilitate the ease of completion for the respondent. The order of items may be important to 
consider if they are required to be answered sequentially, have similar response scales, or a 
subsequent question is dependent on the answer of the preceding item for example. Decisions 
are to be made on the presentation, including the use of tick boxes, circles or numbers; boxes 
to clearly separate out items; instructions to skip questions; page breaks, and font size or type 
115. Indeed, a simple improvement such as increasing the font size and having thicker paper 
may significantly increase the response rate and completeness by respondents 145. If the 
instrument is likely to be administered in electronic format then this may also influence the 
way items are presented. For instance, items may be presented on a single page in order that 
respondents only see one item at a time before moving on to the next item. Modifications 
from an original paper administered instrument when changing to electronic mode may result 
in the electronic version having to be validated separately to ensure the instrument is still 
understood as expected 146.   
2.12 Cognitive interviews 
Cognitive interviews follow the concept elicitation phase and generation of the draft 
instrument to be tested. There are two primary objectives, firstly to ensure that the PRO 
instrument content is representative of the most important concepts of interest to the studied 
population within the intended context of use. Secondly, to assess the respondents’ 
understanding of the instrument including the facility of completion, their comprehension of 
the items and response scales and appropriateness of the chosen recall period. The evaluation 
and documentation of patient understanding of the PRO measure by cognitive interviews 
provides evidence for content validity 115. One aspect of content validity is ‘face validity’. This is 
essentially whether the items appear on the surface to be measuring what they actually intend 
104. If items appear to be irrelevant to users the respondents may not answer the item, 
(irrespective of whether the item is psychometrically robust). Face validity is addressed by 
essentially asking the intended respondents to provide feedback on the relevance of the item, 
and can be part of the cognitive debriefing process. 
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2.12.1 Cognitive debriefing study sample 
The number of cognitive interviews required will be variable for different studies and will 
depend on the complexity of the questionnaire, the concepts measured, and the diversity of 
the sample population 115,141. A sample of seven to ten interviews has been suggested to 
confirm patient understanding of an item 141. Other studies complete successive rounds of 3-5 
interviews whilst making iterative improvements after each round 124. The main requirement is 
that subjects recruited for the cognitive interviews should represent the target population in 
which the PRO instrument will be used (e.g. age, sex, ethnicity, socioeconomic status, literacy 
and characteristics of condition), so the overall feedback from the participants will be 
representative of the population of interest. Any participants which may have unique or 
different requirements when completing the instrument (e.g. visually impaired, low reading 
ability) can also be purposively sampled to capture their perspectives.  
2.12.2 Cognitive interview process 
The standard cognitive theory model on which cognitive interviewing is based consists of four 
stages to explain how items are processed and answered by subjects 147. Respondents must 
first understand the question, then recall the item-specific information, assess the type of 
information required and finally decide on the response. During cognitive interviews patients 
are asked to read an item, then asked a series of questions by the interviewer exploring how 
they interpreted the item and what it meant to them. 
The cognitive interview process is based on a ‘thinking aloud’ approach 148, where the subject 
is encouraged to verbalise their thought processes as they complete the questionnaire. A semi-
structured interview guide is a useful tool for the interviewer to guide the subject through a 
series of systematic questions which direct the process. A useful starting question can be a 
simple question such as ‘can you tell me in your own words what you think this question is 
asking you about?’ This is then followed up by more specific probes to ask about the 
comprehension of other aspects of the items, such the response options, recall period, and 
format of the item. Essentially, the interviewer is checking whether the subject is interpreting 
all aspects of the item as expected. If there are any inconsistencies, ambiguities or difficulties 
in comprehension then the interviewer may ask if the subject has any suggestions for changing 
the question so that it is easier to complete. Difficulties with understanding of the items may 
not be verbally communicated so it is important that the interviewer is aware of body 
language, facial expressions and other signs such as flipping pages back and forth which may 
indicate confusion. Every aspect of the questionnaire is checked in this way, including any 
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initial instructions, the recall period which is applicable to items, and the format and layout of 
items 115.  
The purpose of a probing question in an interview schedule is to elicit a particular 
communication. Nevertheless, however standardised the questions are, there are likely to be 
differences in the way each question is put to the respondent. The ideal scenario would be 
that the subject provides all the information with the minimum of questioning, however, 
probes used to direct the interview will invariably be necessary. This opens up the possibility of 
interviewer bias 103. Poorly worded questions can lead the subject into affirming responses 
that the interviewer would like to hear, or cause misunderstandings that obstruct the flow of 
the interview. In addition, the subject forms an ‘inner picture’ when deciding how to respond 
which can be influenced by many factors such as maintaining appearances, poor rapport with 
the interviewer, and other private restraints on wishing to divulge information. These 
influences may or may not translate to important differences in interpretation of the results. 
However, to minimise any potential bias effects, questions should be open ended and carefully 
worded. For example, when investigating whether or not the questionnaire is an appropriate 
length (that the subject does not consider it burdensome) 115: 
Poorly worded: “Is the questionnaire too long? Too short? 
Preferred wording: “What did you think about the length of time it took to complete the 
questionnaire?” 
During the interview, notes are taken in response to the key questions for each question on 
the interview guide. In addition, the interviews are audio recorded and then transcribed 
verbatim to allow subsequent review of the patient responses and for documentation 
purposes. After a round of 3-5 interviews the researcher prepares a summary of the responses 
of the subjects for each item or line of questioning, including key quotations that represent 
particularly relevant views on items or concepts.  
Based on the feedback from the interviews, decisions are then made to revise items or other 
aspects of the instruments. If four out of five of the subjects in a round of interviews found a 
particular item confusing, then it is quite clear that the item may need revision or removal. 
However, it is less clear if only one subject has difficulty; here the researcher must make the 
decision whether to modify the item, which may not be straightforward. Common reasons for 
modification of an item is unintended ambiguity, misinterpretation and lack of clarity 115. The 
end goal is to reach saturation of the cognitive evaluation of the instrument. This is achieved 
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when all items are fully understood or interpreted as expected and the questionnaire is easily 
completed by several successive subjects. 
The results of cognitive interviews may be presented in an item tracking matrix. Information 
that is included details the initial wording of the item, and each modification made after each 
round of interviews are included, along with patient quotes which provide evidence to support 
why modifications were made. Items which were removed as a result of the cognitive 
interviewing process are also included with the rationale provided. This evidence is part of 
documenting content validity of the instrument 115. 
Following the cognitive interview process the end result should be an instrument which is 
easily completed and understood by the target population. The instrument is then ready for 
the next phase of development and to undergo the psychometric testing of its measurement 
properties. 
2.13 Psychometric evaluation methods 
Psychometrics in questionnaire development is the scientific method which provides evidence 
of these capabilities in order that users may have confidence in the measurements made 
104,113. The information collated by patient-reported questionnaires is inherently subjective in 
nature. Psychometrics in this context is the standardised methodology used to quantify and 
lend objectivity to the evaluation of their measurement properties. Generally, this is evaluated 
by another sub-study, with a further sample of the target population. Respondents are asked 
to complete the instrument to be evaluated and amongst other comparisons, the responses to 
the items are compared with the responses given to a repeat administration of the instrument. 
The following section of the chapter describes the methodology by which aspects of validity, 
and reliability and responsiveness may be quantitatively evaluated. 
2.13.1 Content validity 
It has been discussed in detail how the process of concept elicitation, literature review, the 
consultation of clinical experts in the field and the process of conducting cognitive interviews 
contribute to content validity. When assessing the psychometric properties of the PRO 
measure, the following analyses also contribute evidence for content validity. 
Missing data - The level of missing data is explored for each item, when the questionnaire is 
administered to the target population. If items are consistently missed by respondents this 
may indicate that an item is irrelevant, or difficult to answer. Identification of these poorly 
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answered items allows the items to be flagged for possible modification or consideration for 
removal, in order that higher rates of completion may be achieved.  A level of missing data of 
3-5% in PRO items is generally considered acceptable 149,150.  
Floor and ceiling effects - The presence of floor or ceiling effects within instrument items can 
adversely affect the range which an instrument is able to measure 151. Items are considered to 
have a floor or ceiling effect if a relatively high proportion of respondents give answers in the 
lowest or highest response option respectively. Ideally, a well-designed item should elicit 
responses with an even spread across all response options when administered to potential 
respondents, in order to maximise the item’s potential to detect sensitivity to change in a 
population. The identification of these effects allows the potential modification of items, and 
thus, optimise the assessment of the patient’s condition 152.  
2.13.2 Construct validity 
Construct validity is the aspect of validity that provides confirmation that the instrument is 
measuring the underlying concept that it intends to measure, by comparison with known 
theory 101. Hypotheses of how the instrument should ‘behave’ when compared with expected 
relationships according to known theory are explored. Construct validity is supported when 
the PRO instrument is shown to measure constructs that are consistent with these hypotheses 
108. The demonstration of construct validity is particularly important for PRO instruments, as 
often these aim to measure attributes that are reported by patients and cannot be directly 
observed (e.g. symptoms, emotions, psychological effects).  For example, based on known 
theory, stress urinary incontinence is known to be more prevalent in women 153, so an 
instrument should be able to detect this. However, construct validity only lends weight to the 
validity of the instrument if both the theory and the instrument are correct. It is important that 
the theory is well evidenced, or the apparent failure of an instrument to detect a relationship 
may be not due to the instrument but the inadequacy of the theory 101.  
There are two fundamental types of construct validity. Convergent validity is the extent to 
which the instrument correlates with other ways of measuring the same construct. For 
example, a measure demonstrates incontinence is more prevalent in women. Conversely, 
discriminant validity is when a measure is shown not to correlate with a measure which 
purports to measure dissimilar variables 101,108. For example, an instrument should not 




Construct validity is usually demonstrated by correlating subgroups of the sample (e.g. by 
gender or age) with hypotheses of how the instrument should perform for these groups. 
However, ideally, a number of sub-studies are performed that evaluate the PRO measure 
against other ways of observing the construct (e.g. clinical measurement, objective 
performance tasks). The rationale here is that the score obtained by the PRO measure under 
evaluation is not just determined by the concept being measured, but also by aspects of the 
instrument itself 104.  
2.13.3 Criterion (concurrent) validity 
Criterion validity refers to the correlation with a ‘criterion’ scale. This is a measure that may be 
considered a ‘gold standard’ by which the PRO measure to be evaluated is compared. 
However, when a new PRO is under development, there is often no existing gold standard, so 
other existing PRO measures which measure similar constructs are used for comparison. 
Concurrent validity is a type of criterion validity, and is when an instrument is compared with 
an existing validated measure that measures the same attributes. The PRO measures to be 
compared are usually administered at the same time, so ‘concurrently’ 104. 
2.14 Reliability 
An instrument will also require testing for its reliability, that is, the ability of the measure to 
perform in a stable, reproducible and consistent manner 101,103. The following discusses two 
methods which provide evidence of reliability; internal consistency and test-retest reliability. 
2.14.1 Internal consistency  
Internal consistency is the extent of the homogeneity of the items, or the degree to which the 
questionnaire measures the same concepts 103. Correlations are performed within the items of 
the scale, or within groups of items (domains) to explore how related (consistent) the items 
are to one another. The calculation of Cronbach’s alpha (α) gives a statistical indication of this, 
by returning a value of between 0 and 1. A value of zero means that the items are entirely 
unrelated to one another, and a value close to 1 would indicate that the items were measuring 
almost exactly the same attribute. However, care should be taken when interpreting α, as the 
value is not only dependent on the correlation of the items, but also the number of items. The 
larger the number of items the more likely the instrument will have a high α. If the number of 
items or α is high, then this suggests that a number of items are asking about the same 
concept in slightly different ways, so probably there is redundancy and scope for the removal 
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of items 103. Thus, a Cronbach’s α of ≥0.7 is generally considered acceptable and >0.9 to 
indicate redundancy within the item pool 154.  
2.14.2 Test-retest reliability 
The test-retest reliability gives an indication of the reproducibility or stability of the 
instrument.  It is evaluated by individual response consistency between repeat administrations 
of the instrument over a time-frame in which the responses are not expected to change 108. 
The scores obtained from an instrument (X) consist of two components: 
 X = Ts + es  
where Ts is the hypothetical ‘true’ measurement and es is the random ‘error’ 155. A reliable 
measurement depends on maximising the true score and minimising the error score. The error 
consists of an unsystematic variation (due to random errors when judgements are made by 
humans) which affects the accuracy of the instrument, but do not result in an overall bias 156. 
For this reason, one cannot expect perfect reliability 103, but an acceptable level of reliability, 
the criterion of which is determined by the selection of the appropriate statistical test.  
The Pearson product correlation coefficient can be used to give a measure of the strength of a 
linear relationship between the two administrations. However, this may be misleading as these 
correlations are not sensitive to systematic variation in scores due to unknown differences 
over time. For example, the second administration may have consistently and artificially 
inflated scores due to a ‘learning effect’, or some other external factor or bias which have not 
been accounted for. Thus, the intraclass correlation coefficient (ICC) is increasingly used as a 
way of assessing test-retest reliability as it takes systemic variation in scores and variability 
between groups into account 155,156. The ICC ranges from 0-1 with the generally accepted 
criterion for adequate reliability as ≥0.7, and >0.9 as excellent 154. 
When evaluating pairs of scores for individual items derived from test-retest data, there is a 
high chance that the scores will agree by chance, especially if the response options are ordinal 
(e.g. mostly agree, completely agree etc.) or dichotomous (e.g. yes/no). The kappa coefficient 
is therefore an appropriate statistical test when comparing pairs of scores for individual items, 
as it provides a chance-corrected measure of agreement. The Kappa statistic provides an 
indication of agreement from 0-1 where 1 is perfect agreement whereas 0 is no better than it 
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would be by chance. (Kappa statistic (κ): 0 = poor, 0.01-0.20 = slight, 0.21-0.40 = fair, 0.41-0.6 = 
moderate, 0.61-0.8 = substantial, and 0.81-1 = almost perfect agreement 157).  
2.15 Responsiveness or sensitivity to change 
If a PRO instrument is intended to be an effective outcome measure for clinical assessment or 
research purposes, then it must be shown to be sensitive or responsive to the change in 
condition of a patient. Hays and Hadorn (1992) and others 158–160 include responsiveness as one 
aspect of an instrument’s validity. Others argue that it is distinct concept of a measure and 
separate to validity and reliability, and should be evaluated, if necessary, as a psychometric 
property in its own right 161,162. 
A PRO measure ideally aims to be sensitive to changes in a patient’s condition over time. If an 
effective intervention is administered in the time period between administrations then the 
scores are expected to change, so the questionnaire must be responsive to any change in the 
‘true’ values of the underlying construct 101. In order to be sure that any change detected is not 
due to chance, when testing responsiveness to change the instrument’s scores should be 
correlated with those of another validated measure or treatment administered at the same 
time. For example, a depression scale might be correlated with the results of a psychiatric 
interview. 
Sensitivity to change can be evaluated using percentage change in total score before and after 
an intervention of known efficacy 96. When comparing paired ordinal data, the Wilcoxon 
matched pairs signed rank test with a Bonferroni correction can be used to establish the 
statistical significance of any change calculated 160,163. 
2.16 Factor analysis 
Factor analysis is a useful statistical technique used to identify and define the separate factors 
that can group an instrument’s concepts 101. It operates on the theory that the measured 
concepts share underlying latent variables, which are identified by their common variance 164. 
Factor analysis is used to find the number of factors which influence the variables and to 
discover which items may be grouped together. The aim is to find the smallest number of 
common factors which describe the correlations 165. It can be used to identify potential items 
for removal, to group items, determine how strongly items are related, and to provide 
information that informs scoring 154. A large sample size of 300 participants with 5-10 
observations per variable is recommended, although smaller sample sizes will still yield useful 
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results 164, and are commonly evident in PRO development studies 124. Expert clinical opinion 
should be sought when interpreting the results of factor analysis, as although an item may 
appear to be weakly grouped and marked for removal, it may have significant clinical value or 
importance to patients so should be retained. Decisions are made surrounding the inclusion or 
removal of items in combination with the information surrounding their reliability, validity and 
sensitivity to change. 
2.17 Item response theory  
There are two main approaches to evaluating PRO measures 166: classical test theory (CTT) 167 
and item response theory (IRT) 168. Classical test theory is the traditional and dominant 
paradigm, and is the conventional approach to evaluating the validity and reliability of an 
instrument discussed so far in this chapter. Item response theory (IRT) refers to a collection of 
mathematical models that may be used to explain the relationship between the responses to 
items and an underlying, unobserved construct 169. IRT can be used when this unobserved trait 
may be considered to exist on an underlying continuum, such as the constructs ‘fatigue’ or 
‘physical functioning’ 170. The probabilities of the respondent to the questionnaire selecting 
each of the given response options are expressed as a function of this underlying construct, 
shown graphically by an item response curve (or item characteristic curve). It is then possible 
to identify which items are most useful in assessing this construct, and to assess the 
respondent’s own position on the continuum. There are several IRT models which may be 
selected according to how many parameters and the type of items (e.g. dichotomous or 
polytomous) which the data has. For example, models that assume unidimensionality (items 
that measure one concept) include the partial credit model 171, generalised partial credit 
model, and the graded response model 172.  
One example of a questionnaire in which both CTT and IRT was used in its development is the 
Pain Impact Questionnaire (PIQ-6). This is a six-item measure of pain impact and severity on 
health-related quality of life 173. Initially, eight items were selected from an item bank made 
from items from 16 widely used pain measures. The final six items were selected using factor 
analysis to assess unidimensionality (whether there was a single underlying construct) and 
therefore suitability for IRT. The inspection of the item response curves showed that the 
response categories were ‘functioning well for all items’. One item was removed because of 
‘item misfit’ and another because the ‘item parameters were almost identical’; essentially they 
covered too similar concepts. The item response curves also informed the weighting of the 
scoring (the flatter the slope of the curve the less discriminatory power for severity, so less 
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weighting is given on the score). Alongside this analysis, traditional CTT psychometric 
techniques assessed internal consistency, convergent validity, divergent validity and known 
group validity, providing additional information on the properties of the final questionnaire.  
The use of CTT is usually advised for initial descriptive evaluation of the psychometric 
properties of a new instrument 169. IRT is often used to provide additional, in-depth 
information in later stages of psychometric testing, particularly as larger sample sizes of 
several hundred are required (depending on the numbers of items and response categories) 
166. IRT is particularly useful for informing decision making when at the item reduction stage, as 
it has the capability of reducing the length of questionnaires without making compromises on 
reliability or sensitivity 170. However, both approaches can be used successfully when assessing 
the content validity of a new PRO measure, with final decisions on the inclusion of items made 
on the basis of both quantitative and qualitative findings 166. 
2.18 Scoring 
Most PRO instruments have a straightforward scoring system with each item scored in the 
same way, with equal weighting. The item scores are then summed up to produce a total score 
101. The issue with the equal weighting of items means that there are multiple ways of 
achieving the same score using the same items in the questionnaire. Thus, the instrument 
score itself can only give an indication of the severity of the overall condition, not any detail of 
the patient outcome. Differential weighting of items can be used to assign higher importance 
to items.  However, this raises questions about how much relative weight should be assigned 
to each item and contributes to complex scoring algorithms that can be cumbersome for 
analysis. One method is to assign equal scoring importance to domains of items within the 
instrument, with each domain consisting of different numbers of items. However, in scales 
with fairly homogenous items or large numbers of items, the weighting of scoring of items can 
make little difference in practice 104. People who score heavily in one section of the 
questionnaire are likely to score highly in another. 
2.19 Translation and cultural adaptation 
It is often required to translate a PRO into another language from the original. This may be 
done during the development process to allow the evaluation of its properties in culturally 
diverse populations, or after the PRO has been finalised to broaden its clinical application. It is 
important that guidelines are followed when carrying out translational and cultural adaptation 
to ensure the instrument’s conceptual equivalence, cultural relevance, and facility of 
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understanding 174,175. This is a rigorous process with multiple steps involved. The main steps are 
a forward translation into the target language conducted by a native speaker of the target 
language who is fluent in the original language, followed by a back translation conducted by a 
native speaker of the original language and fluent in the target language. The back translation 
is then reviewed and compared with the original and harmonized to achieve consensus. A 
small number of cognitive interviews with relevant patients who speak the target language are 
then used to check the understanding and interpretation of the items 174.  
2.20 Conclusion 
The development of a rigorously validated questionnaire is a lengthy process that involves 
several sub-studies. The initial drafting of the items follows a literature review, consultation 
with clinical experts and in-depth interviews or focus groups with patients. Patient 
involvement in the initial stages of developing a questionnaire is given particular emphasis by 
regulatory guidelines for industry and good practice. In addition, the psychometric testing of a 
questionnaire is crucial for the establishment of its fundamental properties of validity, 
reliability and responsiveness. Figure 1 summarises main stages of PRO measure development 
described in this chapter.  
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Stage 2: Concept elicitation interviews 
 Conduct semi-structured qualitative interviews or focus groups 
to explore the patient experience of the intervention/condition 
 
Stage 1: Define context of use 
 Formulate preliminary conceptual framework using input of 
expert clinical panel and existing literature documenting 
patient experience of the intervention/condition  
 
Stage 3: Development of draft items 
 Decisions on the inclusion of items, including their content, 
language and response items, are made on the basis of the 
qualitative evidence and consultation with the expert panel 
 
 Stage 4: Cognitive debriefing 
 Conduct cognitive debriefing interview in target population to 
assess patient understanding of the draft  items and to make 
necessary iterative modifications 
 
Stage 5: Psychometric testing 
 Subject the questionnaire to statistical tests in order to assess 
validity, reliability and responsiveness of the new instrument 
 
Stage 6: Item reduction and scoring 
 Final questionnaire refinement and develop scoring algorithms 





Chapter 3 Evaluation of existing measures for LUTS 
3.1 Introduction 
As discussed in chapter 1, there is a call for a validated condition-specific questionnaire to 
facilitate the assessment of underactive bladder in clinical practice. The primary purpose of 
this chapter is to determine the necessity for the development of a new condition-specific 
measure for UAB. The current literature suggests patients with DU may present with a range of 
storage, voiding and post-micturition lower urinary tract symptoms (LUTS). It is recognised that 
there is a significant clinical overlap with many of the symptoms experienced by patients with 
bladder outlet obstruction (BOO) and overactive bladder (OAB), including high urination 
frequency, nocturia, urgency, and incontinence 14,25. PROMs that assess the common signs and 
symptoms of lower urinary tract dysfunction, BOO and OAB are reviewed for their content and 
potential relevance to an outcome measure for UAB. Associated quality of life measures are 
also reviewed in order to explore the range of patient-centered measures available. These are 
discussed in the context of current regulatory requirements and their published evidence of 
reliability, validity and sensitivity to change.  
3.2 ICI grades of recommendation for questionnaires 
The committee 5B for the 6th International Consultation on Incontinence (ICI) 2016 reviewed 
the available evidence of the psychometric properties for published self-completion 
questionnaires 97. The result was a comprehensive publication and review of the measurement 
properties and status of validity of the published PRO measures relating to the assessment and 
screening of LUTS, associated HRQL, bother, measures relating to urgency, faecal incontinence 
and associated sexual function. Each questionnaire reviewed by the ICI received a grade based 
on the documented evidence of the reliability, validity and responsiveness of the 





Table 4. ICI grades of recommendation 
Evidence required Grade of recommendation (+ sign may be 
added if published evidence of content 
validity) 
Published evidence of validity, reliability and 
responsiveness to change. ‘highly 
recommended’ 
A  
Published evidence of two of the three main 
aspects of validity and reliability and 
responsiveness to change. ‘Recommended’ 
B  
Published evidence (including abstracts) 
indicating the ‘potential’ for validity, reliability 
and responsiveness to change. 
C  
 
3.3 Current review inclusion and exclusion rationale for existing PROs  
For the current review, the content of questionnaires reviewed by the ICI committee 97 were 
investigated for their potential relevance for the assessment of symptoms of UAB. Of 
particular interest were those which aimed to measure symptoms and their impact suggested 
to be associated with a diagnosis of DU or UAB in the literature. Hence, PRO measures which 
included storage, voiding and post-micturition LUTS and associated HRQOL items were 
evaluated.  
The full text of published evidence of validity was accessed for any PROM that assessed the 
common signs and symptoms of lower urinary tract dysfunction, including measures for BOO, 
OAB and associated HRQL. Although questionnaires of grade A or A+ status were of primary 
interest, questionnaires with a grade of B or lower were also investigated for their potential 
relevance in content. 
In addition, a comprehensive literature search of Medline, Embase, PsycINFO and Google 
scholar was performed with combinations of the search terms (and associated acronyms): 
Patient Reported Outcome, Questionnaire, Validation, Lower Urinary Tract Symptoms, 
Detrusor Underactivity, Underactive Bladder, Overactive Bladder, Benign Prostatic 
Hyperplasia. The intention was to identify questionnaires of interest that had been developed 
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since the ICI review, including those which have no evidence of published psychometric 
testing.  
3.3.1 ICI review 
Of the 74 measures relating to LUTS and impact on HRQL reviewed by the ICI, 51 
questionnaires were Grade B or lower or had a specific focus such as incontinence, pelvic floor 
distress, patient satisfaction or bowel symptoms. These were not explored further. 23 PROMs 
assessed the storage and voiding symptoms, signs or HRQL that warranted the further 
investigation of their content. Upon obtaining the full text for associated publications for of 
these questionnaires, 12 questionnaires had a specific focus that did not include storage or 
voiding LUTS (e.g. urinary incontinence, urinary tract infection, post-operative assessment, 
sexual function) and were not included further in this review.  The International Prostate 
Symptom Score (I-PSS) 176 has a grading of B, which reflects that patients were not involved in 
its development. Nevertheless, it is widely used in research and clinical practice as an 8-item 
screening tool for capturing the severity of symptoms relating to BPH, so was reviewed further 
for its content.  
3.3.2 Database search 
A search of the databases was carried out to identify publications of the psychometric 
properties of PROMs relating to LUTS that were not included in the ICI review. Search terms 
were generated to cover the population of interest, questionnaires and psychometric 
terminology. Each term were combined with the Boolean operator “AND”. Searches were 
carried out in February 2015 and then an updated search in October 2017 using the same 
terms as the initial search. Reference lists of articles were also checked for other potential 
articles of interest. Abstracts were screened and included studies were in the English language 
and were a psychometric validation of the properties of a PROM. Studies that were not 
considered further were those that had patient cohorts that did not have LUTS, or where the 
questionnaire was not patient reported (e.g. clinician or proxy). Abstracts, conference papers, 
editorials and review articles were also not considered. The full text of the publications were 
retrieved for all manuscripts that met these criteria for detailed screening for suitability and 
final inclusion in the review. Using this process a further 2 questionnaires related to the 
assessment of LUTS, the LUTSS 177 and LUTS 9,178 tools. The search of Google scholar identified a 
single questionnaire provided by the Underactive Bladder Foundation, the UAB-q 179. Figure 2 





Figure 2. Flow chart of the process by which PROMs were selected for review. 
 
Table 5 describes PRO measures which aim to detect the presence (or lack of) symptoms, their 
frequency and associated bother. Table 6 describes PRO measures which aim to assess the 
impact on HRQL. There is a description of the content of the tool and their target population. 
In addition, their published psychometric properties of validity, reliability and responsiveness 









Description of Tool Validity Reliability Responsive
-ness Content 
 







A 8-item for LUTS for  
women and validated 
in men in 2014 
Literature review and 








A 7-item tool, overactive 
bladder symptom 
score for men and 
women 
Initial questions derived 
from expert panel. 
Patients involved in 








A 12-item tool to assess 
voiding problems and 
associated bother in 
men with LUTS 
suggestive of BPH 
Literature review and 
cognitive debriefing but 









A 14-item tool to assess 
male LUTS and BPH 
with associated 
bother.  Derived from 
long form ICS-male 186 
In-depth interviews 





and correlation with I-
PSS  





A 13-item tool to assess 
female LUTS, 
(particularly UI), and 
associated bother.  
Adapted from ICS-male 
Consultation of expert 
panel, literature review 
and  discussion with 
patients 
Compared with sample 








A 8-item tool to assess 
severity of urinary 
storage and voiding 
symptoms in women 
No evidence of method 
of item generation 
Concurrent and 
criterion evaluated 







Description of Tool Validity Reliability Responsive
-ness Content 
 






A 8-item tool, aimed as a 
screening tool for OAB 
in men and women.  
Adapted from the 
OAB-q 188 
Focus groups and a 
literature review for 
OAB-q but not 
specifically for OAB-V8 
Concurrent and 
discriminant 
evaluated for OAB-q 






14 item tool, LUTS for 
men and women 
Expert panel developed 
questionnaire from 
patient interviews 
followed by subject 




   
LUTS (Lower 
Urinary Tract 
Symptom Tool) 9,178 
Not 
graded 
16-item tool assessing 
frequency and bother 
of 18 LUTS in men and 
women 
Focus groups used to 
explore patient 
descriptions of LUTS 
and perspective on 
treatment outcomes. 
No published 










6-item tool assessing 
UAB 
Preface stating 
developed by experts in 
bladder research but no 
published psychometric 
evidence 




Table 6. Selected PROs related to the assessment of LUTS on HRQL. Adapted from Castro-Diaz et al. 2017 97. 
PRO name ICI 
grade 
Description of tool Target 
population 
Validity Reliability Responsiveness 



















and lit review 
    
ICIQ-Nqol(ICIQ Nocturia 
Quality of Life 
Questionnaire)149 
A+ 13 item tool to assess 
impact of nocturia on 
quality of life. 




4 Focus groups of 
7-8 men, clinical 
opinion and 
literature review. 
Only validated in 
men. 
    
ICSQol190 A 8-item tool to assess 
the impact of LUTS 










  (but low)   
ICIQ-LUTSqol (Lower 
Urinary Tract Symptoms 
– quality of life)191–194 
A+ 21-item tool, impact 
of LUTS, associated 
bother and HRQL. 









US population 192   
    
LIS (The Leicester Impact 
Scale)94 











    
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3.4 Evaluation of the psychometric properties of selected PROs 
The literature search confirmed that that there are no existing, fully validated measures for 
UAB patient-centered evaluation. The UAB-q provided by the Underactive Bladder Foundation 
supplies no supportive evidence, published or otherwise, of psychometric properties. 
However, a number of well validated PROs for the patient-centered evaluation of LUTS and 
HRQL exist which are likely to capture some of the symptoms experienced by patients with 
UAB. The current review provides an overview of the extent of published psychometric 
validation for the selected instruments related to the assessment of LUTS. This also draws 
attention to where published evidence may fall short of the highest standards of PRO 
development practice. In addition, the extent to which their published properties are adequate 
for the standards required by the FDA: ‘Guidance for industry for PRO measures: use in 
medical product development to support labeling claims’ 99. 
All of the evaluated PROs except the ISS and UAB-q had associated publications which included 
the method of initial development of items for the questionnaire. The use of a literature 
review, existing questionnaires, a panel of experts and discussion or interviews with patients 
were mentioned as the sources by which items were devised, and to ensure the items included 
were of relevance to the context of use. Current recommendations for PRO development 
emphasise the particular requirement for the patient perspective through in-depth interviews 
early on in the questionnaire development process 9,99,195. Despite their A or A+ grading status, 
this may be highlighted as a limiting factor in many of the included questionnaires, as for many 
of the included questionnaires a literature review and consultation with a panel of experts 
were the sole sources. The result is that issues of importance to patients may be missed, 
particularly condition indicators relating to quality of life. Although some of the PROs 
mentioned patient involvement in item development (ICIQ-MLUTS, ICIQ-FLUTS, ICIQ-OABqol, 
ICIQ-LUTSqol), only the recently developed Lower Urinary Tract Symptom tool (LUTS) 9,178 
included the extensive qualitative documentation of patient input through the analysis and 
reporting of in-depth patient interviews in-line with current regulatory requirements. 
However, it may be that extensive interviews were completed but the source evidence is no 
longer available, or published in the public domain (the case for the ICIQ-MLUTS and ICIQ-
FLUTS). Nevertheless it remains that the necessary detailed documentation of qualitative 
research, through in depth-focus groups, or interviews with patients and subsequent applied 
qualitative methodology is essential in the development of any new PRO measure 195. 
Table 3. Selected PROs related to the assessment of LUTS on HRQL 
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Direct patient input is also crucial in order to inform the appropriate patient-centered 
terminology when developing the items of the questionnaire. In addition, the involvement of 
patients in the process of cognitive debriefing interviews used to refine the draft instrument 
are an essential component of demonstrating content validity 196. Current regulatory 
requirements require rigorous documentation of patient understanding of all concepts, 
response options, recall period and overall readability 99. The ICIQ-LUTSqol (King’s Health 
Questionnaire) demonstrated this aspect of content validity by a well evidenced retrospective 
cognitive debriefing study. In-depth interviews with 24 patients in the US provided feedback 
on the instructions, items and response items 192. The use of subject feedback to confirm 
patient understanding was also described in the OAB-SS and ICSQol publications 182,197. The 
DAN-PSS-1 paper was regarded to have demonstrated face validity as a result of a preliminary 
trial with patients  184. The LUTSS publication included some description of revisions made 
following the feedback supplied by 30 patients who completed the first version of the 
questionnaire 177. However, in general, the current review found limited evidence of 
modifications made as a result of feedback from patient interviews. Evidence from patient 
cognitive debriefing interviews (e.g. a list of actions taken as a result of patient feedback, 
concepts elicited by an item) can help confirm content validity by providing evidence that a 
concept is adequately captured and understood 99. 
Aspects of construct validity were demonstrated in some capacity for all of the PROs 
evaluated. This was achieved by the consistency of responses with a measure which is known 
to assess the concept of interest in accordance with known theory. For example, the ICIQ-
MLUTS was able to detect the expected increase in severity of urinary symptoms with age in a 
community sample 185. Several of the measures demonstrated the degree to which the scale 
did not correlate with a measure designed to assess dissimilar constructs (discriminant 
validity), or correlates with a measure that should be related (convergent validity). For 
example, the DAN-PSS-1 showed good correlation with the extensively used Madsen-Iversen 
symptom score for prostatic obstruction. The Leicester Impact Scale (LIS) was compared with 
both the Hospital Anxiety and Depression Scale and the Negative Affect Subscale of the 
Bradburn Affect Balance Scale and correlations were found to be statistically significant. It is 
important that a PRO tool is able to clearly discriminate between patients from control 
subjects. This meaningful detection of symptoms was confirmed in the DAN-PSS-1 by 
comparison of a group of men with no urinary symptoms to a group diagnosed with BPH. The 
KHQ (now the ICIQ-LUTSqol) was considered a sufficiently validated tool for this to be used as 
a reference measure for evidence of criterion validity. The B-SAQ was compared directly with 
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the symptom severity scale of the KHQ, returning high Pearson’s correlation values 180. 
Evidence of construct validity is evaluated by the FDA when considering a PRO measure, 
including criterion validity when appropriate.  
Elements of reliability (the ability for the instrument to be stable, consistent and reproducible 
over time) were assessed in all the available publications of the reviewed PRO measures. This 
property is vitally important for any PRO, particularly for one which aims to measure a long-
term chronic condition over time, either in research or clinical practice. From the FDA 
perspective these properties are essential for instruments intended for use as an outcome 
measure in clinical trials, in order to provide reliable and credible estimates of patient-
reported treatment effect 99. Internal consistency (the relationship between items) should be 
high if a measure is able to be scored as a single coherent group. This may be assessed using 
Cronbach’s α statistic, for example high level of internal consistency was observed between 
the 7 OAB-SS items (Cronbach’s α = 0.83) 182. However,  the ICSQol showed poor internal 
consistency (Cronbach’s α = 0.59) 197 demonstrating that the items, although related, should be 
considered separately. This would make the PRO unlikely to be suitable for clinical trial 
purposes due to the general desire for score comparisons. Reproducibility, the ability of a 
questionnaire to produce stable results when the condition of a patient has not changed, may 
be assessed by a test-retest study. For example, the ICSmale (ICIQ-MLUTS) was tested on a 
sub-group of 40 patients who were asked to complete another questionnaire at home within 2 
weeks of completion in clinic 185. The test-retest reliability for the ICIQ-FLUTS was also good; 
78% answered identically and 97% within one response category when administered with a 
two week interval 150. This time period between administrations should be chosen carefully to 
reflect the true condition in stable patients and avoid natural variability (for example, 
anticipated effects of the menstrual cycle) but also in order to minimise memory effects 99. 
The responsiveness of the questionnaires was evaluated in 9 of the 15 PROs included in Table 
5 and Table 6. This is the ability of an instrument’s sensitivity to detect change, and is tested in 
response to an intervention in which the patient’s state has altered with respect to the 
concept of interest. For example, the responsiveness of the DAN-PSS-1 was evaluated in 29 
patients following a prostatectomy and found a median reduction in score of 80%, 
demonstrating good sensitivity to change. The ICIQ-FLUTS (BFLUTS) was evaluated alongside a 
randomized controlled trial comparing tension-free vaginal tape with colposuspension in 344 
women with stress urinary incontinence 163. Details were documented of the modifications 
made to the questionnaire using responsiveness data evidence, including the use of factor 
analysis to understand the clustering of items to develop a suitable scoring system. However, 
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the specificity of the responsiveness data to a population of women consenting to a surgical 
trial for stress incontinence is stated as a limitation of the study. Further testing may be 
required to determine the responsiveness of the questionnaire in less severe incontinence 
groups, including those with other LUTS. Indeed, the consequences of an inability to detect 
change may be to reduce any detection of treatment effect. The extent to which the 
instrument’s ability to detect change in different patient subgroups (e.g. gender, ethnicity, 
age) should be known, in order that any differences may be taken into account 99.  
3.5 Content of selected PROs 
The full item wording was obtained for each questionnaire of interest for analysis of the 
content. Items were categorised to broader symptom concepts such as ‘daytime frequency’, 
‘intermittency’ or ‘hesitancy’. The same process was applied to the questionnaires which 
measured the impact on HRQL. The aim was to gain some insight into the symptoms, signs and 
HRQL measurement concepts and to allow comparison between the different PRO tools. An 
awareness of the content of existing PROs also serves a function of allowing the identification 
of any new concepts or symptoms which emerge as a result of the development of a more 
specific UAB PRO. The symptoms and signs for the symptom PROs could be categorised into 14 
broad concepts shown in Table 7. Although details of the items which relate to these concepts 
are not included in the tables, the items and their response options were related to the 
associated symptom frequency, severity and context. For example, ‘incontinence’ groups 
together all items which explore the frequency, type (e.g. stress, urge, enuresis, during 
physical activity) or severity of the leakage of urine. ‘Urgency’ groups together all items which 
explore the circumstance, frequency and severity in which the patient may experience 
urgency. Similarly, the PROs measuring the impact of symptoms on quality of life had items 
which could be categorised into 11 main concepts, shown in Table 8. For example, ‘journey 
planning’ covers all questions which explored the necessity to ‘carefully plan your journey’ 
around the location of toilets, or ability to travel. ‘Activities or hobbies’ includes any item 
which aims to identify any impact on hobbies, exercise and sport or other daily activities (e.g. 
housework, shopping). 
The recently developed LUTS tool 9,178 had the most comprehensive coverage of the symptoms 
with items related to 11 out of the 14 concepts in Table 7. The ICIQ-LUTSqol covered all 11 of 
the HRQL concepts categorized in Table 8. The questionnaires which are designed to assess 
overactive bladder (e.g. OAB-SS, OAB-V8, ICIQ-OABqol) have a particular focus on questions 
relating to urgency and incontinence, associated with the condition. Questionnaires for 
51 
 
patients presenting with LUTS or BPH (DAN-PSS-1, ICIQ-MLUTS, LUTS) have additional items 
associated with flow, hesitancy and straining. The I-PSS does not include some LUTS which 
have considerable burden, most notably urinary incontinence 198. The single questionnaire 
which is specific to UAB (UAB-q) has items relating to the symptoms of daytime frequency, 
nocturia, straining, sensation of incomplete emptying and retention, so evaluates no new 

















































































B-SAQ               
OAB-SS               
DAN-PSS-1               
ICIQ-MLUTS               
ICIQ-FLUTS                
ISS               
OAB-V8               
LUTSS     Information not available 
LUTS               
I-PSS               
UAB-q               
 




































































ICIQ-OABqol            
ICIQ-Nqol            
ICSqol            
ICIQ-LUTSqoL            





The evaluation of the extent of the published psychometric evidence of the selected PROs 
highlighted a plethora of questionnaires, some of which have been robustly validated. 
However, evidence of patient involvement in the initial development and refinement of items, 
aspects of reliability, and the testing of instrument responsiveness in multiple patient sub-
groups was lacking (although it is acknowledges that the latter is often the subject of ongoing 
development). The continual development of PRO measure good practice guidelines ensure 
PROs accurately capture patient-centered information for clinical practice and research, as 
well as enabling the rigorous use of tools as outcome measures in clinical trial settings. The 
new LUTS questionnaire 9,178 shows promise as the first questionnaire for the assessment of 
LUTS to be developed with published evidence of content validity according to FDA regulatory 
standards 99. 
The current review of the existing literature has confirmed that no fully validated PRO 
measures exist which have been specifically developed for the assessment of UAB. The UAB-q 
is the only available tool which specifically aims to assess the symptoms of UAB but there is no 
published evidence of its psychometric properties. A number of PROs which evaluate LUTS and 
associated HRQL to a high degree of evidenced validity were identified. The content of these 
measures was evaluated in order to gain insight into the symptoms and concepts covered by 
existing PROs in this area. Although the LUTS tool, ICIQ-MLUTS and ICIQ-LUTSqol are likely to 
capture some of the UAB symptoms and impact, these PROs were developed for a specific 
context of use. The inclusion of items, including the wording and content of the PRO measure, 
should be based on the patient-centered input of the specific population of interest. The 
understanding of the patient experience of underactive bladder is so little understood, this 
supports the qualitative exploration of this during the development phase of a PRO for UAB. In 
addition, evidence of its utility in the target population is required in order for a PRO to be 
considered a credible measure for research and clinical practice 112. From a clinical trial 
perspective, in order for a PRO measure to be used to support a labeling claim, it must be 
shown to reliably measure the concept in the patient population in which the clinical trial is to 
be conducted 99. This is also important in clinical practice where treatment decisions may rely 
on PRO evidence to reflect the patients’ perspective. In conclusion, the lack of an existing tool 
validated in the UAB target population to current regulatory standards supports the 




Chapter 4 Concept elicitation and development of the initial 
draft ICIQ-UAB 
4.1 Introduction 
The literature review in chapter 1 established that the clinical symptoms of DU are not well 
defined, although it is recognised that there is a significant clinical overlap with many of the 
symptoms experienced by patients with BOO and overactive bladder (OAB) 21. These 
symptoms include high urination frequency, nocturia, urgency, and incontinence 14,25. Other 
symptoms suggested to be associated with DU include hesitancy, a sensation of incomplete 
emptying, straining, a weak stream and persistent urinary tract infections (UTIs) 25.  
As described in chapter 3, no PRO instruments currently exist, to assess UAB symptoms and 
impacts, that would meet the standards of validation described by the FDA’s guidance for 
Industry 99. The International Consultation on Incontinence Questionnaire (ICIQ) modules offer 
a range of psychometrically robust instruments for the self-assessment of lower pelvic 
dysfunction including LUTS 199. Due to the recognised need for a new specific PRO measure for 
UAB, the Bristol Urological Institute (BUI) initiated the development of a new ICIQ module, the 
ICIQ-UAB, with the aim of capturing the patient reported symptoms and impact of the 
condition UAB, for eventual use as an outcome measure in future clinical trials and in clinical 
practice. 
This chapter describes the consultation with an expert clinical panel of experts and the 
exploration of the patient experience of UAB by semi-structured interviews with patients. In 
addition to the literature and PRO instrument review described in chapters 1 and 3, this 
informs item generation for the developmental instrument and supports content validity 99,114. 
As data is collected, the developmental conceptual framework and quality of life components 
of the disease model are revised. The chapter then describes the rationale for the choice of 
items, response options, format, wording and recall period and presents the first version of the 





4.2 Clinical review panel 
A nine-membered clinical panel consisting of one nurse, two clinical scientists and six 
urologists (Appendix 1) were recruited for their experience in urodynamic assessment from 
different sites across 4 NHS trusts over the UK. All those were invited to be on the panel 
agreed to be involved. Each member was consulted on hypothesised concepts of relevance to 
UAB. A cross-section of health professionals were chosen to represent different perspectives 
on the condition: 
Urology Clinical Nurse: Specifically, a nurse providing assistance with catheter use, as they will 
have significant contact with those patients suffering with retention. 
Clinical Engineer: This role has a functional knowledge of urodynamic assessment and 
diagnosis. 
Urology Clinician & Senior Urology Clinician: This role benefits from an in-depth knowledge of 
urological conditions, developed over a number of years. 
A pragmatic approach was used to collect the opinions from the clinical experts. Initially, a list 
of hypothesized concepts of relevance derived from the literature review were proposed by 
email, whereupon they provided feedback at the level of ‘essential’, ‘desirable’ or ‘not 
required’. This feedback was used to generate the initial interview schedule and conceptual 
framework. Additional comments or suggestions for items were also recorded and 
incorporated into the development of the initial conceptual framework. Members of the 
clinical panel were then involved in the generation of the individual items before the cognitive 
interviewing.  
Table 9 shows that most clinical panel members considered the number of urinations after 
waking (before sleep), the number of urinations after sleep (before waking), the strength of 
flow rate, the use of straining to start and/or to continue voiding, intermittency, post-
micturition dribble, the sensation of incomplete emptying, the awareness of leakage, and the 
sensation of urgency as ‘essential’ or ‘desirable’ to include in a PRO instrument for the 
assessment of UAB. Green shading indicates when there was consensus and amber when 






Table 9. Clinical panel rating of proposed symptoms and impacts to include in the ICIQ-UAB. 
Item Essential Desirable Not required No Entry 
Symptom Component- 
Number of urinations after 
waking, before sleep 
4 2 1 1 
The clustering of 
urinations, for example in 
the morning 
0 2 5 1 
Number of urinations after 
sleep, before waking 
3 3 0 2 
Strength of flow rate 6 1 1 0 
The use of straining to 
start voiding 
6 1 1 0 
The use of straining to 
continue voiding 
6 1 1 0 
Intermittency 6 1 0 1 
Hesitancy 6 0 1 1 
Post-micturition dribble 3 3 1 1 
Sensation of incomplete 
emptying 
5 2 1 0 
Is the individual aware of 
leakage, when it occurs? 
0 4 3 1 
Does the individual 
experience the sensation 
of urgency? 
2 2 3 1 
How long after the first 
desire to void, before 
feelings of urgency, 
measured in...? 
1 0 6 1 
Impact components 
Sleep/Rest 4 4 0 0 
Physical activities 3 2 3 0 
Social impact 3 5 0 0 
Psychological wellbeing 2 5 1 0 
Planning & task 
management 






4.3 Preliminary conceptual framework 
The expert clinical review panel, literature and instrument review (chapters 1 and 3), informed 
the development of a preliminary conceptual framework (Figure 3). This defines the concepts 
measured by the instrument in a diagram which presents a description of the relationships 
between items, domains (sub concepts), in the PRO instrument 99. The conceptual framework 
informed the interview guide for the initial qualitative concept elicitation interviews. 
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4.4  Concept elicitation  
4.4.1 Aims and objectives  
Qualitative interviews with patients who had been diagnosed with DU were used to elicit the 
patient experience of associated urological symptoms and their impact on day-to-day life. 
Individual interviews were chosen over focus groups as they are better suited to topics which 
are personal or sensitive in nature or when a discussion requires particularly detailed 
experiential information on a topic which is little understood 112. Specific objectives included: 
 The documentation of the patient reported signs, symptoms, and impacts in patients 
with urodynamically confirmed DU. 
 The exploration of patients’ words to describe the severity, frequency, duration and 
impact of patient reported signs or symptoms. 
4.4.2 Sample size  
It was anticipated that 40 interviews would be required in order to achieve sufficient concept 
saturation. This sample estimate was based on previous experience and the literature 
9,121,124,125. This is a relatively large sample for a qualitative interview study, but was considered 
appropriate to allow the exploration of a relatively heterogeneous sample. As patients 
diagnosed with DU often present with other co-existing urological conditions, those with co-
existing DO, SUI, urodynamic stress incontinence (USI), bladder outlet obstruction in the 
equivocal range (BOO-E), and BOO, were also interviewed.  
4.4.3 Site selection and recruitment 
Patients were recruited at the Bristol Urological Institute (BUI), Southmead Hospital, Bristol. 
This is a tertiary referral centre with increased access to patients with a wide range of 
symptoms. The BUI also has a unique database that contains detailed urodynamic data for all 
patients who have attended the site over the last 30 years, giving a large pool of potential 
patients.  
Patients were identified based on their historical urodynamic records, accessed through the 
Clinical Information System Suite at the North Bristol NHS Trust (NBT). The Urodynamic clinic’s 





4.4.4 Inclusion and exclusion criteria 
Identification of potential patients for recruitment to the study was according to the following 
inclusion criteria: 
 Male and female patients, 18 years old or older 
 Registered at Southmead Hospital, Bristol  
 A confirmed urodynamic diagnosis of DU within the last eighteen months 
 Able to speak, read, and write in English 
 Willing and able to participate in a face-to-face interview session.  
The following were excluded: 
 Patients with disorders interfering with the study conduct (such as some psychiatric 
disorders, malignant disease) 
The pressure flow study (PFS) parameters used to identify potential patients were the bladder 
contractility index (BCI) and bladder outlet obstruction Index (BOOI) for males, and detrusor 
pressure at maximum flow (pdetQmax), and maximum flow rate (Qmax) for females. Patients were 
categorised in the diagnostic groups to facilitate the analyses of the data, as detailed in Table 
10. 
Table 10. Diagnostic group inclusion criteria. 
DU (only) 
 Patients with a confirmed diagnosis of DU on urodynamics and a 
diagnosis of no other co-existing urological conditions 
Males:      BCI <100 
                    BOOI <20 
Females:   pdetQmax <20 
cmH20 
                   Qmax <15ml/s 
DU + mild DO 
 DU + co-existing mild DO (based on investigator urodynamic 
assessment and patient records) 
DU + Mild SUI/USI 
 DU + co-existing mild USI/SUI (based on investigator urodynamic 
assessment and patient records) 
DU + BOO-Equivocal (males only) 
 BCI <100, BOOI ≥20–<40 
DU + BOO (males only) 
 BCI <100, BOOI ≥40 
BOO (males only) 




Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 
calculated by BOOI=pdetQmax-2Qmax. 
4.4.5 Concept elicitation study process 
Patients who met the inclusion criteria were sent a postal invitation, the patient information 
sheet (Appendix 2), a stamped addressed envelope, and a form to express their interest to 
take part. Patients were given the option of having their interview at their home, in the 
hospital, or over the telephone. In each setting, the interview was conducted in a room which 
minimised the risk of interruption and maintained the privacy of the patient. For telephone 
interviews, recorded verbal consent was taken and the interview recorded whilst on 
speakerphone in a private room.  
4.4.6 Interviewers and quality assurance process 
The first 44 interviews were conducted by a study researcher, previously assigned to the 
project. The author then assumed full responsibility for the remaining interviews and analysis. 
Transcripts were coded on an ongoing basis to inform study progression. Regular meetings 
between the project supervisor and the interviewers were held in order to discuss the 
interview process, content and technique. Upon completion of all interviews, all transcripts 
were independently analysed by the author. 
4.4.7 Interview guide 
The interview guide passed through four iterations, comprising of minor additions to allow 
further exploration of emerging concepts in subsequent interviews. The final version is 
included in Appendix 3.  Open ended questions were favoured such as ‘Which of your 
symptoms do you find most bothersome?’, instead of specific probes, to elicit more 
spontaneous responses.  
4.4.8 Ethics and informed consent 
The study was conducted with favourable opinion from the Southmead Research Ethics 
Committee (REC), now the Bristol South REC: REC reference 087/99. For face-to-face 
interviews (n=20) the patients read and signed an informed consent form (Appendix 4). For 




whereupon they provided a verbal response which was recorded at the beginning of the 
interview.  
4.4.9 Data management 
All interviews were audio recorded and transcribed verbatim. Transcripts were checked for 
accuracy using referral to the original audio recording and analysed using NVivo v10, a 
qualitative data software package. Files were stored on the NBT secure server and all patient 
data was anonymised using a unique study identifier. A hard copy of contact details and 
unique identifier, along with a case report form were kept in a locked office on NBT premises. 
4.5 Concept elicitation results 
4.5.1 Sample demographic and urodynamic characteristics 
In total, 44 patients with DU were interviewed; 32 of which were male and 15 female. All 
patients were White British. The age range was 27 to 88 years, with a mean of 64 years. The 
patient characteristics summarised by diagnostic group are given in Table 11. Twelve patients 
provided information regarding educational background. These patients came from a variety 
of educational backgrounds (ranging from left school at 16 or younger, college or university 
educated) and occupations (manual, service and professional). In addition to the 44 patients 
with DU, three patients with BOO were interviewed in order to explore possible differences in 
symptoms experienced by patients with DU and patients with BOO.  The number of invited 
participants was not recorded at this stage (by the previous researcher who conducted the 
concept elicitation interviews). However, reasons given for any non-participation were 
primarily that the patient was non-contactable by telephone or post. Although the non-
recruitment of any ‘true decliners’ is acknowledged as a limitation, the intention for this study 
was to elicit the patient experience, so any decliners were considered unlikely to significantly 







Table 11. Summary of demographic and clinical characteristics. 








DU + DO 
DU + SUI 
DU + BOO-E 







Mean age and range 
(years) 
64 (27-88) 59 (27-88) 68 (38-87) 
Gender, male n (%) 29 (66) 12 (63) 17 (68) 
Intermittent self-
catheterisation n (%) 
(Historical or current) 
23 (52) 10 (53) 13 (52) 
PVR >30ml* n (%) 34 (77) 14 (74) 20 (80) 
PVR >30ml* (ml) (median 
and IQR) 
199 (100-492) 335 (119-492) 170 (100-360) 
BCI (median and IQR) 62 (49-79) 62 (48-82) 62 (50-77) 
BOOI (median and IQR)** 18 (8-28) 15 (6-18) 25 (9-41) 
pdetQmax (cmH20) (median 
and IQR) 
25 (12-35) 24 (12-29) 26 (12-36) 
Qmax (ml/sec) (median and 
IQR) 
8 (6-10) 8 (6-11) 6 (5-9) 
*In the absence of any evidence base for the lower limit of a ‘significant’ PVR we chose >30mls. 
**Males only 
Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 
calculated by BOOI=pdetQmax-2Qmax, Post Void Residual (PVR).  
 
4.5.2 Qualitative coding  
Following familiarisation with the data, the transcripts were inductively coded 134 to reflect the 
content of the interviews. This involved identifying sections or phrases of text and categorising 
quotes into an ongoing coding framework. Data collection and analysis continued 
concurrently, using a constant comparison approach informed by grounded theory 133. Any 
concept or code that was considered spontaneously reported in the interview (without 
prompting by the interviewer) was coded separately. Towards the end of data analysis and 
during reporting, concepts were further defined by known urological symptoms (e.g. 
‘incontinence’, ‘nocturia’, ‘straining) 
200,201




theoretical context according to the principles of thematic analysis 
126
. It is acknowledged that 
the reliability of the findings is dependent on the continual reflexive appraisal by the 
researcher and referral to the original data during the analytical process 127. The themes and 
sub-themes were backed up by multiple quotations from different respondents wherever 
possible, in order to provide alternative perspectives of the same contextual reality and to lend 
credibility to the conclusions. 
4.5.3 Saturation of concept 
The transcripts of patients with DU without co-existing urological conditions were analysed 
first, in the order in which they had their interviews. This was so the developing codes were 
defined primarily by the diagnostic group of primary interest. Data saturation was achieved by 
the first 19 interviews with DU patients (Table 12). The additional groups with co-existing 
urological conditions were then analysed to achieve full exploration among those who 
represented potential respondents. There continued to be a small number of new codes from 
these groups. However, upon inspection these were considered to be sub-concepts more likely 
to be related to the co-existing conditions. Additional interviews were unlikely to result in 



















1 P2 DU 22 
2 P11 DU 24 
3 P12 DU 20 
4 P13 DU 14 
5 P14 DU 5 
6 P15 DU 2 
7 P16 DU 9 
8 P17 DU 7 
9 P18 DU 2 
10 P20 DU 4 
11 P21 DU 5 
12 P22 DU 8 
13 P23 DU 0 
14 P32 DU 2 
15 P34 DU 1 
16 P35 DU 2 
17 P36 DU 1 
18 P37 DU 0 











20 P1 DU & DO 2 
21 P3 DU & DO 1 
22 P6 DU & DO 4 
23 P10 DU & DO 2 
24 P19 DU & DO 1 
25 P30 DU & DO 0 
26 P33 DU & DO 2 
27 P38 DU & DO 0 
28 P4 DU & SUI 0 
29 P5 DU & SUI 0 
30 P7 DU & SUI 1 
31 P8 DU & SUI 2 
32 P9 DU & SUI 3 
33 P26 DU & SUI 0 
34 P29 DU & SUI 2 
35 P24 DU & BOO-E 1 
36 P25 DU & BOO-E 0 
37 P27 DU & BOO-E 0 
38 P28 DU & BOO-E 1 
39 P31 DU & BOO-E 0 
40 P40 DU & BOO 1 
41 P41 DU & BOO 0 
42 P42 DU & BOO 0 
43 P43 DU & BOO 1 
44 P44 DU & BOO 0 
45 P45 BOO 0 
46 P46 BOO 1 
47 P47 BOO 0 







Twenty distinct lower urinary tract symptoms, signs or experiences were described by the 
patients. For each, a qualitative description of the reported patient experience with supportive 
patient quotes from the interviews is given. If an ICS urological definition exists for the 
described symptom then this is included within the description. The number of patients who 
experienced each symptom is given separately for the DU sample, and for those with co-
existing urological conditions. 
Daytime frequency of urination  
The definition provided by the ICS for increased daytime frequency of urination is ‘the 
complaint by the patient who considers that he/she voids too often by day’ 200. Most patients 
from the DU sample (13/19) and slightly less than half of those with co-existing urological 
conditions (12/25) reported high urinary frequency, often spontaneously, and as one of their 
most bothersome symptoms. 
P22: “it’s the keep having to go to the toilet all the time” 
P34: “Just sort of constantly going back and to and from the toilet sort of it’s just sort of a 
pain really” 
 However, a small number in the DU sample (n=3/19) described either ‘normal’ or low 
frequency of urinations (once or twice a day).  
P11: “No I can go quite long periods without going.” 
Although for most patients there was no difference in time of day, some patients (n=4/19 in 
the DU sample) described having to urinate more often in the morning or many times in short 
succession immediately after rising from bed. 
P16: “When I wake up I have a cup of coffee and then go again and then again and then 
maybe again.”  
Hesitancy 
The definition of hesitancy provided by the ICS is ‘an individual describes difficulty in initiating 
micturition resulting in a delay in the onset of voiding after the individual is ready to pass 
urine’ 200. This was a common symptom reported spontaneously by most patients of either 
gender in the DU sample (13/19) and amongst the other groups with co-existing urological 




the flow of urine would start. The process was a combination of relaxing and ‘getting into the 
right frame of mind’ in order to facilitate the onset of urination. 
P11: “You stand there you can’t go. You take a while to go.”  
P11: “It seems to travel a long distance before it comes out and I stand there sometimes 
and I think I’ve got to concentrate for it to come out.” 
The delay for most patients was usually a few seconds but for some individuals there could be 
a wait of up to twenty minutes.  
Researcher: “How long do you have to wait sometimes?” 
P35: “Sometimes twenty minutes.” 
Urinary incontinence 
The ICS definition of urinary incontinence is ‘the complaint of any involuntary leakage of urine’ 
200. This symptom occurred in a few of the DU patients (5/19) but was not often mentioned 
spontaneously in this group. Circumstances of incontinence in the DU group was generally 
when they felt they were ’cut short’ or that they ‘did not quite make it in time’ to the toilet. 
Leakage described in the DU sample was otherwise reported as occurring more occasionally 
and in ‘small amounts’. 
P35: “Sometimes I do and sometimes it leaks and I’ve had a few leakages that’s my fault 
though for trying to hold it in too long.” 
Episodes of incontinence were often more severe and frequently occurring in the other groups 
with co-existing urological conditions (15/25), and particularly in patients with DO and SUI. The 
impact and level of ‘bother’ described by patients experiencing incontinence was often very 
high.  
P7: “I don’t feel like I need to go it just literally it’s involuntary if you know what I mean it 
just kind of happens. I’ve got no control over it whatsoever.” 
Nocturia and/or nocturnal voids 
Nocturia, the complaint that the individual has to wake at night one or more times to void’  200 
was a common symptom in the DU only group (15/19) and the group with DU and co-existing 
urological conditions (19/25). It was frequently talked about spontaneously as one of their 
most bothersome symptoms.  
P20: “Yes I used to wake up, well I still do wake up a couple of times at night to go to the 
toilet and I just presume this is perfectly normal.” 





The number of nocturia episodes was variable between patients, one DU patient described 
having to get up to urinate as many as nine times a night, but most described getting up out of 
bed between one and four times a night to pass urine. Some would know when and how many 
‘almost to the minute’, however for others the number of times per night showed day to day 
variability. 
P22: “One night it can be twice and another night it can be five times you know, you just 
don’t know.” 
Sensation of incomplete emptying 
Patients described the feeling that urine remained in the bladder soon after urinating, often 
resulting in having to return to the bathroom again within a short period of time. Although not 
often mentioned spontaneously, this symptom was often present in all groups (8/19 in the DU 
group and 11/25 in those with co-existing urological conditions.  
P34: “Sometimes it’s just I know instantly that in a couple of well, 10 minutes, I’m gonna 
need to go again.” 
Some patients described their tendency to wait in the bathroom or continue sitting down on 
the toilet for a few minutes after urinating in order to empty their bladder as much as possible.  
P3: “You’ve got to sit there a bit longer, like, because you know you’re going to do a bit 
more.” 
Others suspected they were not emptying their bladders properly each time they urinated, 
due to voiding only small volumes per urination. 
P11: “When I do pass it’s not a lot. It’s not a tremendous amount.” 
Slow stream 
The strength of flow is clarified by the ICS as ‘his or her perception of reduced urine flow, 
usually compared to previous performance or in comparison to others’ 200. This was a very 
common symptom with both male and female patients describing, often spontaneously, a 
‘slow’ or ‘weak’ flow with an associated prolonged urination time (13/19 in the DU group and 
15/25 in those with co-existing urological conditions).  
P39: “I can pass urine with a reasonable stream at sometimes and sometimes it's sort of 




Some male patients described the flow as coming out as a ‘vertical drop’ or just going ‘straight’ 
down.  The flow rate could also be variable during the process of passing urine and dependent 
on the fullness of the bladder or strength of the urge to go.  
P22: “Sometimes it start of it slow and then it suddenly becomes faster and other times it 
will come out fine and then slows right down.” 
Reduced sensation of bladder fullness  
A few of the DU patients (2/19 and 3/25 in the groups with co-existing urological conditions) 
would feel empty after urinating but nevertheless could not be sure that they had fully 
emptied the bladder. There was a perceived lack of sensation of the fullness of the bladder 
which caused them to doubt whether they had emptied properly, despite not having any 
sensation of a residual.  
P35: “Yeah it does feel like I have emptied it yeah but I don’t get- it’s difficult to tell 
because I don’t get the sensation of full or not full” 
Acute retention  
Some patients experienced retention: ‘patient is unable to void without catheterisation’ 200 
(4/19 in the DU only group and 2/25 in the group with co-existing urological conditions). This 
was the clinically termed ‘acute’ retention pertaining to the hospitalisation of a patient who is 
unable to urinate at all, and the insertion of a catheter is required to drain the bladder. In 
these cases, it was often volunteered as the event for which they first sought medical 
assistance for their urological symptoms. 
P35: “Can’t go to the toilet on full bladder can’t wee without running the taps trying 
everything sitting on the toilet showers things like that to try and help but nothing would 
come out.”  
Temporarily unable to pass urine 
For some patients (4/19 in the DU group), there were infrequent circumstances in which they 
were unable to voluntarily pass urine, such as whilst standing at a urinal, during the night, or 
when asked to pass urine by a medical professional. These patients reported that they would 
usually return to the bathroom a few minutes later to try again. 
P2: “I mean sometimes, you know, you go standing up, no problem at all, everything’s 
fine. Other times, I could be in there, stood for half a minute or two, nothing. I think, well, 
alright, I’ll go and do summat and I’ll come back a minute later, still standing up and I can 





The ICS defines straining as ‘The muscular effort used to initiate, maintain or improve the 
urinary stream’ 200. A large proportion of the DU group (14/19) and 9/25 in the groups with co-
existing urological conditions reported, often spontaneously, the  ‘pushing’, ‘straining’ or 
‘squeezing’ when starting, during or finishing urination. Straining was generally a behaviour 
which was a consequence of a number of other symptoms. Patients would strain to start 
urination if there was a delay (hesitancy), to maintain their flow or in order to restart 
urinations when it stops (due to an intermittent stream), or to try and ‘push’ any perceived 
remaining urine out.  
P12: “There would be very little natural flow and the majority of the flow would be as a 
result of having to strain.” 
P6: “I do try to squeeze every last drop out so I don’t have any accidents.” 
Intermittency 
Intermittency is defined as ‘when the individual describes urine flow, which stops and starts, 
on one or more occasions during micturition’ by the ICS 200. Patients described the flow of their 
urination not being continuous with multiple breaks of a few seconds. This was a common 
symptom in the DU sample (11/19) and occurred in the groups with other co-existing 
urological conditions in 6/25 of the interviews.   
P39: “It will take several starts and stops for it to get rid of that particular bladder full” 
Post-micturition dribble 
The ICS defines dribbling as when an ‘individual describes the involuntary loss of urine 
immediately after he or she has finished passing urine, usually after leaving the toilet in men, 
or after rising from the toilet in women’ 200. Patients in the DU sample (7/19 and 10/25 in the 
groups with other co-existing urological conditions) described the leakage of a small amount or 
‘a few drops’ of urine shortly after urinating and having got dressed. This symptom was 
described as bothersome as patients worried about smell or having a small damp patch on 
their trousers. Only one female patient mentioned this as a bothersome symptom in the 
sample. 
P39: “You think you've shaken everything off get back in to bed and there's just one drop 





This is a symptom which is defined as ‘a sudden compelling desire to pass urine which is 
difficult to defer’ by the ICS 200. Patients described the sudden onset of a strong desire to 
urinate which they were unable to ignore and had to ‘rush to the toilet’. Patients in every 
group experienced urgency in accordance with this description (11/19 in the DU group and 
11/25 in the groups with other co-existing urological conditions).  
P12: “It’s almost coincidental the trigger in your mind; ah I think I need to go to the loo 
within seconds its saying let me get there quickly” 
Lower urinary tract pain 
Bladder pain as defined by the ICS ‘is felt suprapubically or retropubically, usually increases 
with bladder filling and may persist after voiding’ 200. Several of the DU patients (6/19) and 
5/25 in the groups with co-existing urological conditions described pain but there was variation 
in their accounts of the type, source and level of pain experienced. When prompted, patients 
described the location or origin of the pain as ‘across the stomach’, or in the ‘pelvic’ or ‘kidney’ 
area. The level of pain described ranged from sharp and ‘excruciating’ to mild ’discomfort’.  
P36: “Terrible- it’s terrible I normally get sharp sharp pains if I have to hold it in I gotta go 
straight away.” 
P18: “It’s usually when I’ve got a full bladder and then it hurts when I’ve emptied the 
bladder.” 
Spraying 
A few male patients (4/19 in the DU group and 5/25 in the groups with co-existing urological 
conditions) reported a lack of control over the direction of their urinary stream. This included 
spraying or involuntary ‘sideways’ splitting of the stream. Various strategies were reported to 
reduce this inconvenience including four patients regularly urinating into a jug and several men 
choosing to sit down to avoid ‘splash’. No female patients reported this as a symptom. 
P35: “I seem to splash a lot when I go I do spray so it doesn’t come out in a straight line it 
sometimes goes a bit sideways” 
Associated bowel symptoms 
All patients were asked if they had any bowel difficulties and a small number of both male and 
female patients (3/19 in the DU sample and 5/25 in the groups with co-existing urological 
conditions) experienced problems in this area. Two female patients had noticed that when 




P13: “I was going to say my bladder is massively affected by my bowel. So the more 
constipated that I am it brings all of my bladder symptoms out.” 
The other patients who experienced bowel problems did not necessarily relate the process of 
opening their bowels to their urinary difficulties. 
4.5.5 Impacts  
The impact of symptoms reported by patients on their day to day lives ranged from extremely 
severe to very little. Several of the patients described how they adapted their lives around 
their condition so that any impact was minimised and asserted that they had become ‘used to 
it’ due to the chronic nature of their condition (5/19 in the DU group and 7/25 in the groups 
with co-existing urological conditions). Nonetheless, patients described different aspects of 
their lives which could be inconvenienced or made impossible by the ramifications of their 
symptoms. 
Planning life around location of toilets 
Several of the symptoms, in particular high frequency of urination and urgency led to their 
adjustment of their plans around the location of toilets (13/19 in the DU group and 14/25 in 
the groups with co-existing urological conditions). Patients reported that when leaving the 
house they needed to plan toilet stops for long journeys, or to know in advance the location of 
toilets at the place of destination. Others mentioned the considerable impact that their 
reliance on the location of toilets had on planning holidays, the adaptations to their work life, 
physical activities, and aspects of their social lives.  
P34: “Well I’m just constantly being aware of where my surroundings sort of making sure 
there’s a toilet nearby if I’m going to a meeting I’ll go before and then sometimes during 
or straight afterwards” 
P12: “I always have to sort of have a plan in my mind as to where we’re going to go where 
there are toilets that I can use. Whereas I never used to give it a thought.” 
Impact of nocturia and/or nocturnal voids  
Tiredness, fatigue and having to have naps in the middle of the day as a result of ‘broken sleep’ 
were commonly reported by those patients who suffered from nocturia. This had a significant 
effect on quality of life for many of the patients (7/19 in the DU group and 5/25 in the groups 
with co-existing urological conditions).   
P21: “I really would crave a decent night’s sleep” 
P13: “My sleep as such is rubbish I’m always fatigued... I rarely feel full of energy or not 




P36: “Then going to bed for a couple of hours this is what I’ve had to do during the day 
just to compensate getting not enough sleep at night.” 
Feelings about self 
Some of the patients described the effect of their condition as making them ‘feel old’, less 
motivated to do things, and the negative effect on self-esteem and confidence (3/19 in the DU 
group and 11/25 in the groups with co-existing urological conditions).  
“P18: Well it makes me feel old” 
“P6: Well I suffer a bit with depression for a while and it was making it worse” 
However, most of the patients who gave answers to this in the DU group did not consider their 
condition to affect the way they felt about themselves. It was reported they had adapted their 
lifestyles and psychological approach to accepting their condition and hence their symptoms 
had minimal impact. 
P4: “I don’t worry. I mean if you let it get you down it will get you down. But I don’t. You 
know I mean you’ve got to just carry on and think well, there are other people worse than 
me.” 
P7: “I’ve come to terms with it a bit more now.” 
Embarrassment 
Situations which caused patients embarrassment were mentioned spontaneously as a 
demonstration of the effect and inconvenience that their urinary symptoms could have on 
their lives (4/19 in the DU sample and 7/25 in the groups with co-existing urological 
conditions). Typically this was due to their high frequency of urination or length of time 
required in the bathroom. Several male patients mentioned their reluctance to use urinals due 
to hesitancy or poor flow.  
P17: “I’m a bit embarrassed about saying excuse me I just need to go to the toilet again 
you know” 
P12: “A young boy came in emptied his bladder and by the time he’d finished and gone I 
hadn’t even started and I became a bit embarrassed by it by that situation because I was 
just stood there doing nothing” 
Fluid intake 
The monitoring of their fluid intake was often offered spontaneously as an adaptive strategy 
for many of the patients in order to minimise the effect of their urinary symptoms. This could 
be either the type of drink or volume and was particularly in relation to alcohol or caffeinated 
drinks which many perceived as exacerbating their symptoms (8/19 in the DU sample and 7/25 




ability to partake in certain social situations and was part of the general inconvenience and 
effect that their urinary symptoms had on their lives. 
P12: “I deliberately avoided taking any fluids, which made me at times feel quite 
uncomfortable dehydration and I thought this is getting silly and I need to drink more 
fluids particularly on a day like today you know where you could dehydrate.” 
Impact on family and friends including sex-life 
This was primarily the impact on a partner of having to get up multiple times during the night.  
However, others intimated that they felt that symptoms put up a barrier with family members 
as they found it difficult to talk about their symptoms, effect of low mood on relationships, and 
the pragmatic inconveniences on others of having to be in close proximity to a toilet (5/19 in 
the DU sample and 5/25 in the groups with co-existing urological conditions). 
P16: Well I think over the years I just got used to it; its fine, but I think my husband 
because I wake him up getting up and up. 
A question about difficulties of a sexual nature was not included in the interview guide. 
However, most of the patients who talked about this described no effect on their sex life or 
that it was no longer an important part of their lives. However, a small number of patients 
(1/19 in the DU only group and 3/25 in the DU with co-existing urological conditions group) 
talked about their difficulties in this area and the associated impact on their intimate partners. 
This was of considerable impact for the few that mentioned these issues. 
P29: “Yeah if you love your wife you want to sort of physically show that and I can’t now 
of course.” 
 
4.5.6 Specific groups 
Catheter use 
The majority of patients in the DU group (10/19) and 13/25 in the groups with co-existing 
urological conditions were currently self-catheterising or had done so in the past. There were 
varying reports of the impact on daily life of catheter use. Some described it as very 
inconvenient and uncomfortable whilst for others it enabled them to continue with their lives 
without being hampered by the effect of their urinary symptoms. Some patients reported self-
catheterising sometimes every time they urinated so up to five times a day. Others would only 




catheterising at least once a day but not every time they urinated. One patient, who 
performed intermittent self-catheterisation, described some relief of her storage symptoms 
(particularly nocturia).  
P23: “One of the things self-catheterisation did was that I could go for quite a long period 
without having to go to the loo. But now I'm having to go what I would say is more 
normally and I'm not aware that I've got any residual or anything like that and I think I'll go 
maybe maximum twice in the night maximum sometimes not even once” 
Urinary tract infections 
Many of the patients mentioned that they had experienced urinary tract infections (UTIs) (8/19 
in the DU group and 9/25 in the groups with co-existing urological conditions). The impact on 
lifestyle and level of bother described was very high when suffering with an UTI and was often 
mentioned spontaneously without prompting. Urinating was extremely uncomfortable and 
frequent, with often cloudy or ‘smelly’ urinations, with some patients having a noticeable 
effect on their cognitive function.  
P23: “What I did get was a certain feeling of feeling unwell and irritable and more or less 
um unable to cope basically.” 
P2: “The other thing about it, as well, is all the infections you get whilst that’s going on, 
because that is a nightmare as well, because it’s agony.” 
Bladder outlet obstruction 
The symptoms the three patients with BOO reported overlapped with those of DU patients. 
This included the main symptoms of high frequency, nocturia, hesitancy, intermittency, 
nocturia, and slow flow. One patient reported straining towards the end of urination; another, 
however, found that straining did not help with flow: 
P46: “Well I do um although I've found I've learnt the opposite is the best way to try and 
relax rather than strain” 
Two of the BOO patients mentioned pain around the prostate area or in the penis as 
particularly bothersome: 
P46: “The one that bothers me the most is the acute pain get in my prostate gland or in 
that in that sort of area behind my um behind my testicles by my anus it's that sort of area 
that that's because that is acutely uncomfortable acutely painful and coupled very closely 





4.6 Discussion  
The findings demonstrate a comprehensive patient-centered account of the symptoms, signs 
and impact of UAB, elicited from a large purposive sample of male and female patients with a 
primary diagnosis of DU. The patient reported experience of UAB has been revealed to be a 
complex myriad of storage and voiding symptoms. These findings provide the basis for 
essential evidence of content validity for the ICIQ-UAB. 
The voiding symptoms of a slow stream, hesitancy and straining were reported by the majority 
(over 50%) of the patients in the sample. The flow rate was usually described as reduced, and 
in some individuals could be very severe and bothersome. A delay before urinating (hesitancy) 
could last for a few seconds to several minutes, dependent on the individual and the context.  
The symptom of straining (to initiate, maintain or finish urination) is of particular note as it was 
particularly well represented in the DU (only) group and is not currently included in the 2015 
symptomatic definition 14. These classic voiding symptoms are consistent with a weak bladder 
contraction and are in accordance with symptoms associated with DU in the literature 15,19,21,25. 
Other voiding symptoms including intermittency, spraying (in men only), and urinations of a 
small volume per void were also elicited in several of the patients. 
The storage symptoms reported by a large proportion of the patients included nocturia, 
increased daytime frequency, urgency and incontinence. These symptoms were key to the 
patient reported UAB experience, with a high prevalence of spontaneous reporting and often 
severe associated bother. Nocturia was the most commonly reported overall symptom as most 
patients described having to get up at least once in the night to urinate. Daytime urinary 
frequency was described by patients as being symptomatically bothersome in both low and 
high urinary frequencies. However, the higher prevalence and severity of incontinence in the 
groups with co-existing DO and SUI suggests that this symptom may be more related to these 
co-existing condition rather than underlying DU. The underlying aetiology of nocturia is also 
known to be complex, and  may be more often a consequence of health or behavioural factors 
unrelated to lower urinary tract dysfunction 47,48.  
A number of postmicturition symptoms including a sensation of incomplete emptying, the 
need to immediately re-void, and dribbling were frequently reported in the sample. A few 
patients described a perceived reduction in sensation of the fullness of the bladder, which also 




patients perceived an association with bowel issues and the severity of their symptoms. A 
feeling of incomplete emptying, absent or reduced sensation, bowel straining and a feeling of 
incomplete bowel emptying has been linked to DU patients by a recent database study of DU 
patients 21. The majority of the participants had a post void residual (77% had a PVR of >30ml). 
Perhaps as a result, there was a high proportion of patients who were historically or currently 
self-catheterising and experienced UTIs in the past, including some who had experienced acute 
retention episodes. Lower urinary tract pain was reported by a minority of patients but the 
accounts were variable with regard to the type, source and level of pain experienced, 
suggesting a number of possible aetiologies. 
Previous qualitative research into the impact of LUTS supports the findings that there can be a 
broad impact on patient’s lives associated with these symptoms 9,49,50. Disruption to sleep due 
to waking several times in the night and the lifestyle inconveniences caused by increased 
daytime urinary frequency were particularly apparent in the current study. The requirement to 
plan ahead around the location of toilets, detrimental effect on social life, embarrassment in 
certain situations and knock-on effect on self-esteem and confidence are supported by other 
qualitative studies in male patients with LUTS 50,51. The inconvenience of self-catheterisation 
and impact of urinary tract infections also had a significant effect on quality of life for some 
patients. Incontinence, although more associated with patients with DU and co-existing DO or 
SUI, was often very bothersome with an associated effect on aspects of quality of life. 
However, many of the UAB patients also felt they were able to manage their symptoms to 
minimise the impact on their lives, as also documented in Glover et al (2004).  
The necessity for the development of non-invasive tests for DU has been highlighted by 
previous studies 15,20. The distinction between DU and BOO is of particular interest, as 
corrective surgery for voiding LUTS may be of little benefit for DU patients 203,204. The current 
study did not identify any clear unique symptoms that may be attributed to UAB and the 
presence of co-existing urological conditions and associated overlap of symptoms in the 
sample further complicates diagnosis. The ICIQ-UAB instrument is intended to be an outcome 
measure rather than a diagnostic tool. However, recent research which showed differences in 
relative prevalence of symptoms in DU and BOO patients is encouraging for further research 
into the development of scoring algorithms to detect DU severity 21. The combined use of the 
PRO tool and other non-invasive techniques such as ultrasonic measurement of the detrusor 




Strengths and limitations 
A strength of this study was that all patients were clinically verified to have a primary diagnosis 
of DU by urodynamics, confirming their likely status as patients with UAB. Although a 
qualitative study design has many advantages, it does not include the corroboration of 
reported findings with objective clinical measures (e.g. bladder diaries). For this reason, any 
indications of prevalence or severity of symptoms should be interpreted within the 
appropriate subjectivity of their context. Indeed, the study is not intended to produce 
representative epidemiological data but to elicit the overall patient experience of UAB. 
Although the patients interviewed were all White British, further interviews are described later 
in the thesis with patients from the US and Japan. These will explore potential differences in 
how patients describe the UAB experience from other cultures and ethnicities. Any further 
concepts elicited as a result of these interviews will increase our understanding of the 
condition and inform culturally adapted versions of a PRO instrument for its assessment. 
4.7 Development of the draft ICIQ-UAB v1 
The qualitative interviews represented progress in our understanding of how the clinical 
diagnosis of DU manifests as symptoms, by a thorough exploration of the lived experience of 
patients. This knowledge informed the following update of the preliminary conceptual 







4.7.1 Updated conceptual framework 
    Symptoms and signs 
of UAB and impact on 




         
  Symptoms       Signs  Impact 
 








    




































































 Planning life around 














Careful about fluid 
intake 
 
Family and friends 
  





4.8 Instrument development and item selection  
Layout 
The layout of the initial draft ICIQ-UAB was based on the template of existing ICIQ modules. 
These have been designed to be simple and easy to read, with items that are short, with clear 
response options 199. The layout and facility of understanding will be assessed further at the 
cognitive interview stage and any necessary changes made. 
Recall period 
The recall period was selected as 24 hours for the symptom questions, which reflected the 
necessity for a specific time period and to facilitate the ability of patients to accurately recall 
their symptoms. The recall period was selected as ‘over the last four weeks’ for the impact 
questions. These recall periods are subject to change following further evidence at the 
cognitive interview stage. 
Items 
Decisions were systematically taken regarding the importance of inclusion of items, including 
their content, language and response items. A concept was deemed sufficiently important for 
item inclusion if it was considered the following:  
 Well represented from the qualitative evidence in the DU only group.  
 Deemed essential or desirable for inclusion by the CRP. 
 Mentioned spontaneously by patients. 
The following were considerations that reduced the importance of the inclusion of an item or 
multiple items, to cover a particular concept: 
 More qualitative evidence for representation in the groups with DU and co-existing 
urological conditions (e.g. incontinence) than in the DU only group. 
 Not mentioned spontaneously by patients. 
 Deemed not essential for inclusion by the CRP. 





 The idiomatic use of language from the patient accounts to ensure specificity to the 
UAB population. 
 Existing validated ICIQ module questions that covered the same concept. For some 
items, these were used as a starting point before the cognitive interview stage allowed 
iterative revisions to improve their relevance and specificity to the UAB population. 
 ICS definitions of the target symptom. 




Table 13. Summary evidence for inclusion of concepts for ICIQ-UAB v1. 














































13 6 0 2 3 Yes. Strongly 
mentioned by 
several. 
Essential ICIQ-MLUTS 1 3 
Straining 14 2 3 2 2 Yes Essential ICIQ-MLUTS LF 
ICIQ-FLUTS 
4 12, 13, 14, 15 
Hesitancy 13 2 3 3 3 Yes. Mentioned 
by several men. 
Essential ICIQ-MLUTS 2 4, 5 
Slow stream 13 3 5 4 3 Yes by many Essential ICIQ-MLUTS 
ICIQ-MLUTS LF 
2 18, 19 














8 1 4 4 2 No Essential ICIQ-MLUTS 
 




12 1 3 1 2 Yes by several Not 
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Urinations of small 
volume 
4 0 1 1 1 Yes Not 
consulted 
None 1 26 
Post micturition 
dribble 















Lower urinary tract 
pain 
6 3 0 1 1 Not specifically Not 
consulted 
ICIQ-FLUTS 2 22, 23 
Clustering of 
urinations* 
6 3 1 1 0 No Not 
essential 
None 0  
Self-
catheterisation 
10 3 1 4 5 No Not 
consulted 
None 1 11 
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4 0 0 0 0 No Not 
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None 0  
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7 2 1 1 1 Yes by several Essential/ 
Desirable 
ICIQ-Nqol 3 29, 30, 31 
Affects physical 
activity 
3 2 1 1 0 Yes Desirable ICIQ-LUTSQoL 
 
1 32 
Feelings about self 3 1 5 2 3 Yes Desirable ICIQ-OABQoL 
 
1 33 
Embarrassment 4 4 2 0 1 Yes Desirable ICIQ-B 
ICIQ-LUTSQoL 
1 34 
Careful about fluid 
intake 
8 3 2 1 1 Yes Not 
consulted 
ICIQ-LUTSQoL 1 35 
Sex life 1 1 2 0 0 No Not 
consulted 
ICIQ-LUTSQoL 0  
Family and friends 5 1 2 2 0 No Not 
consulted 
ICIQ-LUTSQoL 0  
Abbreviations: Detrusor underactivity (DU), detrusor overactivity (DO), stress urinary incontinence (SUI), equivocal obstruction (EO), bladder outlet 
obstruction in the equivocal range (BOO-E), bladder outlet obstruction (BOO), clinical review panel (CRP), International consultation on incontinence 
questionnaire (ICIQ), ICIQ-underactive bladder (ICIQ-UAB), ICIQ-male lower urinary tract symptoms (ICIQ-MLUTS), ICIQ-nocturia quality of life (ICIQ-
Nqol), ICIQ-MLUTS long form (ICIQ-MLUTS LF), ICIQ-Urinary Incontinence short form (ICIQ-UI SF), ICIQ-female lower urinary tract symptoms (ICIQ-
FLUTS), ICIQ-bowels (ICIQ-B), ICIQ-overactive bladder quality of life (ICIQ-OABqol), ICIQ-lower urinary tract symptoms quality of life (ICIQ-LUTSQoL). 






The concept elicitation sub-study represents progress in our understanding of how the clinical 
diagnosis of DU manifest as symptoms, by account of the lived experience of patients. The 
evidence from the literature review, expert clinical panel and the concept elicitation interviews 
were used as the basis for the first draft of the ICIQ-UAB (Appendix 5). This draft version 
represents a comprehensive item list of the concepts which are deemed relevant by patients.  
Following further testing and refinement, the resulting PRO instrument for the assessment of 
UAB is potentially important for the assessment of UAB patients, when used alongside other 
non-invasive methods. This knowledge of the patient experience of UAB is also valuable to the 





Chapter 5 Cognitive interviews 
5.1 Introduction 
The cognitive theory model on which cognitive interviewing is based consists of four stages to 
explain how questionnaire items are processed and answered by subjects. Respondents must 
first understand the question, then recall the item-specific information, assess the type of 
information required and finally decide on the response 147. Cognitive interviews follow a 
‘think-aloud’ methodology, which ask respondents to verbalise the cognitive process they used 
to interpret and answer each of the survey items 115,141. The cognitive interview process is 
essential to demonstrate evidence of content validity, patient comprehension of the draft 
measure, and to make appropriate modifications to the instrument. 
5.2 Aims and objectives 
The purpose of the cognitive interviews was to meet the following objectives:   
 To ensure the items are understood and interpreted as intended by patients, using 
appropriate and patient-centered language. 
 To select appropriate and clear response items to each question with similar and well-
spaced intervals, which reflect the full range and attributes of the concept measured. 
 To select a recall period appropriate to the instrument’s purpose and intended use, 
whilst considering the variability and frequency of the concepts measured and 
characteristics of the condition. 
 To ensure the format, layout, order and sequence of items maximise understanding, 
readability, and facility of completion 115. 
5.3 Methods 
5.3.1 Site selection and recruitment 
Patients were recruited at the BUI at Southmead Hospital in Bristol, Royal Hallamshire Hospital 
in Sheffield and at the Freeman Hospital, Newcastle in May 2015. The medical records of 
prospective participants were screened for their eligibility for this phase of the study. Those 




study, an information sheet and a form which allowed them to indicate their willingness to 
take part by return post. A follow-up call was made if there was no response from the invitee 
within two weeks. If the invitee was unable to take the call, then a voicemail message was left 
and one further call was made before the participant was deemed uncontactable. If a positive 
reply by post was received, the study researcher contacted the invitee by phone and 
negotiated a suitable time to conduct the interview.  
5.3.2 Sample size and target population  
Cognitive interview participants were recruited to be broadly representative of the target 
population in which the PRO instrument will be used (e.g. age, sex, ethnicity, socioeconomic 
status, literacy and characteristics of condition). Based on the complexity of the concepts 
underlying the draft UAB PRO, it was expected that 25–30 interviews would be required with 
3–5 participants per round 124,141.  
5.3.3 Study inclusion and exclusion criteria 
The patient inclusion and exclusion criteria were the same as used for the concept elicitation 
study in chapter 4. All participants had a diagnosis of detrusor underactivity following 
urodynamics. 
5.3.4 Ethics and informed consent 
This study was conducted with favourable opinion from the Southmead Research Ethics 
Committee (now the Bristol South Research Ethics Committee) for ICIQ questionnaire 
development activities: reference 087/99. Before each interview, the participants were 
reminded of the purpose of the interview, the procedure on confidentiality, and were given 
the opportunity to ask questions. Participants signed an informed consent form in-person 
before each interview.  
5.3.5 Conduct of interviews 
A cognitive interview guide was developed to allow for the retrospective (after the patient has 
completed all items on the questionnaire) debriefing of the instrument (Appendix 6). This 
included general readability and layout, length, completion instructions, recall period, item 
content, item clarity and wording, bother items and general comments about item inclusion. A 
practice interview with one participant allowed familiarisation with the guide and to address 




were then scheduled to determine whether the target population understood and interpreted 
the content of the first version of the UAB PRO as intended. Interviews were conducted in a 
room which minimised the risk of interruption and maintained the privacy of the participant. 
Following consent, participants were asked to complete the questionnaire in its entirety with 
minimal input from the interviewer before any probing questions were asked. The audio 
recorder was switched on and subjects were asked to make general comments on the 
questionnaire length, layout, coverage and facility of completion. They were then asked about 
the clarity of the completion instructions and their understanding of the recall period. For each 
item, systematic probing questions were asked which allowed the assessment of the subjects’ 
comprehension in relation to the intended meaning. Subjects were encouraged to ‘think aloud’ 
and to be as ‘open and honest as you like when you tell me your thoughts and comments’. 
Notes were made by the interviewer which summarised the subjects’ responses and were 
documented throughout using the boxes corresponding to each item in the interview guide. 
5.3.6 Data management  
Following each interview, the audio recording was transcribed verbatim. All files were 
password protected and stored on the NBT secure server. All participant data was anonymised 
using a unique study identifier.  
5.3.7 Item tracking matrix  
After each round of interviews, changes were made to the draft PRO instrument according to 
patient feedback consensus. Any changes made, and the rationale for these, were 
documented and described in item tracking matrices prepared in an Excel spreadsheet. A 
summary of each subject’s comments, as well as any input or recommendations from the 
clinical panel or other sources was recorded here. This collated the relevant information to 
facilitate informed decisions during the item development. Changes were only made if several 
patients within a round had the same misunderstanding or made a similar recommendation 
for improvement. This avoided changes being made on the basis of a single patient. The 
responsibility for decisions made on the revision of items after each round was ultimately by 






5.4.1 Cognitive interview participant characteristics 
A total of 36 participants (nine female, 28 male, age range 26–88 years) were interviewed in-
person over 10 successive rounds of semi-structured interviews in March and April 2015. A 
final eleventh round of interviews was conducted by phone to test some final minor changes 
with five previous participants. Twenty eight patients were interviewed at Southmead hospital, 
four at Royal Hallamshire Hospital, Sheffield, and five at the Freeman Hospital, Newcastle. 
Twelve of the participants had previously been interviewed during the concept elicitation 
interviews. All were White British, and came from a variety of different educational 
backgrounds and occupations. Table 14 shows the sample population diagnostic groups and 
demographic characteristics.  
Table 14. Summary of demographic and clinical characteristics. 
Clinical or demographic 
characteristic 
Total sample (n=36) 
DU  
DU + DO 
DU + SUI 
DU + BOO-E 
DU + BOO 







Males n (%) 27 (75) 
Females n (%) 9 (25) 
Age [years] median (IQR) 68 (14) 
ISC current or historical n (%) 11 (31) 
PVR >0ml n (%) 18 (50) 
PVR [ml] median (IQR)  90 (184) 
BCI (males only) median (IQR) 73 (17) 
BOOI (males only) median (IQR) 20 (19) 
pdetQmax [cmH20] median (IQR) 33 (20) 
Qmax [ml/s] median (IQR) 7.5 (6) 
BVE (%) median (IQR) 79 (49) 
Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 





5.4.2 Instructions  
The purpose of the instructions was to provide a brief introduction to the questionnaire. The 
original instructions stated: 
“Many people experience urinary symptoms some of the time. This questionnaire aims 
to find out whether you experience symptoms known to be associated with 
underactive bladder, and whether or not these symptoms have an impact on your 
everyday life. We would be grateful if you could answer the following questions, 
thinking about how your symptoms have been, on average, over the LAST 24 HOURS.” 
The wording and clarity of the instructions were reported to be clear by all subjects and did 
not require any significant changes in content. The final instructions were as follows: 
“Many people experience urinary symptoms some of the time. This questionnaire aims 
to find out whether you experience symptoms associated with underactive bladder, 
and whether or not these symptoms have an impact on your everyday life. Please 
answer the following questions thinking about how your symptoms have been over 





5.4.3 Layout  
The initial layout and formatting were based on the template of the existing ICIQ modules . All 
subjects found the layout to be clear and easy to read, so no changes were made to this 
format. An example item is shown in Figure 5. 
Figure 5. Example item. 
5.4.4 Bother  
Each item has the associated question ‘how much does this bother you?’, which allows the 
subject to indicate their assessment of this on a 0–10 numeric rating scale. All subjects in the 
cognitive interviews were able to answer the question as intended. Two subjects suggested 
that they preferred the question to have worded response options (e.g. not at all, slightly, 
somewhat, very much etc.) but did not regard this as essential. A few subjects answered the 
associated bother question with respect to how they would feel if they had the symptom in 
the future. However, this did not affect how they answered the bother questions for other 
items where the symptom was present.  
5.4.5 Recall period 
The selection of the appropriate recall period depends on the period over which a patient can 
accurately recall the event. The recall period of version 1 was based on a 24-hour recall period 
for the symptom items and a 4-week recall period for the impact items. This underwent 
several revisions during the cognitive interview rounds in to test whether a 4-week, 1-week, or 
  Over the LAST WEEK… 
 
4a. When ready to urinate, was there a delay before the urine flow started? 
 
not at all  0 
   
occasionally  1 
  
 
sometimes  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 




24-hour recall period was the most appropriate for the symptoms and impacts to be measured 
in the study population. 
Some patients favoured the 24-hour recall or the 1-week recall period, while others reported 
that the recall period was too short or too long. For example, a patient who preferred a 
shorter recall period stated: “I was thinking of a day a normal day”. Another patient (CD P2) 
stated: “The questions seemed to come at come at me in a general way you know unless it 
specifically says and you know in like the last 4 weeks or so”. Many of the patients reported 
that they had not seen the recall period or ignored it. After round two, the recall period was 
put as a reminder at the top of each page to encourage subjects to adhere to the recall period 
provided. However, due to continuing issues with subjects not reading or ignoring the recall 
period, a reminder of the recall period was inserted for each question. Two versions of the 
questionnaire were tested and retained from the eighth round of cognitive interviews. One 
version has a 24-hour recall period and only contains the symptom questions. The other has a 
recall period of over the ‘last week’ for symptom as well as impact questions. 
5.4.6 Response options 
The response options were tailored to the item in question and are discussed where relevant 
to the item. However, many required more general response items. The initial response 
options for these items were ‘never, occasionally, sometimes, most of the time, all of the 
time’. After round 1, the response options were changed to ‘never, occasionally, sometimes, 
often, every time’. It was noted by several subjects that the response options did not 
encourage them to think about a short recall period of 24 hours. After round 4, alternative 
response options were designed for a shorter recall period: ‘not at all, once, a few times, many 
times and every time’. However, following feedback from patients in rounds 6 and 7, it was 
clear that different response options were required for different recall periods. The final 
response options were introduced in the eighth round of interviews and in each version 
thereafter with a ’24-hour/Last week’ recall period. The respective options were ‘not at all/not 
at all, on occasion/occasionally, about half the time/sometimes, most times/most of the time, 




5.4.7 Symptoms  
Daytime urinary frequency 
The original item was ‘How often do you pass urine during the day, on average? (1–6 times, 7–
8 times, 9–10 times, 11–12 times, 13 or more times)’. An important alteration to the response 
options was to include a frequency option of 1–3 times, as this reflected the infrequent 
number of urinations by some UAB patients. The final item for the version with a 24-hour 
recall period was ‘How many times did you urinate during the day? (1–3 times, 4–6 times, 7–9 
times, 10–12 times, 13 or more times)’ and for the version with a 1 week recall period: ‘During 
the day, how many times did you urinate, on average? (1–3 times, 4–6 times, 7–9 times, 10–12 
times, 13 or more times)’. 
Hesitancy 
The original item was worded ‘Is there a delay before you can start to urinate? The words 
‘when ready to urinate’ were added to the item stem to improve the clarity of circumstance in 
which the question was being asked. The final item was ‘When ready to urinate, was there a 
delay before the urine flow started?’  
Need to concentrate to start void 
The original item was ‘How often do you feel like you have to concentrate to start urinating?’. 
Patients understood the item as intended, for example CD P2 reported: “your brain's telling 
you you've got to go and then for some reason you can't go and it's a battle then within the 
mind”. At the seventh round the item was changed to its final iteration: ‘When ready to 
urinate, did you feel you had to concentrate to start urinating?’ 
Urinary incontinence  
The original item stem was ‘Do you ever leak urine before you can get to the toilet?’. Patients 
mentioned different types of incontinence, for example after exercise or when coughing or 
sneezing CD P21: “I think once I've got a cold and a cough then I often [leak]”. The item 
modified to give examples of circumstances of leakage ‘before you could get to the toilet, or 
when you cough or sneeze’. This clarified the intention of the question and to distinguish this 




urine (e.g. before you could get to the toilet, when physically active, or when you coughed or 
sneezed)?’.  
Nocturia and/or nocturnal voids 
The original item was interpreted as intended: ‘During the night, how many times do you have 
to get up to urinate, on average? (none, one, two, three, four or more)’.  
Reduced sensation of bladder fullness 
The original item was ‘Would you say that your sensation of how full your bladder is… (not 
reduced, a little reduced, reduced, very reduced, extremely reduced)’. Following patient 
feedback this item was reworded for clarity of language and replaced with a question which 
aimed to establish how well respondents could detect fullness of their bladder. For example, 
CD 26: “Yeah it’s very difficult to know how full your bladder is, although I have some sort of 
feeling there”. The final item was ‘Did you find it difficult to tell how full your bladder was? 
(not difficult, a little difficult, difficult, very difficult, and extremely difficult)’. 
Sensation of incomplete emptying 
The original item was ‘How often do you feel like your bladder has not emptied properly after 
you have urinated? Patients understood the item as intended, for example, patient CD P2: 
“you know, you're out with company and you fancied a toilet and you think, have I emptied?”. 
However, subsequent cognitive interviews showed that subjects who were either aware or 
unaware of a residual would respond positively to this question i.e. those who could feel it or 
those who were just ‘suspicious’ there was still a residual due to other cues. The item was 
changed to ‘After you have urinated, how often do you have a sensation that your bladder is 
not completely empty?’. The word ‘soon’ was added to the item to further improve clarity 
around context. The final item was ‘Soon after you had urinated, how often did you have a 
sensation that your bladder was not completely empty?’. 
A second item was included from patient feedback that the item on the length of time spent in 
the bathroom was not covered by the slow stream item. The included item was interpreted as 
intended: ‘How often did you wait a bit longer in the bathroom after urinating, to make sure 





The original question was worded: ‘Have you ever blocked up completely so that you could not 
urinate at all and had to have a catheter passed to drain the bladder?’ Two patients in round 2 
interpreted the question to mean self-catheterisation. This was addressed by changing the 
order of the question to after the self-catheterisation item to improve the distinction between 
these items. Adding ‘and had to go to hospital’ also improved the clarity of context. The final 
question was worded, ‘Have you ever been unable to urinate at all and had to go to hospital to 
have a catheter tube inserted to drain the bladder?’.  
Self-catheterisation 
The item was worded ‘How often do you need to self-catheterise?’ with response options 
‘never, less than once a month, a few times a week, once a day, every time’. The main 
modification to the original question was to establish the most appropriate response options 
based on patient feedback. Incorporating an item-specific recall period of ‘over the last month’ 
was considered necessary as some subjects may have tried self-catheterisation in the past. The 
final wording of this item was ‘Over the last month, how often did you self-catheterise (not at 
all, about once a week or less often, two or three times a week, about once a day, more than 
once a day, every time you urinated)’. 
Straining 
The original question was worded: ‘Do you have to strain or squeeze to urinate? (never, 
occasionally, sometimes, most of the time, all of the time)’. The words ‘squeeze’ and ‘strain’ 
seemed to be contradictory, for example, CD P2: “I don’t know about squeeze I mean straining 
it’s the force to balance to try and you know to activate…”. The question also appeared to be 
unclear as to when during urination straining occurred. Three items were tested that probed 
more specifically about whether straining was involved in initiating, maintaining and the end of 
urination. The first asked ‘Do you have to strain to start urinating? (never, occasionally, 
sometimes, most of the time, all of the time)’. This was more relevant CD P16: “Yeah I mean to 
force it to force your muscles and trying to make something happen”. The final item was ‘How 
often did you strain to start your urinations? The second item ‘Do you ever strain to try and 
improve the flow of your urination’, although relevant to a minority of patients, was removed 
after the third round of cognitive interviews due to the perceived overlap with the other items 




patient strained to finish urination: ‘How often did you strain towards the end of your 
urinations to try and empty your bladder?’  
Urgency 
This item was intended to measure the frequency that a patient experiences urgency (a 
sudden compelling desire to pass urine which is difficult to defer). The original question was 
‘How often do you experience a sudden desire or urge to urinate which you are unable to 
ignore?’. Patients interpreted the question as intended with one respondent (CD P2) saying: 
“absolutely must go feeling”. The words ‘urge’ and ‘desire’ were explored in relation to this 
concept but following patient feedback from the cognitive interviews and input from the CRP 
‘a sudden or strong need’ was confirmed as eliciting the intended response in the subjects. The 
addition of ‘and had to rush to the bathroom’ further clarified the context of the question. The 
final item was ‘How often did you experience a sudden or strong need to urinate which you 
were unable to ignore, and had to rush to the bathroom?’.  
Urinary tract infection 
The original item was ‘Have you had a urinary tract infection in the past month? (Yes, No)’. 
Patients could be unsure when they had their last UTI, or if in fact it was a UTI, such as patient 
CD P28: “You know and in the last year, I don’t think it is I think it’s over a year the last time”. 
An ‘unsure’ option and clarification ‘for which you took medication’ improved understanding. 
The final item was ‘Over the last 12 months, have you had a urinary infection for which you 
took medication? (no, unsure, once, twice, three or more times)’. 
Slow stream 
The original item was worded ‘Would you say the strength of your urinary stream is: normal, 
occasionally reduced, sometimes reduced, reduced most of the time, reduced all of the time’. 
This was generally interpreted as intended but subjects were more concerned with the 
severity of their slow stream than the frequency of the symptom. For example, CD P6 stated: 
“it was extremely reduced, it would be like dripping out.” This question replaced with ‘Would 
you say the flow of your urinary stream is: not reduced, a little reduced, reduced, very 
reduced, extremely reduced. The words 'Strength of' were also added before ‘flow’ in this 
round. ‘Normal’ was added to the first response option to give the respondents some 




flow of your urinary stream was… (Normal (not reduced), a little reduced, reduced, very 
reduced, extremely reduced)’.  
The second item was introduced when recommended as a potential question by a member of 
the clinical panel: ‘How long do you stay in the bathroom to finish urinating? (less than a 
minute, 1–5 minutes, 6–10 minutes, 11–15 minutes, more than 15 minutes)’. After some 
rewording to improve clarity, the final item was ‘What was the longest time that you needed 
to spend in the bathroom to finish urinating? (less than a minute, 1–5 minutes, 6–10 minutes, 
11–15 minutes, more than 15 minutes)’.  
Intermittency 
The original item was ‘Do you stop and start more than once while you urinate?’. Patients 
understood the item as intended, for example CD P2: “it stops… and then you’ve got to wait 
for it to come on stream again”. The reversal of the order of the words ‘stop’ and ‘start’ was 
considered and tested but ultimately the original order was maintained as it was more 
colloquial. The final item was ‘How often did you stop and start more than once, during your 
urinations?’. 
Post-micturition dribble 
The original item was worded ‘How often does a few more drops leak out into your underwear 
shortly after you have finished urinating and have dressed yourself? This question was 
understood as intended. For example, patient CD P6 stated: “well it can be a bit embarrassing 
as though you've wet yourself but like I say it's never it was never bad”. The final item was 
‘How often did a few drops leak out into your underwear shortly after you had finished 
urinating and had dressed yourself?’.  
Bladder pain 
The original item was ‘Do you experience pain in your bladder?’. The item was removed in the 
third round of cognitive interviewing as there was no consensus on the type, location or 
circumstance. Pain also did not appear to be a ubiquitous problem either in the concept 
elicitation or the cognitive interviews. Several also interpreted the question as their normal 




Need to immediately re-void 
The original item was ‘Do you have to urinate again (within 15 minutes) after you thought you 
had finished urinating?’. After patient feedback, for example CD P3: “I can't say it's within 15 
minutes or anything like that it could be half an hour” and patient CD P17: “for me I think 
maybe the less it could be is half an hour later” the question was reworded for clarity around 
the length of time. The final question was ‘After you had urinated, how often did you have to 
return to the bathroom to urinate again, within a short space of time (e.g. within 15 
minutes)?’.  
Temporarily unable to pass urine 
This item was introduced in round 2 of the cognitive interviews and was originally worded 
‘How often have you been unable to urinate when you would like, and had to come back 
later?’. The aim was to capture those who cannot voluntarily urinate unless feeling urgency as 
well as those who sometimes find themselves unable to voluntarily urinate independent of 
desire. The wording was reworded for clarity around circumstance: ‘How often did you go to 
the toilet to pass urine but were unable to urinate at all, so had to return to the bathroom to 
try again later?  
Spraying  
The original item was worded ‘How often do you feel like you have no control over the 
direction of your stream?’. Although several of the men reported lack of control over the 
direction of the stream, this was primarily due to poor flow, for example CD P8: “I can’t 
control, I can’t control the strength”. It was also considered less relevant to women due to 
their sitting down position whilst urinating. The question was deemed the lowest priority by 
the clinical panel so was removed after the second round of interviews. 
Small volume of urine per void 
The item was originally worded, ‘How often do you feel like you were not able to pass what 
you might consider a satisfactory amount of urine?’. There was some feedback from patients 
that the question was too subjective due to there being no point of comparison. However, it 
was acknowledged that for subjects for whom this was a symptom, the item was interpreted 
as intended, for example CD P10: “yeah that’s what I am saying to me the volume is not great 




Associated bowel symptoms 
The original question was worded: ‘Are your urinary symptoms affected by your bowel 
movements?’. The intent of the item was to measure the frequency with which a patient 
experiences an association between bowel problems and the severity of their urinary 
symptoms. The question was reworded in round 4 to improve clarity because of the many 
different ways that bowels can interact with the urination process. The final item was ‘Did you 
have problems with your bowels? (no, yes) If so, were your urinary symptoms made worse by 
this?’  
Clustering of symptoms 
This item was included in round 7 due to feedback from the cognitive interviews and concept 
elicitation evidence that some subjects experience more severe symptoms at a specific time of 
the day or night. The original question was worded ‘Were your symptoms worse at particular 
times? Please tick those that applied… (no, in the morning, in the afternoon, in the evening, at 
night)’. It is acknowledged that the specific symptom or symptoms which the respondent may 
be reporting is not known; nevertheless the wording of the question was confirmed as being 
interpreted as intended. The final item was ‘Were your urinary symptoms worse at particular 
times? Please tick those that apply… (no, in the morning, in the afternoon, in the evening, at 
night)’.  
5.4.8 Impact items 
Planning around toilets 
The original item was worded, ‘How much do you have to plan your life around the location of 
toilets? (never, occasionally, sometimes, most of the time, all of the time)’. The patients 
interpreted the item as intended and gave feedback that this item was both relevant and 
important. For example, CD P3: “if I do go out if I go out to the theatre or cinema it's a basic 
question of scanning the area to see where the toilet is”. The only change was the replacement 
of the words ‘How much’ with ‘how often’ for consistency with the other questions and the 
change to past tense. The final wording of the item was ‘How often did you have to plan your 





The original item was worded ‘How often do you feel that your urinary problem interferes with 
your social life?’. Patients interpreted ‘social life’ as intended, for example, CD P17: “relaxing 
time enjoying time with friends”. The final wording of the item was ‘How often did you feel 
that your urinary symptoms interfered with your social life?’ 
Sleep 
The original item was ‘How often do your symptoms prevent you from getting the amount of 
sleep you needed?’. After round 1 ‘urinary’ was added to precede ‘symptoms’ for clarity. After 
the second round the item was considered to be more concisely captured by the more general 
nocturia impact question, described below. As the item was also deemed the lowest priority by 
the clinical panel, it was not included in the questionnaire.  
Tiredness 
The original item was worded ‘How often do you feel tired the next day because of having to 
get up at night to urinate?’. As above, the general nocturia impact question below was 
retained in favour of this item due to its increased relevance. 
Impact of nocturia and/or nocturnal voids 
The item was originally worded as ‘Overall, how much impact does getting up at night to 
urinate have on your day to day life?’. After round 1, ‘at night’ was underlined for emphasis. In 
round 4, following feedback from the patients, ‘impacts’ was changed to ‘affects’ to improve 
comprehension. The item was interpreted as intended, for example CD P12: “it does impact 
because at the end of the day I’m awake when I would be asleep”. The final item was ‘How 
often did you feel getting up at night to urinate affected your day to day life?’  
Physical activities 
The item was originally worded as ‘How often do you feel that your urinary problem limits 
your physical activities (e.g. exercise, sport)?’ Many reported that doing just ‘sport’ was not 
applicable to them. For example CD P12: “I would say any kind of walking, exercise, any kind of 
sports”. Patients gave feedback that their physical activity was more ‘affected’ (not limiting 




you feel that your urinary symptoms affected your physical activities (e.g. walking, swimming, 
sport)?’ 
Feelings about self 
The original question asked ‘Does your urinary problem affect the way you feel about 
yourself?’ Patients understood the item as intended, for example CD P16: “Well does it make 
me feel any less confident than I would normally be?”. Others mentioned anxiety or depression 
when considering how to answer this question; for example CD P12: “yes, I personally suffer 
from depression, someone else might not”. The final item was ‘Did your urinary problem affect 
the way you feel about yourself?’  
Embarrassment 
The original item was worded ‘Does your urinary problem cause you to feel embarrassed?’. 
Patients understood the item as intended, for example CD P12: “Okay people don’t realise that 
I have got problems and they just think oh he needs to go to the toilet, but it still don’t change 
the fact that I might feel a bit embarrassed about it”. The final item was ‘Did your urinary 
problem cause you to feel embarrassed?’  
Fluid intake 
The original item of the question was ‘Are you careful how much fluid you drink?’. After round 
1, it was noted that the both the amount and type of drink are monitored by patients so the 
item was altered accordingly. The final item was ‘Did your urinary symptoms cause you to be 
careful about how much or the type of fluid you drink?’  
Overall impact  
The original item was ‘Overall, how much would you say your urinary symptoms interfere with 
your everyday life?’. The response frame remained an eleven point Likert scale ranging from 0-
10. No changes to the item stem were required.  
5.5 Discussion 
The current chapter documents the refinements to the draft ICIQ UAB version 1 during the 
cognitive interviews. The subsequent ten versions underwent modification from the original 




input from the clinical panel. Areas for improvement were highlighted throughout the 
cognitive interview process, including suggested changes to wording, clarity, and content 
which were implemented and further tested. The resulting versions of the ICIQ-UAB reflect the 
input of both patients and clinicians. The following discusses specific items and aspects of the 
instrument which were highlighted by this study which can be explored by the further 
investigation of the instrument’s psychometric properties. 
The item ‘How often did you feel you have to concentrate in order to start urinating?’ was 
found to be highly relevant to many of the cognitive interview subjects as many subjects 
related to this concept of ‘having to concentrate’ in order to start passing urine. The inclusion 
of the specific terminology used by patients is considered to particularly capture the difference 
between the concept of concentrating and the physical symptom of hesitancy captured by an 
alternative item. Any overlap in underlying concept is possible to explore in the next stage of 
the development process.  
The items which related to bladder sensation underwent some exploration. These included: 
‘Did you find it difficult to tell how full your bladder was?’, ‘Soon after you have urinated, how 
often did you have a sensation that your bladder is not completely empty?’, ‘How often were 
you only able to pass a small volume of urine?’ and ‘After you have urinated, how often did 
you have to return to the bathroom to urinate again, within a short space of time (e.g., within 
15 minutes)?’. Respondents may consider whether they are able to predict the volume of urine 
left in their bladder, including whether they trust the accuracy of their bladder sensations 
post-urination when answering each of these items. These items share underlying concepts 
due to a post-void residual being ubiquitous in the UAB population but elucidate different 
contexts. Any overlap will be explored in the next stage of the development process. 
The concept elicitation interviews and clinical panel provided evidence that for some subjects 
there is an association between bowel problems and urinary symptoms resulting in the 
inclusion of the item: ‘Did you have problems with your bowels? Then ‘if so, are your urinary 
symptoms made worse by this?’. However, the inclusion of this item was subject to some 
scrutiny during the cognitive interview process due to it lacking sufficient specificity to be well 
understood by subjects. Further expansion into a number of different items was not 
considered desirable as the primary focus of the PRO was urinary symptoms. The item will be 




The item ‘Were your symptoms worse at particular times?’ was included as several subjects 
experience more severe symptoms at a particular time of the day or night. It is acknowledged 
that the specific symptom(s) which the respondent is thinking about are not specified. Further 
study will help decide the merit of including this question.  
The impact questions overall required very little modification. The final version included one 
nocturia-related impact question rather than the initial three items that were debriefed. 
Furthermore, for many respondents there is a necessity to be in close proximity to a toilet, 
covered by the item ‘How often did you have to plan your life around the location of toilets?’ 
This fundamental inconvenience has a secondary impact covered by the following two items: 
‘How often did you feel that your urinary symptoms affect your physical activity (e.g. walking, 
swimming, sport)?’ and ‘How often did you feel that your urinary symptoms interfere with 
your social life?’. Although there is an overlap of an underlying concept, these additional items 
clarify the context which justifies their inclusion at this stage. These are also generally 
supported for inclusion as fundamental features of the quality of life definition in any context. 
The cognitive interviews uncovered that in some cases, patients would answer the bother 
questions according to ‘hypothetical bother’ if they did not have a particular symptom, rather 
than ‘actual bother’ related to their experience of a symptom. Any analysis of bother in further 
pilot testing will exclude bother scores for items in which a symptom was not reported by a 
patient. An electronic version of the questionnaire will also address this limitation as a bother 
question would only be asked if patients experience the symptom in question. 
An appropriate recall period for the population is important so the instrument has an 
interpretable score within the specific context of measurement. The current recommendations 
are that a shorter recall period is advised in order to improve recall accuracy and provide 
specific rather than general data 99,115. However, although some patients preferred a longer 
recall period for symptoms, there is a delicate balance between responding to the data and 
current thinking in the field. Two versions of the ICIQ-UAB will therefore go on to further 
psychometric testing. One version has a recall period of the ‘over the last week’ which applies 
to all items, including the impact questions. The other version has a recall period of ‘the last 
24-hours’ and only contains the symptom questions.  
It is acknowledged as a possible limitation the subjectivity that a single researcher may bring 
when doing qualitative research. There may also be a difference between what an interview 




was dependent on the continual reflexive appraisal and referral to the original transcripts, 
particularly during the analytical process. It is also acknowledged that the subjects of the study 
may be influenced by an overt presence of the researcher (e.g. the effect of a male researcher 
when eliciting sensitive topics) and why the findings should always be interpreted in context 
138. In addition, it is acknowledged that as prior knowledge of underlying urological theory 
derived from the literature is likely to have had an influence on the decisions made. For 
example there may be a danger that only evidence that agrees with preconceived ideas are 
identified 205. For this reason, care was taken during the interviews and analysis to ask neutral 
and non-leading questions in order to elicit reduce the chance of bias in the participant’s 
responses. It was also noted if something was not mentioned, as this may be equally as 
important as what is verbalised. It is acknowledged that using patients to revise the 
questionnaire who were involved in the elicitation of concepts could be construed as biasing 
the development of the items. However, the impact of including 12 interviewees from the 
concept elicitation interviews in the cognitive interviews was considered unlikely to have 
influenced the decisions made as the further 24 interviews, including in-depth interviews from 
different sites in Newcastle and Sheffield were carried out until all questions were completed 








The elicitation of concepts, development of a draft version of the instrument, the process of 
conducting cognitive interviews in the target UAB population and subsequent revisions of the 
instrument conclude the initial qualitative phase of the questionnaire development. The 
documentation of this process in the current report provides support for its content validity 
and aids determination its context of use. As a result of the cognitive interviews, the revised 
versions of the draft instrument are considered comprehensive and ready for the next phase 
of development, psychometric testing. Figure 6 shows the item concepts and 31-item pool.  
 





Chapter 6 Quantitative psychometric evaluation 
6.1 Introduction 
This chapter details the studies undertaken to assess the initial psychometric properties of the 
draft ICIQ-UAB, developed as a result of the qualitative phase detailed in chapters 4 and 5. This 
pilot study was designed for the initial quantitative exploration of the validity and reliability of 
the draft questionnaire in a new sample of patients diagnosed with DU. The aim was to 
provide additional evidence for decisions to be made surrounding the items to be included in 
the final questionnaire. 
6.2 Methods 
6.2.1 Study design 
The study was designed to assess the preliminary psychometric properties of the draft ICIQ-
UAB in the target population, using a standard test-retest design. The qualitative interview 
phase described previously, resulted in a developmental version of the ICIQ-UAB consisting of 
31 items: 
 Medical history and bother (3 items) 
 Symptoms and bother (20 items) 
 Impact and bother (8 items) 
For the symptom items, a version with a 24 hour recall period was also tested, to allow 
comparison of the suitability of the recall periods. The two versions were as follows: 
 ICIQ-UAB 1-week – all items with a 1 week recall period (31 items) 
 ICIQ-UAB 24hrs – only symptom items, with a 24 hour recall period (20 items) 
Participants were asked to complete a demographic and health information form (DHIF), both 
of the versions of the ICIQ-UAB, and concurrent instruments of known evidenced validity 
(detailed below) over a period of 10 days. A period between test-retest of approximately two 
weeks is considered reasonable to ensure the condition severity is not expected to change and 
there is sufficient time to reduce possible learning effects 103. Table 15 details the content of 




questionnaires were compiled into a questionnaire booklet to direct the order of completion. 
Approximately half of the participants completed the ICIQ- UAB 1-week first at baseline (day 1) 
followed by the concurrent PROs and the ICIQ-UAB 24hrs at the end. For the other half of the 
participants the order of the UAB PROs was reversed to eliminate possible order effects of 
administration. The allocation to which PROM was administered was by subject ID, (odd 
numbers completed the ICIQ-UAB 1-week first). 
Table 15. Study flow chart. 
 Day 1 Day 2 Day 3  Day 8 Day 9 Day 10 
DHIF x       
ICIQ -UAB 1-week x    x   
ICIQ-MLUTS/FLUTS x       
ICIQ LUTSqol x       
PGI-S x    x   
PGI-C     x   
ICIQ-UAB 24hr x x x  x x x 
 
6.2.2 Concurrent PRO measures used in study 
 ICIQ-MLUTS (International Consultation on Incontinence Questionnaire - Male Lower 
Urinary Tract Symptoms) 
- LUTS and bother in males (13 items)  
 ICIQ-FLUTS (International Consultation on Incontinence Questionnaire - Female Lower 
Urinary Tract Symptoms) 
- LUTS and bother in females (13 items)  
 ICIQ-LUTSqol (International Consultation on Incontinence Questionnaire - Lower 
Urinary Tract Symptoms Quality of Life) 
- Impact of LUTS symptoms on health related quality of life (22 items)   
 PGI-S  (Patient Global Impression of Severity) 
- Single rating of severity of their condition on a 4 point scale 
 PGI-C (Patient Global Impression of Change) 
- Single rating of change of status of subject’s symptoms on 7 point scale 
6.2.3 Translation 
The PRO measures were completed in the language of the respective country in which they 
were administered using linguistically validated versions (English, Dutch and German). The 




validation methodology to ensure conceptual equivalence 175. The process was outsourced and 
coordinated by MAPI, an external patient-centered research company that has expertise in 
translation of PRO measures 174. The author was responsible for reviewing the back 
translations to ensure the original concepts were retained. 
6.2.4 Recruitment 
Participants were recruited from sites in the UK, Netherlands and Germany using a purposive 
sampling approach. Study management was outsourced to a company (Pharmerit), based in 
the Netherlands. The author was responsible for the recruitment of subjects and 
administration for the Bristol site.  
Patients were sent a postal invitation to participate in the study, containing a patient 
information letter. If interest was expressed then informed consent was taken by further 
postal correspondence. A case report form was also signed and completed and checked for 
conformity with the inclusion and exclusion criteria by the author. After written informed 
consent was obtained from patients, the study package containing the questionnaires was sent 
out to subjects to be completed. 
6.2.5 Inclusion and exclusion criteria 
Patients were recruited using the following inclusion and exclusion criteria. 
 Male or female and at least 18 years of age. 
 Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved 
written Informed Consent and privacy language as per national regulations must be 
obtained from the subject prior to any study-related assessments. 
 Patient was willing and able to complete the PRO instruments. 
 Patient had a primary diagnosis of DU for at least 3 months, with stable symptoms. 
 Patient was able to void spontaneously and pass at least part of their urine by voiding. 
 Patient was willing and able not to make changes to concomitant medication and life 
style, which may have an effect on lower urinary tract symptom (LUTS) (e.g., start 
urological treatment or change fluid intake) during the study period (10 days). 





 Stress urinary incontinence (SUI), unless mild, and DU were the predominant 
conditions. 
 Detrusor Overactivity (DO) unless mild and DU is the predominant condition. 
 Patient had a neurological cause for DU (e.g., neurogenic bladder or systemic or 
central neurological disease such as multiple sclerosis and Parkinson’s disease). 
Patients with diabetic neuropathy could be enrolled. 
 Patient had received treatment that may impact the pressure flow dynamics since the 
last pressure flow study (PFS), which confirmed DU diagnosis. 
 Patient was participating in an investigational trial. 
Further criteria: 
 Patients with or without a post-void residual were included in the pilot assessment, if 
they met all the above-mentioned inclusion and exclusion criteria. 
 Patients using intermittent self-catheterization were included in the pilot assessment, 
if they met all the above-mentioned inclusion and exclusion criteria. 
 Patients with an acontractile bladder were included in the pilot, if they met all the 
above-mentioned inclusion and exclusion criteria. 
The same urodynamic inclusion and exclusion criteria as for the concept elicitation and 
cognitive interviews were used to select participants with a primary urodynamic diagnosis of 
DU. As before, prospective patients for the Bristol site were screened for suitability by the 
author. 
The pressure flow study (PFS) parameters used to identify potential patients were the bladder 
contractility index (BCI) and bladder outlet obstruction Index (BOOI) for males, and detrusor 
pressure at maximum flow (pdetQmax), and maximum flow rate (Qmax) for females. Patients were 






Table 16. Diagnostic group inclusion criteria. 
DU (only) 
 Patients with a confirmed diagnosis of DU on urodynamics and a 
diagnosis of no other co-existing urological conditions 
Males:      BCI <100 
                    BOOI <20 
Females:   pdetQmax <20 
cmH20 
                   Qmax <15ml/s 
DU + mild DO 
 DU + co-existing mild DO (based on investigator unrodynamic 
assessment and patient records) 
DU + Mild SUI/USI 
 DU + co-existing mild USI/SUI (based on investigator urodynamic 
assessment and patient records) 
DU + BOO-Equivocal (males only) 
 BCI <100, BOOI ≥20–<40 
DU + BOO (males only) 
 BCI <100, BOOI ≥40 
DU + Mixed (other)  
 DU + BOO-E and Mild SUI/USI or mild DO as defined by the 
above 
Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 
calculated by BOOI=pdetQmax-2Qmax. 
6.2.6 Sample size 
A minimum sample size of 40 is advised in order to obtain reliable estimates when assessing 
item performance and tests of reliability in pilot studies such as the current study 206. The aim 
was to recruit at least 50 participants to fulfil these criteria. 
6.2.7 Scoring 
A pragmatic approach to the scoring of the ICIQ-UAB was taken in order to undertake the 
current analyses, as scoring algorithms based on psychometric evidence will be derived at a 
later stage. The response option of ‘never’ or ‘not at all’ was scored 0 with subsequent options 
scoring 1, 2, 3 or 4 for the response options of increasing severity. For the ICIQ-UAB 1-week, 
items 1-3 (medical history) were not included in the calculation of the overall score, as these 
would not be expected to change. Item 22 (bowel associations) was not included due to the 
first part of the item being dichotomous (yes/no). Item 23 (clustering of symptoms) was on a 
nominal scale so was not included in the total score. Item 31 was an overall question on 




24hrs the corresponding item 19 (bowel associations) and item 20 (clustering of symptoms) 
were not included. Table 17 summarises how the scores were calculated for each domain. 
Table 17. Scoring in each of the versions. 
Domain ICIQ-UAB 1-week ICIQ-UAB 24hrs 
Item number Range of 
possible total 
scores 






Symptom items 4-21 0-72 1-18 0-72 
Impact items 24-30 0-28  
 
6.2.8 Psychometric methodology 
The following details the analytic methodology that was performed on the data. These 
included descriptive analyses (e.g. missing data, floor and ceiling effects) and assessment of 
the instrument’s psychometric properties (aspects of validity and reliability). 
Missing data 
The percentage of missing responses was calculated for each administration. A level of missing 
data of 3-5% was generally considered acceptable 149,150.  
Floor and ceiling effects 
Items were considered to have a floor effect or ceiling effect if more than X% of respondents 
answered the highest or lowest option respectively, where X is 100/the number of response 
options.  
Bother 
The bother scores associated with each item ranged from 0 – 10, where score of 0 represents 
no bother and a score of 10 maximum bother. The reported score was only included in the 
calculation of the average bother score for each item if the patient experienced the 
symptom/impact (i.e. did not answer ‘not at all’ on the item). Thus, each item has a different 
denominator depending on the number of patients who experienced the symptom/impact. 
The mean bother scores were calculated at baseline (day 1) for each item in the ICIQ-UAB  1-




groups of severity (PGI-S score at baseline). This was to assess sensitivity of bother scores to 
severity of condition. 
Construct validity 
Although the literature links UAB with older adults 31,207,208, the link of impaired detrusor 
contractility with ageing per se has yet to be conclusively demonstrated 18,41. However, urinary 
retention, hesitancy, and incontinence have been associated with UAB and advancing age 16,25. 
It is also known that symptom of nocturia is highly correlated with increasing age in the 
general population 47,48. The sample was stratified by participants ≤65 years of age and those 
>65 years, to investigate a potential positive relationship of age and reported symptom 
occurrence. 
The prevalence of UAB symptoms in males and females is poorly understood in the literature. 
A recent retrospective database analysis of patients referred for pressure flow studies (PFS) by 
Gammie et al. 21, elucidated some of the symptom prevalence for men and women with DU 
compared to those with normal PFS and BOO. The difference in symptom prevalence between 
men and women with DU was not compared. However, stress incontinence was reported by 
25% of men and 79% of women with DU in the sample. Urinary incontinence is also known to 
be less prevalent in the male general population 153,209,210 so may provide some proxy for 
comparison in the absence of data for other symptoms that are perhaps more associated with 
UAB. The sample was investigated for any relationship between symptom prevalence and 
gender. 
Clean intermittent catheterisation (CIC) or intermittent self-catheterisation (ISC) has been 
recommended and used successfully for neuropathic bladder problems and bladder drainage 
for patients for a number of years 211. However, the apparent clinical benefits to patients with 
UAB are not well documented, despite being the only current intervention available for UAB 25 
(sacral neuromodulation (SNM) also shows promise in appropriately selected patients 19). The 
use of ISC was investigated for association of symptom relief with reported symptoms. 
Incomplete bladder emptying is considered a classic symptom of UAB 25,26. The presence of a 




Criterion validity  
There are no existing validated PRO measures to assess UAB against which the ICIQ-UAB can 
be compared, as is most often the case when the development of a new PRO is justified. 
However, concurrent validity was assessed by evaluating responses to items within the ICIQ-
UAB 1-week at baseline for associations with responses to related items in other PRO 
measures of known validity. Items within the ICIQ-UAB were paired with similar items in the 
ICIQ-MLUTS, ICIQ-FLUTS and ICIQ-LUTSqol. A Spearman’s correlation coefficient of >0.7 was 
used as the accepted cut-off to indicate a correlation 212. 
It was hypothesised there should be a very good correlation between paired items which have 
identical shared target concepts. Reasonable correlations were expected between paired 
items with similar or ‘best fit’ measured concepts.  
Known groups analysis 
Known groups of severity were designated by the responses given to PGI-S data at baseline (no 
symptoms n=7, mid n=11, moderate n=27, severe n=4). It was hypothesised that the mean 
score of both versions of the ICIQ-UAB would increase with the level of severity.  
Internal consistency  
Cronbach’s alpha was calculated for the baseline scores for all respondents (n=54) in order to 
explore the extent of the homogeneity of the items, or the ability of the questionnaire to 
measure the same concept 103. A Cronbach’s alpha of ≥0.7 was considered acceptable and >0.9 
to possibly indicate redundancy within the item pool 154.  
Test –retest reliability 
The stability of the items was measured by the scores obtained on separate occasions in a 
‘stable’ population, or over a period of time where there are not expected to be any change in 
their symptoms 99. The test-retest responses were analysed using only the data from the 
patients who gave an answer ‘no change’ to the PGI-C on day 8. The PGI-C items have been 
widely used to assess the subject’s perspective of improvement, and have been shown to have 




The Intraclass correlation coefficient (ICC) was calculated between scores returned on day 1 
and day 8 for ICIQ-UAB 1-week, and between successive pairs of administrations for ICIQ-UAB 
24 hrs. The accepted criterion for reliability was ≥0.7, and >0.9 was considered excellent 154. 
The extent of agreement between item-level responses for repeat administrations was also 
evaluated. The kappa coefficient was used to give a chance-corrected measure of agreement 
at the item-level (Kappa statistic (κ): 0 = poor, 0.01-0.20 = slight, 0.21-0.40 = fair, 0.41-0.6 = 
moderate, 0.61-0.8 = substantial, and 0.81-1 = almost perfect agreement 157).  
6.3 Results 
A total of 54 patients with a primary diagnosis of DU were recruited from 4 sites in the UK 
(n=29), 3 sites in the Netherlands (n=16) and 1 site in Germany (n=9). The sample was entirely 
Caucasian and predominantly male (80%), had a mix of employment status, were diagnosed 
with or without co-existing urological conditions and had a range of self-reported severity of 
symptoms and urological medications. The summary of demographic characteristics and 
urodynamic parameters is included in Table 18. 












Abbreviations: Standard Deviation (SD). Intermittent self-catheterisation (once a day or more) (ISC), 
Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder contractility index 
(BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) calculated by 
BOOI=pdetQmax-2Qmax, Post Void Residual (PVR), Bladder Voiding Efficiency (BVE) calculated by voided 
volume/total bladder capacity) × 100. Detrusor Overactivity (DO). 
Clinical or demographic 
characteristic 
Total sample (n=54) 
DU (only) n (%) 33 (61) 
DU + mild DO n (%) 10 (19) 
DU + mild BOO n (%) 8 (15) 
DU + mixed (other) n (%) 3 (5) 
Mean age and range (years) 61.2 (19-88) 
Gender – male n (%) 43 (80) 
ISC n (%) 10 (19) 
PVR >30ml n (%) 36 (67) 
PVR <30ml n (%) 16 (30) 
No PVR (0ml) n (%) 11 (20) 
BVE(%) mean (SD) 64.9 (31.3) 
BCI mean (males only) (SD) 76.0 (19.3) 
BOOI mean (males only) (SD) 19.4 (12.1) 
PdetQmax (cmH20) mean (SD) 30.5 (12.6) 





6.3.1 Missing data 
Missing data at baseline for the ICIQ-UAB 1-week was very low (no responses missing or <3%) 
for all items and administrations, with the exception of item 23 ‘Were your symptoms worse at 
particular times? Please tick those that apply’ which had 7% missing data at baseline and on 
retest at day 8. No patients ticked multiple boxes for this item. The missing data for ICIQ-UAB 
24hr was also very low for all items at all administrations (no responses missing or <5%). At day 
1, one patient did not complete 6 items and another patient missed the whole day 10 
administration. 
6.3.2 Floor and ceiling effects 
All three of the medical history items (Q1-3) in the ICIQ-UAB 1-week showed strong floor 
effects.  Item 2, ‘urinary tract infections’ also showed a ceiling effect, of which 26% of 
responses were the ‘three or more times’ response option. A total of 9/20 symptom items 
showed a floor effect. The largest floor effects (>50%) were observed in the ‘incontinence’, 
‘temporarily unable to pass urine’ and ‘post-micturition dribble’ items at 70%, 61% and 50% 
respectively.  All impact items showed strong floor effects with over 40% of responses  given as 
‘not at all’ in 6/7 items. The highest response option was not used in the items for 
‘incontinence’, ‘urgency’, ‘nocturnal voids’, ‘daytime frequency’ and ‘temporarily unable to 
pass urine’.  The second response option for the item ‘length of time in bathroom’ attracted 
70% of the responses with the highest two response options also used very infrequently. 
A total of 12/20 corresponding items in the ICIQ-UAB 24hrs showed a floor effect. The 
additional three items which had a floor effect in this version (compared to the ICIQ-UAB) 
were ‘urgency’, ‘straining towards end of void’ and ‘small volume of urine per void’. It should 
be noted that these additional items were only marginally over the threshold of 26%, 20% and 
22% respectively. The same three medical history items had floor effects above 50% as in the 
ICIQ-UAB. The highest response option was not used in the ‘length of time in the bathroom’ 
and ‘temporarily unable to pass urine’ items. 
Table 19 shows the percentage of responses in the lowest response option, and Figure 7 and 
Figure 8 shows the frequency distribution of the ICIQ-UAB 1-week responses by item, for the 






Table 19. The percentage of responses in lowest response option for each version at 
baseline. A shading of red indicates a floor effect  (≥20% of responses were in lowest 
category). 
Item  (ICIQ-UAB 1-week/ICIQ-UAB 
24hrs) 






Acute retention (Q1) 83  
UTIs over last month (Q2) 59 
Self-catheterisation (Q3) 80 
Hesitancy (Q4/Q1) 9 13 
Need to concentrate to void (Q5/Q2) 28 20 
Small volume of urine per void 
(Q6/Q3) 
15 22 
Post-micturition dribble (Q7/Q4) 50 52 
Incontinence (Q8/Q5)  70 67 
Need to immediately re-void (Q9/Q6) 28 37 
Incomplete emptying (Q10/Q7) 13 19 
Intermittency (Q11/Q8) 15 19 
Straining to start (Q12/Q9) 24 30 
Straining towards end of void 
(Q13/Q10) 
9 20 
Slow stream (Q14/Q11)  15 15 
Urgency (Q15/Q12) 19 26 
Nocturnal voids (Q16/Q13)  9 11 
Daytime frequency (Q17/Q14) 7 7 
Reduced bladder sensation (Q18/Q15) 24 20 
Waiting in bathroom after voiding 
(Q19/Q16) 
24 26 
Length of time in bathroom 
(Q20/Q17) 
15 15 
Temporarily unable to pass urine 
(Q21/Q18)  
61 67 
Bowel association (Q22/Q19)* 78 82 
Clustering of symptoms (Q23/Q20)** n/a n/a 
Impacts 
Planning life around toilets (Q24) 41  
Social life (Q25) 50 
Nocturia/nocturnal voids impact 
(Q26) 
41 
Physical activities (Q27) 46 
Feelings about self (Q28) 46 
Embarrassment (Q29) 43 
Fluid intake (Q30) 30 
*Includes patients who answered ‘no’ in to the initial dichotomous yes/no option. 






















The medical history items (Q1-3) showed relatively high bother ranging from 6.4-7.1. Symptom 
mean scores for the ICIQ-UAB 1-week ranged from 4.5-6.9, ‘clustering of worst symptoms’ 
having the lowest mean bother score and ‘incontinence’ the highest. The ICIQ-UAB 24hrs 
mean scores ranged from 4.5-6.8, ‘clustering of worst symptoms’ having the lowest mean 
bother score again and ‘bowel associations’ with the highest. The mean bother scores for 
corresponding items in each of the recall period versions were very similar. Figure 10 shows 
the mean bother scores were lower in the patients who rated their symptoms as none/mild on 





Table 20. Mean bother scores at baseline day 1 (for those who experienced the symptom) 
for ICIQ-UAB and ICIQ-UAB 24hrs. 
Item (ICIQ-UAB 1-week/ICIQ-UAB 24hrs) ICIQ-UAB 1-week ICIQ-UAB 24hrs 




Acute retention (Q1) 6.4 (3.4)  
UTIs over last month (Q2) 7.7 (2.5) 
Self-catheterisation (Q3) 7.1 (2.3) 
Hesitancy (Q4/Q1) 4.6 (2.8) 5.0 (3.1) 
Need to concentrate to void (Q5/Q2) 5.2 (2.7) 5.3 (3.0) 
Small volume of urine per void (Q6/Q3) 5.6 (2.7) 5.8 (3.0) 
Post-micturition dribble (Q7/Q4) 6.6 (2.4) 6.6 (2.5) 
Incontinence (Q8/Q5)  6.9 (2.6) 6.3 (2.7) 
Need to immediately re-void (Q9/Q6) 6.3 (2.3) 6.6 (2.5) 
Incomplete emptying (Q10/Q7) 5.8 (2.8) 6.0 (3.0) 
Intermittency (Q11/Q8) 5.7 (2.6) 5.4 (3.0) 
Straining to start (Q12/Q9) 5.8 (2.8) 5.7 (3.2) 
Straining towards end of void (Q13/Q10) 5.8 (2.7) 6.3 (2.9) 
Slow stream (Q14/Q11)  5.5 (2.8) 5.2 (3.0) 
Urgency (Q15/Q12) 6.1 (2.6) 6.3 (2.4) 
Nocturnal voids (Q16/Q13)  5.8 (3.0) 5.5 (3.1) 
Daytime frequency (Q17/Q14) 4.9 (3.1) 4.9 (3.3) 
Reduced bladder sensation (Q18/Q15) 4.9 (3.1) 5.1 (3.0) 
Waiting in bathroom after voiding 
(Q19/Q16) 
5.6 (2.8) 5.5 (2.6) 
Length of time in bathroom (Q20/Q17) 5.0 (2.9) 5.1 (3.3) 
Temporarily unable to pass urine 
(Q21/Q18)  
6.0 (3.2) 5.8 (3.1) 
Bowel association (Q22/Q19) 6.5 (2.7) 6.8 (3.0) 
Clustering of symptoms (Q23/Q20) 4.5 (3.6) 4.5 (3.7) 
Planning life around toilets (Q24) 7.1 (2.2)  
Social life (Q25) 6.4 (2.5) 
Nocturia/nocturnal voids impact (Q26) 6.7 (2.5) 
Physical activities (Q27) 6.1 (2.5) 
Feelings about self (Q28) 6.3 (3.1) 
Embarrassment (Q29) 6.6 (2.7) 
Fluid intake (Q30) 5.8 (2.6) 






Figure 10. Mean bother scores for ICIQ-UAB 1-week stratified by those with no/mild symptoms and those with moderate/severe symptoms as 




6.3.4 Construct validity 
Table 21 and Table 22 show the percentage of patients reporting symptoms and impacts at 
baseline (in the ICIQ-UAB 1-week), by the investigated subgroups: age, gender, self-
catheterisation and post void residual. The pairs of values highlighted in green have a 
proportionate significant difference (p<0.05). Unless indicated, the percentage of patients who 
answered ‘sometimes’, ‘most of the time’ or ‘every time’ are given.  
The only symptom/sign that was correlated by age was ‘temporarily unable to pass urine’, 
which was less prevalent in older participants.  
Females were found to be more likely to report increased daytime frequency and 
incontinence. The item for ‘bowel associations’ was reported by a higher percentage of males. 
Those who practice ISC were found to have significantly fewer reported nocturnal voids. This 
did not quite reach statistical significance for the reported impact of nocturnal voids (Table 
22). In addition, those who practised ISC were more likely to report historical urinary tract 
infections. 
No significant difference was found between reported symptoms in participants with a 
urodynamically confirmed PVR. This included the sensation of incomplete emptying.  
There were no significant differences in reported impacts in any of the sub-groups, except for 




























Acute retention episodes (Q1) 18 15 21 0 16 20 25 14 
Urinary tract infections (Q2) 43 35 33 64 30 80 31 39 
Self-catheterisation (Q3) 18 19 12 45   6 22 
Hesitancy (Q4) 54 35 42 55 41 60 56 36 
Need to concentrate to void (Q5) 54 31 44 36 39 60 50 36 
Small volume of urine per void (Q6) 54 54 51 64 48 80 56 50 
Dribbling (Q7) 25 27 26 27 27 20 25 25 
Incontinence (Q8) (Occasionally or more) 25 15 23 55 30 30 13 36 
Need to immediately re-void (Q9) 43 38 42 36 39 50 38 42 
Incomplete emptying (Q10) 46 62 51 55 50 60 56 47 
Intermittency (Q11) 61 58 53 82 61 50 75 50 
Straining to start (Q12) 54 31 42 45 43 40 44 39 
Straining towards end of void (Q13) 68 58 58 82 52 70 69 58 
Slow stream (Q14) (reduced or more) 57 58 58 55 57 60 69 53 
Urgency (Q15) 46 42 44 45 43 50 44 44 
Nocturnal voids (Q16) (twice or more) 54 69 60 64 70 20 63 61 
Daytime frequency (Q17) (10-12 times or 
more) 21 27 16 55 20 40 19 28 
Reduced bladder sensation (Q18) 
(difficult or more) 64 54 53 82 55 80 56 58 
Waiting in bathroom after voiding (Q19) 57 50 51 64 52 60 69 44 
Length of time in bathroom (Q20) 
(6-10 minutes or more) 21 12 16 18 18 10 6 19 
Temporarily unable to pass urine (Q21) 
(occasionally or more) 54 23 40 36 36 50 38 39 
Associated bowel symptoms (Q22) 32 38 42 9 36 30 44 33 
Clustering of symptoms (Q23) 57 62 65 36 64 40 69 56 
Table 21. The percentage of patients reporting symptoms on the ICIQ-UAB 1-week at baseline in each sub-group by age, gender, self-catheterisation and 





Table 22. The percentage of patients reporting impact on the ICIQ-UAB 1-week at baseline in 
each sub-group by age, gender, self-catheterisation and post void residual. Highlighted in 
green are pairs which have a significant proportionate difference (p<0.05). 
 
 























(Q24) 64 54 65 55 59 60 63 56 
Social life 









(Q27) 54 58 53 55 52 60 44 56 
Fluid intake 
(Q28) 61 46 56 27 52 60 63 47 
Embarrassme
nt (Q29) 57 54 58 45 55 60 63 50 
Way feel 
about self 




6.3.5 Criterion (concurrent) validity  
The ICIQ-UAB 1-week symptom items relating to hesitancy, need to concentrate to void, 
straining to start or towards end, slow flow, intermittency, sensation of incomplete emptying, 
post-micturition dribble, nocturnal voids, urgency and daytime frequency all showed a good 
correlation of >0.7 with ICIQ-MLUTS and/or ICIQ-FLUTS corresponding items (Table 23 and 
Table 24). The ICIQ-UAB 1-week ‘incontinence’ item was most correlated with the ICIQ-MLUTS 
‘incontinence when cough or sneeze’ item. Items which showed poor or moderate correlations 
(<0.7) all were ‘best fit’ comparisons which did not measure identical concepts (Table 23).  










Hesitancy (Q1)  Hesitancy (Q4) 0.81  
Need to concentrate to void 
(Q5) 
0.72 
Straining (Q2)  Straining to start (Q12) 0.69  
Straining towards end (Q13) 0.70 
Slow stream (Q3) Slow stream (Q14) 0.72 
Intermittency (Q4) Intermittency (Q11) 0.71 
Incomplete emptying (Q5) Sensation of incomplete 
emptying (Q10)  
0.71  
Waiting in bathroom after 
voiding (Q19) 
0.50 
Urgency (Q6) Urgency (Q15) 0.67 
Incontinence before 
getting to the toilet (Q7) 
Incontinence (Q8) 0.38 
Incontinence when cough 
or sneeze (Q8) 
Incontinence (Q8) 0.67 
Incontinence for no 
obvious reason (Q9) 
Incontinence (Q8) 0.31 
Postmicturition dribble 
(Q11) 




Table 24. Correlations of matched ICIQ-UAB 1-week items with ICIQ-FLUTS items. 
ICIQ-FLUTS item 
description 
ICIQ-UAB item description Spearman’s 
correlation 
coefficient 
Nocturnal voids (Q1) Nocturnal voids (Q16) 0.99 
Urgency (Q2) Urgency (Q15) 0.846 
Daytime frequency 
(Q4) 
Daytime frequency (Q17) 0.95 
Hesitancy (Q5) Hesitancy (Q4) 0.82 
Need to concentrate to void (Q5) 0.79 
Straining (Q6) Straining to start (Q12) 0.91  
Straining towards end (Q13) 0.70 
Intermittency (Q7) Intermittency (Q11) 0.70 
Incontinence before 
getting to the toilet 
(Q8) 
Incontinence (Q8) 0.62 
Incontinence when 
active or cough or 
sneeze (Q10) 
Incontinence (Q8) 0.50 
Incontinence for no 
obvious reason 
(Q11) 
Incontinence (Q8) 0.417 
 
The ICIQ-UAB 1-week impact items all showed reasonable or very good correlations of >0.6 
with the matched ICIQ-LUTSqol items, except for ‘impact of nocturia and/or nocturnal voids’ 
(Table 25). 
Table 25. Correlations of matched ICIQ-UAB 1-week items with ICIQ-LUTSqol items. 
 ICIQ-LUTSqol item 
description 
ICIQ-UAB item description Spearman’s 
correlation 
coefficient 
Impact on physical 
activities (Q5) 
Impact on physical activities 
(Q27) 
0.70 
Impact on ability to 
travel (Q6) 
Planning life around toilet visits 
(Q24) 
0.60 
Impact on social life 
(Q7) 
Impact on social life (Q25) 0.82 
Impact on sleep 
(Q15) 
Impact of nocturia and/or 
nocturnal voids (Q26) 
0.377 
Fluid intake (Q18) Fluid intake (Q30) 0.74 
Embarrassment 
(Q21) 
Embarrassment (Q29) 0.68 
Feel bad about 
yourself (Q14) 
Way feel about self (Q28) 0.61 





6.3.6 Known groups analysis 
The mean score increased with the level of severity in both versions. There was a clear 
differentiation of mean scores between ‘no/mild symptoms’ and ‘moderate/severe 
symptoms’. The analysis of variance showed a significant difference between the mean scores 
of the severity groups in all domains (p <0.05) for both recall period versions. The impact score 
contained a clear outlier which was removed for the purposes of the analysis (patient 305 
responded on the PGI-S as mild symptoms but had high total impact score of 20). Table 26 and 
Table 27 show the results for each of the two versions tested. 
Table 26. Mean score of ICIQ-UAB 1-week domains when stratified by known group as 
determined by the PGI-S at baseline. 
ICIQ-UAB 1-week domains Known Groups Mean score SD P-value 
Total score 
No-Symptom 19.7 13.6 
0.003 
Mild 25.5 11.7 
Moderate 40.0 13.3 
Severe 40.3 5.7 
Symptom items 
  
No-Symptom 19.6 8.78 
0.004 
Mild 19.8 8.67 
Moderate 30.0 9.00 








Mild 5.64 4.86 
Moderate 9.56 5.67 
Severe 11 4.97 
 
Table 27. Mean score of ICIQ-UAB 24 hrs when stratified by known group as determined by 
the PGI-S at baseline. 




No-Symptom 15.3 8.38 
0.001 
Mild 19 9.62 








6.3.7 Internal consistency  
As Table 28 shows, all scores in both versions were within the accepted range of reliability 
Cronbach’s alpha coefficient ≥0.7.  
Table 28. Internal consistency for each version. 
 Cronbach’s alpha coefficient 
Domain ICIQ-UAB 1-week ICIQ-UAB 24hrs 
Total score 0.88  
Symptom  0.84 0.87 
Impact 0.82  
 
6.3.8 Test-retest reliability 
A total of 12 out of the 54 subjects reported that there had been an alteration in their 
symptom severity according to the PGI-C at day 8. These patients were excluded from the 
analysis so the following results represent the test-retest responses of a pool of 42 ‘stable’ 
participants, as determined by the PGI-C. 
Test-retest scores and domains 
Scores were reproducible for the ICIQ-UAB 1-week over the test-retest period with a mean 
score difference of 1.7 for the total score on the total 100-point scale, and 1.4 on the symptom 
item scale (0-72 point scale) (Table 29). The impact items mean score difference was identical 
(0-28 point scale). The largest mean difference between consecutive days for the ICIQ-UAB 
24hrs was 2.6 (0-72 point scale) between day 1 and day 2 (Table 30). 
Both versions returned ICCs of >0.85 in domains and pairs of administrations, indicating 
reliability which was comfortably above the acceptable threshold of 0.7 (Table 29 and Table 
30). Repeated administrations of the ICIQ-UAB 24hrs resulted in a higher ICC, the final pair of 






Table 29. Reliability of the ICIQ-UAB 1-week scores. 
ICIQ-UAB 1-week 
 
Day 1 (mean 
score) 
Day 8 (mean 
score) 
ICC (n=42)  95% CI 
Total score 37 35.3 0.90 0.83-0.95 
Symptom items 28.2 26.6 0.89 0.89-0.94 
Impact items 8.7 8.7 0.89 0.80-0.94 
 






















































Item level agreement between paired responses  
Identical agreement was not found in any of the items in either version. The three medical 
history items (Q1-3) showed very high agreement ≥85%. A total of 12/20 of the symptom 
items in both the ICIQ-UAB 1-week (Q4-23) and ICIQ-UAB 24hrs showed identical agreement in 
≥60% of cases. Only 3/20 symptom items in both the ICIQ-UAB and the ICIQ-UAB 24hrs had 
levels of agreement of less than 50%. The items ‘need to concentrate to void’, ‘small volume of 
urine per void’, ‘daytime frequency’, ‘intermittency’ and ‘reduced bladder sensation’ showed 
the least agreement at 40-49% in one, or both versions. The impact items in ICIQ-UAB all 
showed identical agreement between 50-70%.  
The medical history items were the only items to show almost perfect agreement (κ=0.81-1). A 
total of 4/20 symptom items in the ICIQ-UAB 1-week and 5/20 items in the ICIQ-UAB 24hrs 
showed substantial agreement (κ=0.61-0.8). In both versions, 10/20 of the symptom items 
showed moderate agreement (κ=0.41-0.6). A total of 23/31 items in the ICIQ-UAB 1-week and 
15/20 items showed moderate agreement or better (κ≤0.41). The items ‘need to concentrate 




frequency’, ‘waiting in bathroom after voiding’, ‘reduced bladder sensation’, and 
‘intermittency’ showed fair agreement (κ=0.21-0.40) in one, or both versions. ‘Incontinence’ 
was the only item to show slight agreement, in the ICIQ-UAB 24hr (κ=0.21-0.40). 
In general, most of the items in each version returned very similar statistics for test-retest. 
Some exceptions were the item daytime frequency which showed a clearly higher agreement 
and kappa statistic in the 24 hour version. The item ‘intermittency’ showed higher agreement 






Table 31. Test-retest analysis of each item between day 1 and day 8 for the ICIQ-UAB 1-
week, and between day 1 and day 2 for the ICIQ-UAB 24hrs (Identical agreement and 
weighted Kappa). 











Retention (Q1) 41 (98) 0.92  
Urinary Infections (Q2) 40 (95) 0.92 
Self-catheterisation (Q3) 39 (95) 0.85 
Hesitancy (Q4/Q1) 26 (63) 0.50 25 (60) 0.46 
Need to concentrate to void (Q5/Q2) 20 (48) 0.34 24 (57) 0.47 
Small volume of urine per void (Q6/Q3) 20 (48) 0.31 21 (50) 0.38 
Post-micturition dribble (Q7/Q4) 30 (71) 0.57 28 (67) 0.48 
Incontinence (Q8/Q5) (Occasionally or 
more) 33 (81) 0.57 27 (64) 0.20 
Need to immediately re-void (Q9/Q6) 22 (52) 0.34 29 (69) 0.54 
Incomplete emptying (Q10/Q7) 25 (61) 0.49 28 (67) 0.58 
Intermittency (Q11/Q8) 28 (70) 0.62 17 (41) 0.23 
Straining to start (Q12/Q9) 24 (57) 0.45 23 (55) 0.40 
Straining towards end of void 
(Q13/Q10) 27 (64) 0.55 24 (57) 0.46 
Slow stream (Q14/Q11)  26 (65) 0.53 30 (71) 0.63 
Urgency (Q15/Q12) 22 (52) 0.34 18 (43) 0.23 
Nocturnal voids (Q16/Q13) (twice or 
more) 30 (71) 0.63 31 (74) 0.66 
Daytime frequency (Q17/Q14) 18 (43) 0.30 29 (69) 0.56 
Reduced bladder sensation (Q18/Q15) 27 (64) 0.52 20 (48) 0.32 
Waiting in bathroom after voiding 
(Q19/Q16) 22 (52) 0.39 24 (57) 0.43 
Length of time in bathroom (Q20/Q17) 31 (74) 0.50 33 (79) 0.62 
Temporarily unable to pass urine 
(Q21/Q18)  35 (83) 0.67 35 (83) 0.62 
Bowel association (Q22/Q19) 6 (54) 0.42 9 (89) 0.76 
Clustering of worst symptom 
(Q23/Q20) 26 (74) 0.64 28 (67) 0.55 
Planning life around toilet visits (Q24) 27 (64) 0.50  
Social life (Q25) 27 (66) 0.50 
Impact of nocturia and/or nocturnal 
voids (Q26) 25 (63) 0.51 
Impact on physical activities (Q27) 29 (69) 0.54 
Fluid intake (Q28) 28 (67) 0.54 
Embarrassment (Q29) 23 (56) 0.35 





The current study assessed the psychometric properties of the ICIQ-UAB 1-week and ICIQ-UAB 
24hrs in the target population. The following discusses the results in terms of the conclusions 
which can be made concerning the validity and reliability of the instrument, including possible 
modification to its content and choice of recall period. The generalisability, representativeness 
and limitations of the study are also discussed.  
6.4.1 Validity 
Missing data 
Low levels of missing data levels suggest the instrument was easy to complete and well 
understood in both versions. In the ICIQ-UAB, item 23 performed the worst (7% missing 
responses) and there was a misunderstanding of the ‘please tick all that apply’ instruction. This 
item is to be considered for revision or removal.  
Floor effects 
Many of the items in both versions showed floor effects. This may suggest items are measuring 
a concept which has limited relevance to the targeted population, presents relatively rarely in 
the population, or only occurs in patients with relatively severe symptoms. An item which 
displays a strong floor effect is likely to affect the potential for sensitivity to change of the final 
instrument so it may be necessary to revise or consider removal 99. Items with the largest floor 
effects in both versions were those relating to ‘incontinence’, ‘temporarily unable to pass 
urine’ and ‘post-micturition dribble’ in both versions. Revision of the response options for the 
items relating to ‘incontinence’, ‘urgency’, nocturnal voids, ‘daytime frequency’, ‘temporarily 
unable to pass urine’ and ‘length of time in the bathroom’ are to be considered, as the highest 
response option was not used in one, or both versions. The first response option for the item 
‘length of time in the bathroom’ is also to be considered for revision (‘less than a minute’ was 
used infrequently so may be too short a time to be considered non-symptomatic or ‘normal’). 
All impact items in the ICIQ-UAB may be considered for revision due to large floor effects. 
However, this could also be an accurate reflection of true impact of these symptoms in the 





The bother scores associated with each item were shown to be an effective measure of the 
‘bother’ relating to each symptom, sign or impact. There was a clear relationship between high 
bother scores and reported severity of condition, which supports the content validity for this 
aspect of the instrument.  
Construct validity 
There was some evidence that the high proportion of responses by women for the items 
‘daytime frequency’ and ‘incontinence’ in the current study were in congruence with the 
known higher prevalence of these symptoms in women in the general population 153,209,210. The 
item ‘temporarily unable to pass urine’ was also related to increasing age. This is encouraging 
evidence that that the PRO measure is able to detect trends that is evidenced by the literature. 
However, correlations may be due to the purposive sample selection (all were recruited as 
referred symptomatic patients with UAB), and therefore may not reflect the prevalence of UAB 
within the background population. The high proportion of females who self-catheterised and 
had associated bowel symptoms may also be due to the purposive nature of the sample, or the 
relatively small sample size of the grouped data. The use of ISC appeared to relieve the 
symptom of nocturia and was tentatively as expected according to the literature 25, although 
this did not translate to a clear effect on the reported impact of symptoms. Those who 
practised ISC were also more likely to report historical urinary tract infections, for which there 
is a documented (but not UAB specific) association 215. No difference was found in the reported 
symptoms between those with or without a PVR. There was a gender difference found for the 
way men felt about themselves compared to women. One reason could be that men are 
known to have an increased awareness of their urinary problems when urinating alongside 
others in urinals 8. 
In summary, it was not possible to provide definitive evidence of construct validity, primarily 
due to the current paucity of the UAB specific literature, resulting in a lack of sufficiently well 
evidenced theoretical constructs by which a comparison may be made. Future epidemiological 
studies which elucidate the prevalence of symptoms and trends associated with DU will allow 
construct validity to be assessed. However, it is encouraging that the associations found were 




Criterion (concurrent) validity 
An accepted ‘yard-stick’ measure does not exist for UAB against which criterion validity may be 
evaluated. However, correlations with instruments of well-evidenced validity (ICIQ-MLUTS, 
ICIQ-FLUTS, ICIQ-LUTSqol) provided a quasi ‘gold-standard’ for the evaluation of several of the 
items relating to LUTS and quality of life. 
The concurrent validity of selected items within the ICIQ-UAB 1-week was conclusively 
demonstrated with similar concepts in other instruments of known validity. The ICIQ-UAB 1-
week ‘incontinence’ item’ showed the highest correlation with the ICIQ-MLUTS ‘incontinence 
when cough or sneeze’ item.  This may reflect the predominant type of incontinence 
experienced by the UAB sample. The few items which were moderately correlated (<0.7) with 
their matched counterparts in other instruments were paired with ‘best fit’ items, so 
performed as expected. For example, the ICIQ-UAB item relating to ‘nocturia/nocturnal voids’ 
asked ‘how often did you feel getting up at night to urinate affected your day to day life?’ 
whereas the ICIQ-LUTSqol was ‘does your urinary problem affect your sleep?’.  
Known groups 
Analysis of variance between known groups of symptom severity, as determined by the PGI-S 
at baseline, showed a relationship between a higher level of reported symptom severity and 
increasing score total. Thus, the instrument was shown to be sensitive to the reported overall 
severity of condition. 
6.4.2 Reliability 
Two methods of reliability were used to evaluate the consistency of the ICIQ-UAB, internal 
consistency and test-retest reliability. These methods provided evidence that the score derived 
from the instrument is consistent with itself and that a high proportion of variability within 
repeated administrations of the instrument is due to the underlying scale 103. 
Internal consistency 
The relationship between items showed excellent reliability over the accepted range 
(Cronbach’s alpha ≥0.7) 154 in the tested domain scales of both versions.  Internal consistency 
of the ICIQ-UAB was towards the upper end of the accepted range (Cronbach’s alpha of 0.88) 




due to the current exhaustive inclusivity of items and supports the capacity for the future 
reduction in the number of items.   
Test-retest reliability 
Test-retest reliability in stable patients was shown to be very good with ICCs over 0.85 for both 
versions. This provides evidence that the instrument was capable of reliably measuring what it 
intends to measure, and that findings were not just due to systematic errors 103,104. Repeated 
administrations of the 24 hour version resulted in greater reliability, possibly suggesting a 
learning effect. 
Item-level reliability 
The assessment of reliability at the item level allowed the evaluation of individual item test-
retest performance. Most items in both versions performed well, with ≥60% of responses 
being identical. The items ‘need to concentrate to void’, ‘small volume of urine per void’, 
reduced bladder sensation and ‘daytime frequency’ may be considered for revision, following 
relatively low identical agreement performance (40-49%). The weighted kappa statistic 
provided evidence of ‘moderate’ agreement or better (κ≤0.41) in 23/31 items in the ICIQ-UAB 
1-week and 15/20 in the ICIQ-UAB 24hrs. It is recognised that day to day variability of 
symptoms and impacts (as evidenced in the concept elicitation phase) may affect the 
consistency of identical responses expected, when measured on two separate occasions. 
However, items which performed poorly may be flagged for revision or removal from the final 
instrument, following further testing.  
6.4.3 Scoring 
The format and content of item 22 (associated bowel symptoms) and item 23 (clustering of 
symptoms) did not lend themselves well to scoring so it was necessary to exclude these items 
from contributing to the total score calculations. The first response of the item relating to 
‘daytime frequency’ was ‘1-3 times’ which may be considered symptomatic due to a low 
frequency. The scoring here is to be considered for revision to allocate this option a score of 
‘1’. Thus, the second response option of ‘4-6’ times is scored ‘0’ to approximate what may be 




6.4.4 Recall period 
Both the 1-week and 24hr versions were very similar in terms of the psychometric properties 
they exhibited. Three more items in the ICIQ-UAB 24hrs had floor effects that were marginally 
over the threshold of 20%. However, the highest response option was not used in three more 
of the items in ICIQ-UAB 1-week. The average symptom domain score of the ICIQ-UAB was 
marginally higher than the 24 hour version, suggesting more capacity for sensitivity to change. 
However, the range of mean corresponding scores in the known groups analysis was slightly 
greater in the 24 hour version, suggesting this was more sensitive to reported severity of 
condition. The mean bother scores and internal consistency was very similar for both versions. 
In general, the test-retest identical agreement between repeated administrations was very 
similar, along with the chance corrected weighted kappa statistic. However, there was some 
evidence that a few items could be more suitable for specific recall periods. For example, the 
item relating to ‘daytime frequency’ was more reliable with a 24 hour recall period whereas 
the item ‘intermittency’ was more reliable with the 1 week recall period. 
Therefore, there was no strong evidence to suggest an overall advantage of a 24 hour or one 
week recall period, supporting the conclusion that both versions should go on to further 
testing. 
6.4.5 Strengths and limitations 
The sample was primarily purposive in nature, that is, patients were approached that were 
referred for urodynamic studies at the included sites and met the inclusion/exclusion criteria. 
Although the epidemiology of UAB is not well understood 14,25,26, it is acknowledged the 
demographic characteristics are unlikely to be representative of the prevalence of UAB in the 
background population (by gender, age, ethnicity). For example, there was a larger proportion 
of males recruited (80%) which may reflect that the sample was recruited from patients who 
had undergone urodynamic investigation. There is a necessity for diagnostic pressure flow 
studies in men in order to differentiate DU patients from those with predominant BOO, in 
order to avoid further referral to  corrective surgery for LUTS (for which there may be little 
benefit for DU patients) 203,204. Women who present with these symptoms may be more likely 
to be referred to self-catheterisation management techniques rather than further urodynamic 
investigation. Nevertheless, effort was made to ensure the sample was as representative as 
possible of the referred patient population and of the target population in which the 




pilot study component was that the sites were located in three different European countries, 
which improves the generalisability of the instrument to wider populations.  
It should be acknowledged that the response options of the two versions were worded slightly 
differently to match the recall period set. However, these were not sufficiently different to 
make comparison of the two recall period versions impossible for the corresponding symptom 
items. Each version was independently analysed so the conclusions regarding reliability and 
validity remain unchanged. 
There is no definitive standard for sample size in questionnaire development studies 103 and 
the required minimum sample size of 40 was met 206. However, a larger sample size would 
have further improved the generalizability or strength of the conclusions. Nevertheless, the 
sample was large enough to provide adequate supportive evidence of the validity and 
reliability of the ICIQ-UAB at this stage of initial validation. 
6.5 Instrument modification following the pilot study 
A number of decisions were made surrounding items within the ICIQ-UAB, following the 
evaluation of the pilot study data. These changes were investigated to be understood and 
interpreted as intended by patients by seven additional cognitive interviews. The details of 
these interviews and rationale for each of the changes are given in Appendix 7. 
Modifications to the questionnaire as a result of the psychometric testing were deliberately 
conservative. It is anticipated that the number of items will be reduced using PRO data from 
larger clinical trials, as well as the evaluation of responsiveness to change and item scoring. 
The decisions and main changes made are summarised as follows:  
 The 24 hour recall period was retained for the symptoms items for future clinical trials. 
A longer recall period of 1 week was retained for the impact items due to patient 
preference. However, both versions will remain available for further testing.  
 Corresponding response options were selected from the 24 hour recall period version. 
 Minor revisions to wording were made to aid the clarity of interpretation and address 
floor effects in the following item stems: 
- Intermittency 
- Reduced sensation 
- Waiting in the bathroom after voiding 




- Planning life around toilet visits 
- Social life 
- Way feel about self 
 The response options of the items ‘nocturia/nocturnal voids’, ‘daytime urinary 
frequency' and ‘length of time in bathroom’ were modified to mitigate floor effects. 
 Three items were removed: ‘bowel associations’, ‘clustering of symptoms’ and 
‘embarrassment’. 
 Two items were added; ‘straining (to maintain)’ and ‘how often not getting enough 
sleep’. Further testing of the psychometric properties of these new items will occur in 
alongside planned clinical trials. Their responsiveness to change will provide further 
information on whether both items will be retained in the final instrument. 
 The following items were flagged for potential removal, following the collection of 
sensitivity to change data: 
- Concentrates to start urination 
- Post-micturition dribble 
- Incontinence  
- Temporarily unable to pass urine 
- Physical activity 
- Fluid intake 
6.6 Conclusion 
The pilot study provided initial evidence to support the reliability and validity of both the ICIQ-
UAB 1-week and the ICIQ-UAB 24hrs in patients with a diagnosis of DU with or without co-
existing urological conditions. The evidence was used to make decisions regarding the removal 
or revision of items. Further psychometric testing (beyond the remit of this thesis) in a larger 
sample with the target clinical trial population will allow further evaluation of the instrument, 
including the assessment of sensitivity to change following an intervention and the derivation 





Chapter 7 Concept elicitation in the United States and Japan 
7.1 Introduction 
Direct patient involvement is essential in supporting aspects of content validity when 
developing items for a new PRO measure, to reflect the patients’ perspective and when used 
to support labelling claims 99. Considering the global intention for use of the ICIQ-UAB, a 
diverse sample as possible is required to ensure the eventual instrument represents the 
experiences of the demographic variations of the potential questionnaire respondents 112,216. 
Special attention should be given to include the experiences of a patient population with 
diverse ethnic background during item development, in particular as the interviews in the UK 
were performed in a population of Caucasian patients. The following chapter describes the 
conduct of further concept elicitation interviews conducted in the United States (US) and 
Japan to support the content validity of the ICIQ-UAB instrument.  
7.2 Methods 
The objective was to elicit and document the experience of signs, symptoms and impact of 
UAB in patients diagnosed with DU, at sites in the US and Japan. The Japanese study was 
conducted at Nagoya University Hospital and Harasanshin Hospital. The study in the US was 
conducted at the Langone hospitals located in New York. Both studies were approved by the 
appropriate local ethics board in their respective countries. 
 In-depth qualitative interviews were conducted to explore patient’s experience of UAB 
symptoms and the impact of those symptoms on their day-to-day lives. Patients with DU alone 
and those with other urological conditions were interviewed to capture the range of symptoms 
and impact which patients with UAB may experience. Patients recruited for the study met 
eligibility criteria based on the same urodynamic pressure flow study parameters as the 
interviews carried out in the UK. 
Interviews were conducted by experienced qualitative researchers provided by contract 
research organisations, Pharmerit in the US, and IMS in Japan. Interviews were either face to 
face, or over the telephone. Written informed consent was obtained prior to the start of the 




were guided by the interview schedule that was developed during the UK concept elicitation 
interviews. This was to enable the direct comparison between findings from the US, Japan and 
the Bristol study samples to help the documentation of conceptual adequacy across cultures 
216. The schedule was designed to be conducted in a way to encourage the patient to be as 
open as possible about their experiences in order to spontaneously elicit (without prompts) 
the symptoms and impact of their condition. Open-ended questions were followed by more 
targeted probes if required. The interviews took approximately 60 minutes. 
7.2.1 Data analysis 
Following data collection, the analysis of the transcripts was performed using the same 
approach and coding frame which was used in the UK concept elicitation study 22. This entailed 
an initial inductive approach 134 to the data, which allowed the identification of ‘new’ 
symptoms or impacts if present, then transcript content was categorised or ‘coded’ by existing 
defined urological symptoms (e.g. ‘hesitancy’, ‘urgency’ and ‘increased daytime frequency’) 
201,202. In particular, if new concepts were mentioned spontaneously, or described more than 
once by subjects, these were flagged as potentially new concepts relevant to the respective 
population. All the US transcripts were coded by the author and independent qualitative 
researchers in the US and reconciled for differences following discussion meetings. For 
pragmatic reasons the Japanese interviews were conducted and analysed in the language of 
origin by independent Japanese qualitative researchers. The author was responsible for the 
reconciliation of any coding differences after translation in further correspondence with the 
Japanese researchers.  
7.3 Results 
7.3.1 Sample demographic and urodynamic characteristics 
A total of 21 patients were interviewed, 10 from Japan and 11 in the US. The demographic and 
clinical characteristics of the sample from each country are shown in Table 32. A variety of 
educational backgrounds (ranging from high school to college or university educated), marital 
(single, married, divorced) and employment statuses (student, retired, employed) were 
represented in both population samples. In the US, all patients were Caucasian with the 
exception of one who was native Indian/Alaskan. A history of or current self-catheterisation, 
and the presence of a post void residual was common to many of the subjects in both samples. 
Participants all demonstrated DU, with or without urological co-existing conditions, as 




Table 32. Sample demographic and clinical characteristics. 
Demographic or clinical characteristic U.S. (n=11) Japan 
(n=10) 
Age   
 Mean 60 66 
 SD 18.6 11.5 
 Range 24-86 39-78 
Gender (n)   
 Male 10 7 
 Female 1 3 
Ethnicity (n)   
 Caucasian/White 10  
 Indian/Alaska native 1  
 Japanese   10 
Education level (n)   
 High school 5 4 
 College or university  6 6 
Marital status (n)   
 Single 2 3 
 Married 7 7 
 Divorced 2  
Employment status (n)   
 Student 1  
 Employed (part-time or  full-time) 6 3 
 Retired 4 2 
 Homemaker  2 
 Unemployed  3 
Diagnostic group 
 DU  
 DU + BOO-E 
 DU + SUI 









PVR >30ml* n (%) 9 (82) 7 (70) 
PVR (median and interquartile range) (ml)  230 (163-
900) 
162 (41-217) 
BCI (median and interquartile range) 73 (38-92) 62 (49-75) 
BOOI (median and interquartile range)** 0 (-1.2-11) 21 (16-27) 
PdetQmax (cmH20) (median and interquartile 
range) 
18.4 (16-24) 34 (19-37) 
Qmax (ml/sec) (median and interquartile 
range) 
14 (4-15) 5.5 (3.3-7) 
*In the absence of any evidence base for the lower limit of a ‘significant’ PVR >30mls was chosen. 
**Males only 
Abbreviations: Detrusor pressure at maximum flow (PdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=PdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 





7.3.2 Concept elicitation results 
The following describes the main findings with relevant patient quotes derived from the 
original transcripts. 
Storage symptoms 
In the US sample, nocturia was the most commonly reported storage symptom; most patients 
(n=7/11) described having to get up at least once in the night to urinate.  A high urinary 
frequency was often reported (n=4/11), however, the time between successive urinations was 
up to 12 hours in one patient. A reduced ability to tell when the bladder was full was reported 
(n=6/11). US 201: “I don’t have strong urges to empty my bladder”. Patients (n=5/11) 
described occurrences of a sudden desire to pass urine, which they were unable to ignore 
(urgency). Two participants described occasional stress or urgency urinary incontinence in 
small volumes: “If I sneeze or if I cough...there’s also urination going on at the same time.” 
There was one report of nocturnal enuresis. 
In the Japanese sample, a high urinary frequency was reported by all of the patients 
(n=10/10). The number of micturitions was variable but was up to 13 times a day in one 
patient. Nocturia events of several times a night were also commonly reported (n=8/10). 
Urgency was described by many of the patients (n=7/10): “I get this sudden desire to urinate 
even though I feel like there’s no urine to pass”. Some participants (n=6/10) described urinary 
incontinence in the context of sneezing, doing physical activity or when “touching something 
cold”. A reduced sensation that the bladder was full was reported by a single participant: ”I 
feel abdominal pain when my bladder is full…but once I forget about it, I would not feel any 
sensation…” 
Voiding symptoms 
In the US, the flow rate was usually described as “weak” (n=7/11) and could be very 
bothersome: “At its worst, it was practically down to a trickle”. The symptom of straining was 
described as “pushing” or “squeezing” and was used when starting, maintaining or when 
finishing their urinations to try and empty their bladder as much as possible. Patients 
described (n=4/11) that it would “take a little while to get going” before the flow of urine 
would start (hesitancy). This could last for a few seconds to several minutes, dependent on the 
individual and the context. An intermittent stream (n=4/11) and urinations of small volume per 




Japanese patients (n=9/10) reported their urinary stream as having “weak force”, especially in 
contrast to performance in the past. One patient emphasised the bothersome long urination 
time: “The time it takes to complete urination is longer than it used to be”. Straining was also 
reported by most patients (n=8/10); this was used to initiate or finish urination, or to restart 
due an intermittent stream: “I try to apply a lot of strength around my stomach”. A small 
volume per void (n=8/10) was commonly reported in the context of the other voiding 
symptoms. The symptom of hesitancy (n=8/10) was often described particularly in association 
with when they had been holding their urine in for a while: “It doesn’t come out. I would wait 
for 20, 30 minutes…I would sit and wait”. The splitting or spraying of the urinary stream was 
reported by three patients. 
Post micturition symptoms 
In the US, the sensation of incomplete emptying was commonly described (n=6/11). As a 
consequence, there was a need to return and pass urine a short time after (n=3/11), or to 
spend longer in the bathroom to ensure the bladder was as empty as possible: “Whenever I go 
to the bathroom, I have to allow myself time... If I’m in a hurry, then I always regret it because 
I’ll have to go again like 10 minutes later”. A post-micturition dribble was frequently reported 
in the sample (n=5/11).  
Almost all the Japanese patients reported a sensation of incomplete emptying (n=9/10): “I 
would always have that sensation that I haven’t completed released everything”. A post-
micturition dribble was reported by six of the patients: “After I go to the toilet... a little bit of 
urine leaked out…”. 
Other signs or symptoms 
In the US, historical urinary tract infections were commonly reported (n=6/11) as well as a 
history of self-catheterisation (n=5/11). Incidents of acute retention requiring medical 
intervention were reported by several patients (5/11). On other occasions they were able to 
return to pass urine successfully a short time after (4/11). A small number of patients 
described a “dull ache” or a “sharp, uncomfortable pressure” in the bladder area (n=3/11). A 
minority of patients had bowel issues (n=3/11) which they associated with their urinary 
symptoms. 
Japanese patients described the occurrence of bladder discomfort as a “dull pain”, or as a 




(n=8/10). A sensation of “coldness” in the bladder was also reported by one patient. Four 
patients currently or historically self-catheterised but urinary tract infections were not 
mentioned. 
Impacts 
In the US, the impact of their symptoms was variable between individuals. Some had adapted 
their lives around their condition and experienced relatively little impact (n=5/11). Others 
experienced a number of effects on day to day life including a reliance on knowing the location 
of toilets (n=7/11), tiredness from disturbed sleep (n=5/11) and disruption to social or daily 
activities including their work-life (n=3/11). The consequence was an impact on self-image or 
identity (n=6/11), and on relationships with family and friends (n=4/11). The emotional impact 
could be quite severe, resulting in depression in some cases: “I was pretty depressed about it 
for a while, definitely felt like it affected my manhood in a way”. The practicalities of managing 
their symptoms (e.g. self-catheterisation) often led to feelings of anxiety or embarrassment in 
certain situations. Several mentioned the detrimental impact on their sex-lives (n=4/11), 
including a reduction in sex-drive: “As a single person, losing the ability to have sex – that’s a 
significant issue”. Some described having to carefully manage fluid intake to minimise 
disruption to sleep and their daily lives (n=5/11). Additional worry was also described due to 
the financial burden of their condition (n=3/11), as a result of increased medical expenses and 
complications securing medical insurance. 
In Japan, although some of the patients reported little or no perceived impact on their lives, 
the planning of daily activities around the location of toilets such as when travelling, during 
recreational activities or when at work was also reported by most patients (n=8/10). Sleep 
disturbance and tiredness during the day due to nocturia was also a common impact (n=7/10). 
For many, there was a negative impact on how they felt about themselves (n=5/10): “I don’t 
know how women feel…but this condition is unattractive for me”. Feelings of anxiety, 
embarrassment or frustration were common due to their high urinary frequency, or if they 
were unable to access a toilet when required (n=5/10): “I feel embarrassed about visiting the 
toilet multiple times”. Four of the patients described how their high urinary frequency affected 
the completion of physical activities such as hobbies, sport and household tasks. Maintaining 
personal hygiene was an issue for two patients: “Because of the slow stream, my trousers get 
stained…I feel conscious about that.” An impact on sex-life and finances was not mentioned in 





To our knowledge, these studies represent the first qualitative exploration of the patient 
experience of UAB carried out in the United States or Japan. The findings from these studies 
increase the knowledge of the symptoms and impacts associated with UAB in a wider ethnic 
and cultural context. 
The interviews in both countries elicited symptoms and impacts that support the previous 
findings from concept elicitation in the UK 22 and in the literature 21,32. Storage symptoms of 
nocturia, high urinary frequency, urgency and incontinence and voiding symptoms of a slow 
and intermittent stream, hesitancy, straining and small volume per void were frequently 
reported by patients. Other symptoms reported were a sensation of incomplete emptying, a 
post-micturition dribble, a reduced sensation of bladder fullness, and bladder discomfort/pain. 
The signs of history of self-catheterisation and presence of a post void residual were also 
common to both samples. There were no symptoms reported that were unique to the US 
study, when compared to the Japanese and UK findings. However, US patients reported the 
financial impact of their condition, due to increased healthcare costs and health insurance 
premiums. The emotional impact was prominent particularly in the US sample (e.g. anxiety, 
effects on self-esteem and confidence) and several reported a negative impact on their sex-
lives. In contrast, several of the Japanese patients reported the additional symptoms of 
bladder discomfort; a “bloated”, “heavy” sensation or “coldness”. Impacts that were specific to 
the Japanese population included frustration with their symptoms, the ability to maintain good 
personal hygiene, and the impact on the appearance of their clothing. 
There were a number of findings that have implications for the cultural adaptation of the UAB 
PRO instrument. The increased prominence of the reporting of impact on sex-lives in the US 
sample could reflect cultural openness of talking about sex-related issues. However, it is 
recognised that side-effects of urological surgery or medication which can affect sex-drive 
and/or erectile dysfunction in men 217 complicates measurement of this concept. Additional 
items or modification to the existing items in the ICIQ-UAB which measure the emotional 
impact (e.g. frustration, anxiety, effects on self-esteem and confidence) could be considered. 
The financial impact of UAB reported in the US is unlikely to be included as an additional item 
as this concept is applicable to any disease requiring healthcare, dependent on income, and 
would not respond to a healthcare intervention. Although coded as ‘lower urinary tract pain’ in 
the UK interviews, the character of any bladder discomfort or pain experienced has perhaps 




residual or full bladder appears to be a concept that is reported frequently, however, the 
location or underlying aetiology of this pain remains uncertain. A long urination time and 
impacts of hygiene and on clothing appearance in the Japanese sample were reported by a 
minority of patients. When making decisions surrounding the modification, inclusion or 
removal of items, consideration must be given to the frequency, bother, and the spontaneity 
by which a concept was reported, as well as their clinical utility.  
Limitations 
Qualitative findings, although transferable, should be interpreted within the context in which 
they were obtained. This study is not intended to provide accurate estimates of symptom and 
impact frequency. The intention was for the experiences to be representative, not the sample 
population 116.  
Despite significant efforts made, no African American patients or Hispanics were recruited in 
the US. However, there was a good spread of demographic characteristics and ages recruited 
which may be typical of men and women who present and are referred for urodynamics in 
these countries.  
Underlying DU is known to have a number of possible aetiologies which may be myogenic, 
neurogenic or idiopathic in origin 24,46,57. Further research is required to establish whether 
there are symptomatic differences in presentation due to classifications of DU by aetiology. It 
is also acknowledged that the underlying aetiology of frequently reported symptoms such as 
nocturia and bladder pain are complex 47,218, which has implications for the potential 
responsiveness of associated items within the UAB PRO measure to an intervention. 
7.5 Instrument modification following the interviews in the US and Japan 
Following evidence from the concept elicitation interviews in US and Japan and discussion with 
clinical study team, some changes were made (to ICIQ-UAB v13 resulting in version 14), which 
were tested by four confirmatory cognitive interviews. The details and rationale for these 
changes are given in Appendix 8. Final decisions implemented in the developmental ICIQ-UAB 
(version 15) are summarised as follows: 
 Minor changes to the initial instructions and daytime urinary frequency item response 
options. 




 The item relating to incontinence item was split into two items, to capture and 
differentiate stress versus urgency incontinence.  
 An item was adapted from the original cognitive interviews in the UK and re-instated 
to capture bladder pain.  
The final ‘developmental version’ ICIQ-UAB (v15) is given in Appendix 9. 
7.6 Conclusions 
The findings in the US and Japan largely corroborate the findings obtained in the UK and 
explores the concepts among alternative populations. This supports the evidence for the ICIQ-
UAB as a tool that can be used globally. These studies also broaden our knowledge of the 
symptoms and impacts associated with UAB in wider ethnic and cultural backgrounds, and 
provided valuable input to the further refinement of the developmental questionnaire. The 
results informed decisions surrounding item modification for the development of the PRO 





Chapter 8 Summary and conclusions 
8.1 Introduction 
The developmental version of the ICIQ-UAB described in this thesis is the culmination of a 
comprehensive set of sub-studies to provide data for its initial validation. The validity, 
reliability and wider cultural applicability of the ICIQ-UAB among men and women with a 
confirmed diagnosis of DU are supported by the findings from interviews in the UK, US, and 
Japan, and European pilot psychometric testing. The ICIQ-UAB is the first PRO measure for the 
assessment of the symptoms and impact of UAB which has been developed using rigorous 
methodology, in-line with the FDA Guidance for Industry 99. Following further planned 
evaluation of the instrument’s responsiveness to change and the derivation of a scoring 
system, the instrument is envisaged as an important tool for the monitoring of future 
treatment strategies for patients with UAB. Extracts from the following summary of the 
development activities to date were submitted as a manuscript to the Journal of Neurourology 
and Urodynamics in May 2018.  
8.2 Summary of development activities  
The review of the contemporary literature identified more than twenty PRO instruments with 
published evidence of psychometric properties, that evaluated storage, voiding and post-
micturition LUTS and/or associated health related quality of life. Although existing PRO 
measures capture some of the symptoms reported by patients with UAB, these instruments 
were developed for populations of individuals with broad LUTS, which defines their context of 
use. The inclusion of items, including the wording and content of the PRO instruments, should 
be based on the patient-centred input of the specific population of interest 99,112. The lack of an 
existing, psychometrically robust PRO instrument for the assessment of UAB developed to 
current regulatory standards justified the development of the new instrument. 
The initial qualitative phase of development with patients from the target population, 
alongside the consultation with an expert clinical panel resulted in a comprehensive 
instrument which included the items of relevance, was interpreted as intended, and easy to 
complete. The concept elicitation interviews elucidated the patient experience of the 




their impact, day to day variability, severity and bother. The results of this qualitative study 
were published in European Urology 22. More than 20 LUTS and signs with associated impact 
on quality of life were described by the patients with DU. Descriptions of the patient 
experience of UAB were consistent with the known symptoms associated with DU in the 
literature 15,19,32 and symptomatic definition of UAB 27. A draft instrument was generated 
following the UK concept elicitation interviews. Rounds of cognitive interviews were then 
scheduled and iterative improvements made until all items were considered to be fully 
understood and interpreted as intended by the respondents. Two revised versions of the ICIQ-
UAB, one with a recall period of 1-week and the other with a recall period of 24hrs were 
considered comprehensive and ready for the next phase of development involving the 
psychometric testing of its properties. 
The pilot testing provided encouraging evidence of the validity and reliability of the draft 
instrument. Test-retest reliability in stable patients was good (ICC ≥ 0.85 for both versions), 
providing evidence of the reliability of scores over the test period of 10 days, and that any 
variability was not due to systematic differences among respondents 104. The score derived 
from the tested domains in both versions demonstrated reliability (α ≥ 0.85) which is over the 
accepted threshold of ≥0.7 154 for internal consistency. Many of the symptom and impact items 
in both versions exhibited floor effects, which can affect the instrument’s sensitivity to change 
99. However, these effects could also be capturing the true severity or impact of the symptoms 
in the studied population. The known group validity of the items was supported for both recall 
period versions, so the instrument score was shown to be sensitive to severity of condition. 
Construct validity was demonstrated by the expected convergent and divergent correlations 
with other PRO measures of known validity. There was no strong evidence from the pilot study 
to suggest an overall advantage for either recall period version. Going forward, a shorter recall 
period is recommended by the FDA guidance for industry to reduce recall bias 99, but this 
should be carefully considered to match the condition, the PRO domain being measured and 
views of patients 219. For example, we know from the patient interviews there was a 
preference for a longer recall period to reflect the variation of some symptoms and in 
particular the required length of time to allow a measureable impact. 
The additional concept elicitation interviews carried out in the US and Japan represented the 
first qualitative exploration of the patient experience of UAB with patients confirmed to have 
DU in these countries. The interviews elicited symptoms and impacts that support previous 




The evidence from the pilot study and the interviews in the US and Japan were used to inform 
modifications to the instrument. These changes were tested for their acceptability by two sets 
of additional cognitive interviews, resulting in the final 33-item ‘developmental version’. 
A flow diagram illustrating the developmental progression of the ICIQ-UAB is given in Figure 
11.  
 







8.3 Further development activities 
8.3.1 Sensitivity to change 
The properties of validity and reliability have been supported by the sub-studies detailed. 
However, responsiveness to change to an intervention has not yet been assessed. As discussed 
in chapter 1, the treatment options for patients with DU are limited, which makes the 
assessment of sensitivity to change problematic. Intermittent self-catheterisation is currently 
the only intervention available to patients, other than the currently unsatisfactory and often 
ineffective surgical, pharmaceutical and electrostimulation options.  
ISC is known to be successful in alleviating symptoms for neuropathic bladder patients and for 
bladder drainage 211, but any apparent treatment benefit for patients with UAB are not well 
established 25. Nevertheless, incomplete bladder emptying is considered an indicative 
symptom of UAB 26 and a high proportion of UAB patients have a post void residual 22,32 so it is 
reasonable to expect some treatment benefit from learning ISC for UAB patients. Indeed, there 
was some evidence from the UK concept elicitation interviews that some relief of storage 
symptoms may occur from practising ISC. Thus, it is hypothetically possible the ICIQ-UAB may 
be sensitive to change following an ISC intervention.  
Two test patients with suspected DU (not urodynamically confirmed) were given the ICIQ-UAB 
in clinic before learning ISC (1st administration) and then again four weeks later at their follow-
up appointment (2nd administration). The Patient Global Impression of Improvement (PGI-I) 
was also given at the 2nd administration. Their total scores for symptom, impact and bother 
domains are shown in Table 33. The scores for selected storage and post-micturition symptom 
items are given in Table 34. 
Patient 1 reported ‘no change’ in their symptoms on the PGI-I at the 2nd administration, and 
patient 2 reported that their symptoms were ‘a little worse’. In both patients there was a small 
increase in symptom, impact and bother scores from the 1st administration to the 2nd 
administration after learning ISC. At the item level (Table 34), the reported scores in the 2nd 
administration for the items relating to urgency, nocturnal voids and daytime urinary 
frequency were higher, but scores for incontinence, need to immediately re-void and 
sensation of incomplete emptying were slightly lower. The other symptom items had a 





Table 33. ICIQ-UAB scores of two test patients before and after learning ISC.  
 Symptom 
score 
Impact score Bother score 
(symptoms) 
Bother score  
(impacts) 
Administration 1st  2nd  1st  2nd  1st  2nd  1st  2nd  
Patient 1 33 36 4 4 69 88 16 17 
Patient 2 55 59 16 18 152 169 55 63 
 






Although no conclusions on sensitivity to change can be made due to the test sample size, it is 
evident further research is required regarding the measurement capabilities of the ICIQ-UAB 
and on the efficacy of learning ISC for patients with suspected underactive bladder. It is also 
important to recognise that any symptom alleviation as a result of ISC must outweigh the 
known inconvenience of self-catheterisation on day-to-day life 22. Although the ICIQ-UAB was 
tested during the qualitative phases of its development with patients who regularly self-
catheterise, it is acknowledged that items that ask about voiding symptoms are not applicable 
if a patient self-catheterises for every void. This may reduce the sensitivity of the ICIQ-UAB to 
change as a result of an ISC intervention.  
The ICIQ-UAB was designed and developed according to FDA guidelines 99 with the intention of 
its eventual use as a primary clinical outcome measure in clinical trials. It is anticipated that 
responsiveness to an intervention will be assessed in a phase 2 trial of a new drug. The ICIQ-
UAB will be administered before and after the intervention and the scores correlated with 
other measures (pad tests, bladder diaries, other validated PRO measures). The ICIQ-UAB is 
currently designed to comprehensively cover all concepts including 30 items, but it is 
anticipated that there is scope for removal of items following further data collection on their 
properties. The item-level analysis of validity, reliability and responsiveness alongside future 
Item Administration item 
total score (n=2)  
Score difference 
1st  2nd 
Urgency (Q16) 1 4 3 
Nocturnal voids (Q17) 2 4 2 
Daytime urinary frequency (Q18) 1 2 1 
Hesitancy (4) 6 8 2 
Incontinence (Q8) 1 0 -1 
Need to immediately re-void (Q9) 4 3 -1 




clinical trials will inform decision making for removing poorly performing items. The resulting 
tool will then potentially be used in phase III trials as a primary outcome measure. 
It is anticipated that alongside responsiveness to change, data from future clinical trials will be 
analysed using factor analysis to explore the PRO’s structure, possible scoring system, and to 
assess suitability for the application of item response theory (IRT) techniques. IRT modelling 
provides additional information on the item properties and is particularly useful when making 
decisions on to reduce the number of items in the questionnaire 166. The use of these 
techniques requires a sample size of several hundred so are often used in the later stages of 
psychometric testing. 
8.3.2 Electronic equivalence and application 
The ICIQ-UAB has been developed and validated for pencil-and-paper administration. 
However, a questionnaire which can be shown to be reliable in different administrative 
formats has further potential for utility in different contexts 220. There are a number of 
potential advantages to electronic data capture when collecting PRO data. These include the 
reduction of administrative data entry workload, greater accuracy and completeness of data 
221–223. Patient acceptance of using tablet computers to complete questionnaires is generally 
high which can also increase compliance 224–226. In addition, a questionnaire which has been 
validated for equivalence over the telephone can provide additional flexibility for delivery 227–
229.  
The conversion to electronic patient reported outcomes (ePROs) requires the demonstration 
of equivalence to the paper-and-pencil version 230,231. Scores cannot be assumed to be 
equivalent 232, and must not differ simply due to the method of data collection that is used. 
Uren et al. (2017) aimed to evaluate whether scores obtained from patient-completed entry of 
four different ICIQ PRO questionnaires on a touch screen device (iPad) were equivalent with 
corresponding data collected using conventional pencil-and-paper methods, or when 
administered over the telephone 233. A total of 491 men and women, attending the Bristol 
Urological Institute complaining of LUTS, were randomised to one of three groups which 
determined the order in which they completed three administrations of the same 
questionnaire: paper, iPad and telephone. Four ICIQ questionnaires were evaluated: ICIQ-
MLUTS, ICIQ-LUTSqol, ICIQ-OABqol and ICIQ-UI SF. The results showed that iPad and paper-
and-pencil administrations of the ICIQ modules tested produced scores that were equivalent. 




administered version with those obtained by repeated paper administrations. Paper and 
phone administrations were less well correlated, although still high, but this may reflect the 
requirement for a proxy required when using the telephone. The ICIQ-UAB formatting, layout 
and response options were based on the existing ICIQ modules so it is reasonable to generalise 
that scores obtained by patients in an electronic version would have the same level of 
equivalence 230,234. Indeed, current evidence recommends that full psychometric validation 
may be unnecessary for minor modifications to questionnaire format 230,234. This study 
provides the validation required for the development and use of an application or ‘app’ to be 
made available for patients to be able to complete electronic versions of the ICIQ-UAB on 
mobile touch screen devices. Alongside the other modules of the ICIQ, this significantly 
increases the versatility of the ICIQ-UAB for use in both clinical and research settings.  
In addition it may be possible to use computer adaptive testing (CAT) to select the most 
appropriate items during administration 172. “CAT is a computer algorithm that selects 
successive items based on an individual’s responses to previously administered items” 170. For 
example, if the first item asks ‘how often do you have to get up and urinate each night, on 
average?’ and the respondent’ answer was 5 times, this may suggest that that underlying 
severity of UAB may be high. The CAT algorithm could then select another question that allows 
greater precision for those who lie in the severe range of population. All items are calibrated 
on to a common scale so scores can then be compared even if different items were used, and 
items may be added or removed without compromising the validity of the overall instrument. 
Thus, the precision is optimised for the given questionnaire length and irrelevant items are 
excluded 235. The precision of the test can also be set to match the needs of the instrument, for 
example high precision may be required for diagnostic purposes. 
These are exciting new directions that could considerably expand the versatility of the ICIQ-
UAB upon completion of the final version. Early awareness of the intended techniques to be 
considered with the questionnaire is useful to prospectively plan future studies and evaluation 
efforts. 
8.4 Strengths and limitations 
It could be argued that it is premature to develop a PRO questionnaire for underactive bladder 
when the symptomatic definition is not yet fully established. Indeed, a symptomatic definition 
is not easy to define, as there are no distinguishing symptoms which encompass the 




urological conditions with entirely different aetiologies, such as bladder obstruction. However, 
the most recent ICS definition has been accepted for publication in Neurology and 
Urodynamics in May 2018, and this area continues to be the subject of considerable attention. 
Recent research also continues to reveal symptomatic differences in presenting symptoms 
between those with DU and those with DU and co-existing other urological conditions 21,236. 
The concept of an ‘underactive bladder’ is one that patients can relate to as a perceived 
weakness of the bladder muscle, manifesting as a reduced flow rate and incomplete emptying. 
For clinicians, it is a useful concept to describe the condition, and one which enables the 
patient understanding of the different urological conditions with distinct aetiologies but similar 
presentation. The choice of further treatment is then easier to explain to the patient, rather 
than having to resort to technical terminology, such as a diagnosis of DU. Thus, the ICIQ-UAB 
has been developed as a useful tool to assess those with suspected or confirmed DU, for the 
further assessment of their symptoms in response to conservative or other suggested 
interventions or monitor symptom status over time, in addition to its widespread research 
potential.  
What information can a PRO measure for underactive bladder provide which other objective 
tests, such as bladder diaries, pad tests or uroflowmetry cannot? Parameters such as the 
frequency of urination, flow rate, and nocturnal urinary episodes can be collected by these 
tests as an adjunct to the questionnaire data. However, PRO measure data captures subjective 
information which only the patient can provide. If well validated, a PRO questionnaire provides 
a way of capturing subjective information in a structured, comprehensive and interpretable 
way. The clinician can then see which symptoms are particularly bothersome to the patient, 
which is useful not only for diagnostic purposes but for the tailoring of possible treatment 
strategies. 
Overall strengths of the study include the recruitment from multiple sites in Europe, the US, 
and Japan; the strict adherence to a priori urodynamic inclusion criteria, and the first conduct 
of robust psychometric PRO development methodology in the target population with UAB/DU.  
A total of 143 individual patients were recruited into all sub-studies. Of these, a total of 65 
qualitative concept elicitation interviews were conducted with patients recruited at multiple 
sites in the UK, US and Japan. It may be considered very likely that the major symptoms, and 
behaviours presented by the target population with underactive bladder have been elicited by 
these interviews. Indeed, data saturation tables for the UK and US interviews confirmed that 




representative as possible of the presenting population with UAB by the purposive sampling of 
the views of possibly underrepresented groups. Ethnic minorities were particularly challenging 
to recruit, however, the input of culturally diverse populations from the US and Japan provided 
further insight into the final choice of items and their wording. The epidemiology of the 
background population of underactive bladder is poorly understood, so the sample is more 
likely representative of the referred populations in participating sites rather than the 
background population. Indeed, the lower number of females may be a consequence of the 
referred nature of the sample as there is a greater necessity for diagnostic pressure flow 
studies performed prior to prostatectomy to differentiate BOO from DU in men 203. The overall 
sample characteristics such as the mean age, high PVR and the reported symptoms were 
comparable to recent publications 21 and are consistent with the recent ICS symptomatic 
definition of UAB. 
The size of the pilot test sample was larger than the recommended minimum size of 40 to 
obtain reliable estimates of item performance and reliability 206. However, decisions made on 
the basis of this evidence were purposely conservative; The ICIQ-UAB is still relatively lengthy 
at 33 items, as it is advantageous to retain all concepts of possible interest to the population at 
this stage until further evidence of item performance is collected. The item-level analysis, 
validity and reliability will be further evaluated alongside responsiveness to change, using data 
from future clinical trials.  
The ICIQ-UAB is designed as an outcome measure and not as a diagnostic tool for DU/UAB, due 
to the overlap of reported symptoms with co-existing urological conditions. Underlying DU is 
known to have a number of possible aetiologies and may be myogenic or neurogenic in origin 
24. Further research is required to establish whether there are symptomatic differences in 
presentation due to classifications of DU by aetiology. It is also acknowledged that the 
underlying aetiology of frequently reported symptoms such as nocturia and bladder pain are 
complex 47,218, which could affect the responsiveness to an intervention of the associated 
items. It is anticipated that when more data is acquired through a larger sample in future 
clinical trials, the symptom severity and prevalence will be further elucidated relative to other 
urological conditions.  
8.5 Summary of future research and direction for the ICIQ-UAB 
As concluded in chapter 1, further research is required in understanding the epidemiology, 




influence the clinical applicability of the ICIQ-UAB and uptake into clinical practice. Thus, 
recommendations for research and the future direction of the ICIQ-UAB are intrinsically linked. 
Consensus of the most recent symptomatic definition has also only just been achieved. Further 
professional consensus of urodynamic parameters that characterise DU for men and women 
are also required to enable multidisciplinary and wider global recognition of the condition. 
Recommendations for the future direction for the ICIQ-UAB: 
 The exploration of an underlying domain structure by factor analysis to explore the 
unidimensionality of the underlying constructs and to develop appropriate scoring 
systems. 
 The sensitivity to change is to be evaluated in a larger population, as part of planned 
clinical trials.  
 The development and use of an electronic version of this and other ICIQ modules. 
 The formation of an ICIQ item bank and the possible use of computer adaptive testing 
to increase the versatility of the ICIQ modules for global users. 
 The improvement of scoring algorithms and PRO accuracy using IRT modelling where 
appropriate, with larger datasets.  
8.6 Conclusion 
The ICIQ-UAB has been developed and tested with symptomatic patients diagnosed with 
detrusor underactivity, with or without co-existing urological conditions. The result is a novel 
developmental instrument, applicable to the heterogeneous target population which is 
encompassed by the symptom complex of underactive bladder. The content validity of the 
instrument is evidenced by rigorous qualitative methodology and patient input, according to 
the latest regulatory guidelines. The initial quantitative evaluation of validity and reliability 
were also supportive of these psychometric properties. The development of the ICIQ-UAB was 
not without its challenges. There is only recent consensus at the level of its symptomatic 
definition, and the understanding of its aetiology, epidemiology and pathophysiology still 
requires much research. Treatment options are still very limited, with available options often 
ineffective or still awaiting clinical trials to evidence their efficacy. However, as the field 
develops there is the promise of more effective treatment options in the future. The ICIQ-UAB 
is envisaged as an important tool for the measurement of outcomes and treatment benefit for 
these new interventions, as it is continues its development as an outcome measure and 
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Appendix 1 Clinical review panel  
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Mr Jason Britton Clinical Scientist Leeds NHS teaching Hospital, UK 
Prof Christopher Chapple Urological Surgeon Sheffield Teaching Hospital, UK 
Dr Nadir Osman Clinical Research Fellow University of Sheffield and Royal 
Hallamshire Hospital, UK 
Prof Robert Pickard Consultant Urologist Freeman Hospital, Newcastle Upon 
Tyne, UK 
Prof Philip Smith Assistant Professor of 
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Centre for Continence and Voiding 
Disorders, Connecticut, US 
Dr Hashim Hashim Consultant Urologist Southmead Hospital, Bristol, UK 
Prof Marcus Drake Consultant Urologist and 
Professor at the 
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Appendix 2 Patient interview information sheet 
 
ICIQ Study 




We would like to invite you to help us develop a new questionnaire to assess underactive bladder 
symptoms and their impact on quality of life. The questionnaire will then be available for use by 
patients to measure the effectiveness of treatments for underactive bladder symptoms. 
 
The questionnaire is called the ICIQ (International Consultation on Incontinence Questionnaire). At 
the moment, the questionnaire is being developed for people suffering from an underactive 
bladder, and we are asking for patients to help us by giving us their opinion on the content of the 
questionnaire with the aim of developing some new questions. This will help us to improve the 
questionnaire and make it a more useful tool in assessing underactive bladder symptoms. 
 
What will I have to do if I take part? 
 
The study will involve 30 patients. If you would like to participate in the study, all that you would be 
required to do is complete a consent form and discuss your experiences of underactive bladder 
with a member of our research team – xxxxxx. 
 
The discussion will take a maximum of 60 minutes and will be held either in a private room within 
the Outpatients Clinic (at the Urology Dept.), at your own home, or over the phone, depending on 
what works best for you. Once the interview has finished, your participation in the study is 
completed. 
 
Are there any possible benefits? 
 
The information that we get from this study will help us to develop a questionnaire schedule for 
measuring patients’ underactive bladder symptoms and their impact. The questionnaire will then be 
used to measure the effectiveness of treatments for these symptoms. 
 
Do I have to take part? 
 
You do not have to take part and your participation is entirely voluntary. If you prefer not to take 
part you do not have to give a reason and your future treatment will not be affected. If you do 





As a small thank you for giving up your time to participate we would like to give you a £50 voucher 
that is redeemable at a number of high street stores. If at any point during the interview you decide 
to withdraw your participation you will still receive the voucher. 
 
What do I do now? 
 
You will be asked by the researcher named above to complete a consent form and participate in a 
discussion about your experiences of underactive bladder. Once the discussion is finished, your 




Please note that the discussion is strictly confidential and anonymous. Information gathered will 
only be used for the purposes of the research mentioned above and the results presented such 
that the information from a single individual cannot be identified. Access to the information you 
provide will be limited to members of the research team and will not be seen by the doctors or 
nurses in the clinic, or by your GP. 
 






Appendix 3 Concept elicitation interview schedule 
 
 
Assessing the signs and symptoms of Underactive Bladder 
Discussion Guide for Interviews 
 
OPENING (5 MINUTES) 
 Introduce interviewer 
 Remind participants of the purpose and format of the interview  
“ During this interview, we would like to discuss with you the signs and symptoms as well as the 
impact of Underactive Bladder/Bladder Outlet obstruction on your life. We are developing a 
questionnaire that will reflect the views of people like you to help us better understand the 
effect of potential treatments on people's lives. So we want to hear about your experiences 
with UAB; we will start with the symptoms you’ve experienced, and the treatment you have 
received. Then we will explore how your condition has affected your life.” 
o Confidentiality:  
“As researchers we would like to assure you that all of the information that you share 
with me today will be treated as confidential by the Bristol Urological Institute. We will 
type up transcripts from the recordings but any names or other personal identifiable 
information will be replaced with pseudonyms. We will use the transcripts for our results, 





HISTORY OF Underactive Bladder (UAB)  (10 MINUTES) 
 
Before we begin, could you list any other illnesses you currently have, besides your bladder condition? 
 
 
How would you describe your bladder condition in one sentence? 
 
Could you describe when your bladder issues first appeared? 
 
 What made you first see a health professional?  
o When was this? 
o How long were you experiencing these symptoms for? 
 Have you talked to anyone else about your condition? 
 How have you managed the condition? 
 Have you had any difficulties with accessing treatment? 
 






Signs and symptoms of UAB  (15 MINUTES) 
Discussion of storage and voiding symptoms 
 
We’re now going to talk for a bit about your bladder and how it is for you when it is filling and when you 
actually go to the toilet. 
 
During the time in between toilet visits, do you experience any sensations? 
 If they mention leakage, do they feel it? 
 What does their bladder feel like? E.g. prickling, tingling. 
 
How does it feel as your bladder is filling up, shortly before you visit the toilet? 
 Feelings of urgency – what brings on this feeling? 
 
How soon do you visit the toilet after you first need to go? 
 Do they feel the need to rush to the toilet? 
 
If you have to wait to use the toilet, how does it feel? 
 
Could you describe how it feels when you go to pass urine? 
 Difficulty passing urine 
 Straining or “letting go” – how do they strain? Hands, muscles etc 
 Is anything different when you go to toilet when other people are present? 
 Intermittency – number of times per urination, how often. 
 Splitting or spraying of the flow 
 Any dribbling  – at what point of the urination does this occur? 
 Any discomfort? 
 
Do you feel satisfied or that you have fully emptied your bladder afterwards? 
 Describe these feelings, or lack of feelings. 
 Where would the understanding of incomplete emptying come from. 
 Or, how do they know they have properly emptied. 
Other prompts: 
 Number of daytime visits to the toilet 
 Waking up at night to urinate 
 
What do you think is the cause of these symptoms? 
 
What symptom bothers you the most? 
 
Are there any concerns you have about your symptoms? 
 
Have you experienced any difficulties with your bowels recently? 
 
Have you had any UTIs over the last 12 months? 
 




These questions are intended to clarify the participant’s earlier statements, and shed light on any 
symptoms that they may have missed in the discussion so far. Each question must be asked. 
 
Remember to ask the participant to quantify items, such as frequency, if they do not spontaneously do so. 
 
1. Hesitancy - also considering any differences in occurrence with an empty, half 
full or over full bladder. 
 
When you go to urinate, do you find that you have difficulty with starting to 
urinate? 
 Is this different depending on how full you feel that your bladder is? 
 Must clarify if it is harder or easier, as the bladder is fuller. 
 
2. Straining - requirement to start flow, to maintain flow and whether they can use 
it to increase flow. 
 
When you go to urinate, do you feel you have to strain or squeeze, or push the 
urine out? 
 Could you describe to me how you strain or squeeze? 
 Do you do this to start urinating, or to maintain your stream, or both? 
 Females: Do you have to push your uterus up to be able to urinate? 
Why do you attempt to strain like this? 
 Need to clarify if they strain to prevent an unwanted outcome, or if they 
feel they still have urine left to void. 
 
3. Incomplete emptying after finish passing urine - does it feel like they've 
emptied their bladder. 
 
After you’ve finished urinating, do you feel that you have emptied your bladder 
completely? 
 How soon do you feel the need to urinate again afterwards? 
 
4. Flow - whether continuous and if so any fluctuations between weak and strong 
during flow, if interrupted - does it stop and start during the void. 
 
How would you describe your urine flow? 
 Is the urine flow continuous, or does it stop and start? 
  How long do you wait for it to start again? 
  How many times does it stop and start during a urination? 
      If the flow is continuous, does the strength of the stream go up and down? 
 Has it always been this way, before you developed your condition? 
 
5. Bladder sensation - do these individuals reach a strong desire to void if they 
hold their urine. It is normal to feel a strong desire to void if urine is held for 
too long but some individuals do not experience this even though they are very/over 
full and we need to know what experience of sensations DU/UAB patients report. 
 
If you hold your urine in, do you feel a strong desire to urinate? 
 How soon does this happen, after you first feel the need to go? 
 
6. Cluster of urinations - passing urine at regular intervals or at different times 
of the day is their frequency increased, and if so, when. 
 
Are there times of the day when you pass urine more frequently? 
Are you aware of having to wait after you think you have finished urinating? 
  
 
 This could be while remaining seated, or dressing, or leaving the toilet and 
returning. Ask the participant to clarify. 
 Differentiate between: the distribution during the day, and clustering per episode (for example, 
toilet hanging).  
 
 
7. General voiding questions – some participants have described a variability in 
their voiding experiences. These questions aim to address that. 
 
Could you describe what your most difficult urination is like? 
 
Could you describewhat your easiest urination is like? 
 
Of these two experiences, which occurs the most regularly? 
 
8. Leakage – to check that the participants do not leak, but if they do then how 
much. 
 
Do you ever leak urine? 
 If so, in what context? 
 How much leakage occurs? 






Exploring IMPACT (10 MINUTES) 
 
Exploration of specific areas of impact 
 
Thinking back to before you developed these symptoms, has your life changed since? 
 If they try to do things normally, explore their adaptive strategies. 
 
How does your bladder condition affect your relationships with the other people in your life? 
 
How does it affect the types of things that you do? 
 Are there areas of your life that you feel excluded from? 
 
How does it affect the way you feel about yourself? 
 Embarrassment, concentration, motivation, satisfaction/happiness, stress/anxiety. 
 
How does it affect your ability to sleep, and get rest? 
 Recovery, daytime function. 
 
 









Importance of areas of impact (5 MINUTES) 
 
 “Thinking about the issues we have been talking about today, which are the most important to 
you?” 
If the participant is having difficulty with recall (either too many or too few points), then ask 





Summing up (5 MINUTES) 
 
“As this is an opportunity for you to have your individual voice heard, is there anything we haven’t 
covered that you would like to discuss?” 
 
Remind participant that everything he/she has said will be kept confidential, and also the need for 
confidentiality from them. 
 
Close the interview 
“Thank you for taking the time to share your thoughts and experiences with us. If you 
have any further concerns or questions following on from today, please do not hesitate 



















Title of Project: Development of the ICIQ Questionnaire 






Please initial box 
 
1. I confirm that I have received enough information about this study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
    at any time without my medical care or legal rights being affected. 
 
3. I am willing to allow access to relevant sections of my medical notes and understand 
that data collected during the study may be looked at by individuals from ICIQ, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this 
research but understand that strict confidentiality will be maintained. The purpose of this 
is to check that the study       is being carried out correctly. 
 
4. I agree to take part in the above study. 
 
 
_____________________       ___________ ________________________ 
Name of patient   Date   Signature 
 
 
________________________ _____________ ________________________ 
Name of person taking consent Date   Signature 
(if different from researcher) 
 
 
________________________ _____________ ________________________ 
Researcher    Date   Signature 
 
ICIQ  Study          Consent Form 
 








Initial number             CONFIDENTIAL                    DAY         MONTH    YEAR       





Many people experience urinary symptoms some of the time. This questionnaire aims to find out 
whether you experience symptoms known to be associated with underactive bladder, and whether 
or not these symptoms have an impact on your everyday life. We would be grateful if you could 
answer the following questions, thinking about how your symptoms have been, on average, over the 
LAST 24 HOURS. 
 
 
1   Please write in your date of birth:   
  
 DAY          MONTH         YEAR 
     
2   Are you (tick one): Female  Male  
 
3a. How often do you pass urine during the day, on average? 
1-6 times  0 
   
7-8 times  1 
   
9-10 times  2 
   
11-12 times  3 
   
13 or more times  4 
3b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
4a. Is there a delay before you can start to urinate? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
4b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 










5a. How often do you feel you have to concentrate in order to start urinating? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
5b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
6a. Do you ever leak urine before you can get to the toilet? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
6b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
7a. During the night, how many times do you have to get up to urinate, on average? 
   
none  0 
   
one  1 
   
two  2 
   
three  3 
   
four or more  4 
7b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 















8a. How often do you feel you bladder has not emptied properly after you have urinated? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
8b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




9a. After you have finished urinating how often do you feel like you could go again even 
though you can’t? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
9b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




10a. Have you ever blocked up completely so that you could not urinate at all and had to 
have a catheter passed to drain the bladder? 
no  0 
   
yes, once  1 
   
yes, twice  2 
   
Yes, more than twice  3 
   
10b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 














11a. How often do you need to self-catheterise?   
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
11b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
12a. Do you have to strain or squeeze to urinate?   
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
12b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
13a. Do you have to strain to start urinating? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
13b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 

















14a. Do you have to strain to try and improve the flow of your urination? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
14b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 





15a. How often do you strain or squeeze at the end of your urination? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
15b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
16a. How often do you experience a sudden urge or desire to urinate which you are unable to 
ignore? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
16b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 










17a. Have you had a urinary tract infection in the past month? 
no  0 
   
yes  1 
   
17b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
18a. Would you say that the strength of your urinary stream is… 
normal  0 
   
occasionally reduced  1 
   
sometimes reduced  2 
   
reduced most of the time  3 
   
reduced all of the time  4 
18b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
19. Would you say that the strength of your urinary stream is... 


























20a. Do you stop and start more than once while you urinate? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
20b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
21a. How often do a few drops leak out into your underwear shortly after you have finished 
urinating and have dressed yourself? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
21b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
22a. Do you experience pain in your bladder? 
   
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
22b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 












23a. If you have to wait to go to the toilet do you have pain in your bladder? 
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
23b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
24a. Do you have to urinate again (within 15 minutes) after you thought you had 
 finished urinating? 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
24b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




25a. How often do you feel that you have no control over the direction of your stream? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
25b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 













26a. How often do you feel that you were not able to pass what you might consider a  
satisfactory amount of urine? 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
26b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 














The following questions relate to how these symptoms may have affected your everyday life. 





27a. How much do you have to plan your life around the location of toilets?   
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
27b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




28a. How often do you feel that your urinary problem interferes with your social life? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
28b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




29a. How often do your symptoms prevent you from getting the amount of sleep  
you needed? 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
29b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 








30a. How often do you feel tired the next day because of having to get up  
at night to urinate? 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
30b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
31. Overall, how much impact does getting up at night to urinate have on 
 your day to day life?  
 
  
   
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
        




never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
32b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 












33a. Does your urinary problem affect the way you feel about yourself? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
33b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




34a. Does your urinary problem cause you to feel embarrassed? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
34b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




35a. Are you careful how much fluid you drink? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
35b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 












36a. Are your urinary problems affected by your bowel movements? 
 
  
never  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
36b. How much does this bother you? 
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 








   
 Please ring a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 











Appendix 6 Cognitive interview schedule 
  
 
UAB PRO CD interview schedule v3 (27/02/15) 
Firstly I will ask you to fill in the questionnaire. This will be timed in order for us to have an idea of how long it takes to complete. After this I will ask you a few 
general questions about the questionnaire. We will then go through each question in more detail asking for your comments on each individual item. Please feel free 
to be as open and honest as you like when you tell me your thoughts and comments. This is a brand new questionnaire so any input you have is extremely valuable 
to us. It will enable us to improve the questionnaire and make it clear, relevant and easy to complete in the future. 
To be completed shortly after initial completion of the questionnaire by the participant. 
Completion instruction Page 1 Purpose: To understand respondent’s interpretation of the task (s) to be performed.  
 Intended 
interpretation 
Participant’s interpretation Comments Suggestions for change 
Can you tell me in your own 
words, what this instruction is 
asking you to do? 
    
Can you describe any confusion 
or difficulty you had in 
understanding these 
instructions? 
    
Are there any words or phrases 
that you would 
change to improve the 
instructions. 
    
Recall timeframe Page 1 Purpose: To identify how patients retrieve information, remember situations or events. 
 Intended 
interpretation  
Participant’s interpretation Comments Suggestions for change 
What does (timeframe e.g ‘past 
24 hours’) mean to you?  
Recall symptoms over 
the last day 
   
What period of time did you 
think about when you were 
completing the questionnaire? 
 
    
 
Describe your experiences with 
your own symptoms over this 
period (timeframe). 
 




Completion instruction Page 10 Purpose: To understand respondent’s interpretation of the task (s) to be performed.  
 Intended 
interpretation 
Participant’s interpretation Comments Suggestions for change 
Can you tell me in your own 
words, what this instruction is 
asking you to do? 
    
Can you describe any confusion 
or difficulty you had in 
understanding these 
instructions? 
    
Are there any words or phrases 
that you would 
change to improve the 
instructions. 
    
Recall timeframe Page 10 Purpose: To identify how patients retrieve information, remember situations or events. 
 Intended 
interpretation  
Participant’s interpretation Comments Suggestions for change 
What does (timeframe e.g ‘past 
24 hours’) mean to you?  
Recall symptoms over 
the last month 
   
What period of time did you 
think about when you were 
completing the questionnaire? 
 
    
 
Describe your experiences with 
your own symptoms over this 
period (timeframe). 
 







Length Purpose: To determine if the length of time it takes to complete the questionnaire is reasonable (does not burden subject). 
 Comments  Suggestions for change 
What did you think about the 
amount of time it took you to 
complete the questionnaire? 
  
If the questionnaire were 
reduced to three quarters/half 
the length would this be a 
burden? 
  
Content coverage Purpose: To determine if the content in the instrument is comprehensive/to assure that there are no missing concepts. 
 Comments Suggestions for change 
What other symptoms do you 
have with DU/UAB that are not 






What other experiences do you 
have with DU/UAB that are not 






Format Purpose: To identify respondent difficulties with the presentation of the questionnaire or diary. 
 Comments Suggestions for change 
What suggestions do you have for changing the 




Observation of questionnaire completion: note facial 
expressions, indications of reading difficulty, flipping 
pages back and forth. Listen for comments about 
difficulty reading or questions that indicate lack of 





Item stem Q3a Purpose: To understand the clarity of the question from the respondent’s perspective. 
 Intended 
interpretation 
Participant’s interpretation Comments Suggestions for change 
Using your own words, how 




The complaint by the 
patient that he or she 
urinates too often by 
day 
   
Could you interpret this question 
in a different way? 
 
    
Please explain any difficulties you 
experience with this question? 
    
Response frame Q3a Purpose: To understand how participants interpret the response options and make decisions around response choice. 
 Intended 
interpretation  
Participant’s interpretation Comments Suggestions for change 
Please read each response choice 
and tell me what it means to you. 
 
 
    
In thinking about your 
experience with [specific concept 
of interest],which response best 
describes your experience? 
 
    
What caused you to choose this 
response? Would you ever 
choose [first response in scale]? 
Why or why not? Can you 
describe an experience where 
you might choose [last response 
in scale]? 
    
Bother question Q3b 
Is this relevant and appropriate 
to this question? 
 











A pilot study was conducted to test the instrument measurement properties, detailed in chapter 6. 
Subsequently, minor changes were implemented to be tested on the basis of this new psychometric 
evidence. The following report details the rationale for the changes made to versions 11b of the ICIQ-UAB, 
used in the pilot study. The resulting version 12 was tested with patients in seven additional cognitive) 
interviews conducted over the phone. This investigated the facility of understanding and interpretation of 




Revisions and rationale for changes to the ICIQ-UAB v11b and ICIQ-UAB v12 
  
The following summarises the rationale for changes made to ICIQ-UAB version 11b and version 12. A 
summary of the patient input during the additional cognitive interviews is included when relevant. Floor 
effect percentages cited are from the pilot study at baseline (percentage of responses with lowest response 
option at day 1 in the 1 week recall period version).  
Additional cognitive interview sample 
 
All participants for the additional cognitive interviews were recruited from the pool of participants who had 
previously participated in the original qualitative phase CE and/or cognitive interviews. Five male and two 
female participants, with or without a range of coexisting conditions, were purposively selected in order to 
ensure multiple gender and participant perspectives on the changes made (Table 35). Informed consent 
was taken over the phone and all were audio recorded. Participants were emailed the draft questionnaire 
in advance of the call. Notes were taken during the interviews using the interview schedule included in the 
Appendices.  









Group Gender Age 
(years) 
PVR ISC 
01 CE P8 
CD P21 DU + USI F 70 Yes No 
02 
CD P6 
DU+ BOO + 
DO M 81 Yes No 
03 
CD P4 
DU + DO + 
BOO M 67 Yes No 
04 CE P23 
CD P30 DU F 75 Yes Yes, twice a day 
05 CD P5 DU M 69 Yes Yes, every day 
06 CD P3 DU + DO 
+BOO-E 
M 69 Yes No 
07 
CD P8 
DU + DO + 
SUI M 75 Yes Yes, occasionally 
Abbreviations: Detrusor underactivity (DU), detrusor overactivity (DO), stress urinary incontinence (SUI), bladder 
outlet obstruction (BOO), bladder outlet obstruction in the equivocal range (BOO-E), Post void residual (PVR) >30ml, 
Intermittent self-catheterisation (ISC). 
 




Clinical experts commenting on the draft version of the instrument felt the term ‘urinate’ was generally 
avoided and ‘pass urine’ was preferred, based on many years of clinical experience. Given that participants 
  
 
involved in the additional cognitive interviews had no preference, it was decided to replace this term 
throughout the instrument. 
The term ‘urinary symptoms’ was also considered to be colloquially preferred due to the negative 
connotations associated with ‘urinary problems’ so this was replaced in all items in which it occurred. 
Recall period 
 
Both versions were very similar in terms of the psychometric properties which they exhibited. Three more 
items in the ICIQ-UAB 24hrs had floor effects that were marginally over the threshold of 20%. However, the 
highest response option was not used in three more of the items in ICIQ-UAB (1 week version). The internal 
consistency and test-retest identical agreement between repeated administrations was very similar for 
both versions but there was correlational evidence that some items could be more suitable for a shorter 
recall periods. There was no strong evidence to suggest an overall advantage of either recall period in the 
pilot study. However, the original and additional cognitive interviews suggested patients preferred a longer 
recall period for the impact items to reflect the length of time that patients required to notice a discernible 
impact. A shorter recall period is recommended by the Food and Drug Agency guidance for industry as it 
reduces recall bias 99 so the 24 hour recall period was preferred for the symptoms and sign items for future 
clinical trials. A longer recall period of 1 week was retained for the impact items.  
Response options 
 
Discussions among the development team suggested that the middle response option of ‘sometimes’ may 
lack specificity and it was therefore suggested to evaluate the alternative response option of ‘about half the 
time’, as incorporated in the 24 hour version. Patients in the additional cognitive interviews were asked if 
they had any preference between ‘sometimes’ and ‘about half the time’ for the third response option. The 
option ‘about half the time’ was perceived as being more precise, but both options were understood as 
intended. The decision was taken to retain ‘about half the time’ due to the compatibility with the 24 hour 
recall period used in version 13. 
Version 11b Version 12 Version 13 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 
most of the time 
all of the time 
Retained 
 
Bother score items 
The pilot study demonstrated a clear relationship between high bother scores and reported severity of 
condition. The bother scores were therefore an effective measure of the ‘bother’ relating to each symptom, 








This item is not part of the scoring as will not change over the study period, but despite a strong floor effect 
(83%) it was considered clinically relevant as a sign and for health care resource utilization. This question is 
to be considered for removal from the tool at a later stage, with the possible inclusion in a baseline 
questionnaire or case report form (CRF) as part of a study, or separately in clinical use. 
Version 11b Version 12 Version 13 
Item 1 Item 1 Item 1 
Have you ever been unable to 
urinate at all and had to go to 
hospital to have a catheter tube 





Three or more times 
Retained Retained 
 
Urinary tract infection 
 
This item is not part of the scoring as will not change over the study period due to the incorporated recall 
period. Despite a strong floor effect (60%) it collects relevant clinical information at baseline and is included 
in the questionnaire at this stage with the same proposed approach as question 1. 
Version 11b Version 12 Version 13 
Item 2 Item 2 Item 2 
Over the last 12 months, have 
you had a urinary infection for 















The pilot study day 1 data returned a strong floor effect for this item (80%).The recall period for this item 
was changed to a shorter period of 1 week in order to capture the information supplied by the target 
population and to be considered more clinically relevant. The associated response options were changed to 
a numerical representation and to be compatible with the new recall period. These were confirmed to be 
well understood and acceptable by patients in the additional cognitive interviews.  
Version 11b Version 12 Version 13 
Item 3 Item 3 Item 3 
Over the last month, how often 
did you self-catheterise? 
Over the last week, how often 
did you self-catheterise? 
Retained 
Not at all 
about once a week or less often 
two or three times a week 
about once a day 
more than once a day 
every time you urinated 
Not at all 
less than once a day (1-6 times 
per week) 
1-2 times a day 
3-4 times a day 







There was some concern due to the evidence of clustering among the middle response options that the 
current wording of the question was capturing non-symptomatic patients so a proposed change to the 
wording was tested in version 12. However, the patients in the additional cognitive interviews preferred 
the brevity and wording of version 11b as ‘more than a few seconds’ was considered to be ‘too 
prescriptive’. The patient also confirmed the ‘delay’ to only be reported when symptomatic. Version 11b 
was retained. 
Version 11b Version 12 Version 13 
Item 4 Item 4 Item 4 
When ready to urinate, was 
there a delay before the urine 
flow started? 
When ready to pass urine, did 
you have to wait more than a 
few seconds for the urine flow 
to start? 
When ready to pass urine, was 
there a delay before the urine 
flow started? 
Not at all 
occasionally  
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 







Concentrate to start void 
 
This item had a high correlation with item 4 and item 12 (Pearson correlation coefficient 0.79 and 0.75 
respectively) indicating potential redundancy within these items. However, further data from 
responsiveness to change data will add to evidence for inclusion or removal. This question item was 
retained with no change. 
Version 11b Version 12 Version 13 
Item 5 Item 5 Item 5 
When ready to urinate, did you 
feel you had to concentrate in 
order to start urinating? 
Retained Retained 
Not at all 
occasionally  
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 




Small volume of urine per void 
 
This item showed a relatively even distribution of answers over the response options in the pilot study. The 
decision was made to keep the item unchanged. 
Version 11b Version 12 Version 13 
Item 6 Item 6 Item 6 
How often were you only able 




Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 




Post micturition dribble 
 
A high floor effect for this item was found in the pilot study data (50%). The item was left unchanged 
awaiting further responsiveness to change data. 
Version 11b Version 12 Version 13 
Item 7 Item 7 Item 7 
How often did a few drops leak 
out into your underwear 
shortly after you had finished 





Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 






A very high floor effect (70%) was found in the pilot study for this item and the highest response option of 
‘every time’ was not utilized. In the CE interviews incontinence was more associated with DU and coexisting 
conditions so there may be a low DU specificity. However as this symptom is very bothersome to those in 
which it occurs and to leak ‘every time’ is theoretically possible, the item is retained unchanged, but may 
be potentially removed following evidence from the responsiveness to change phase of the study. 
Version 11b Version 12 Version 13 
Item 8 Item 8 Item 8 
How often did you leak urine 
(e.g. before you could get to 
the toilet, when physically 
active, or when you coughed or 
sneezed)? 
Retained Retained 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 




Need to immediately re-void 
 
A small floor effect was found in the pilot study data (28%). However, as the distribution of responses was 
otherwise satisfactory, the decision was made to retain this item unchanged. 
Version 11b Version 12 Version 13 
Item 9 Item 9 Item 9 
After you had urinated, how 
often did you have to return to 
the bathroom to urinate again, 
within a short space of time 
(e.g. within 15 minutes)? 
 
Retained After passing urine, how often 
did you have to return to the 
bathroom to pass urine again, 
within a short space of time 
(e.g. within 15 minutes)? 
 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 








No floor effect in this item (<20%) was observed and there was a reasonable division over the response 
options, suggesting a good potential for responsiveness to change. No changes were made to this item. 
Version 11b Version 12 Version 13 
Item 10 Item 10 Item 10 
Soon after you had urinated, 
how often did you have a 
sensation that your bladder 
was not completely empty? 
 
Retained Retained 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 






There was discussion by the development team surrounding whether ‘start and stop’ made more intuitive 
sense than ‘stop and start’. Patients had a preference for the perceived straightforwardness of version 12. 
This was retained with the addition of ‘how often’ for consistency. 
Version 11b Version 12 Version 13 
Item 11 Item 11 Item 11 
How often did you stop and 
start more than once, during 
your urinations? 
When you passed urine, did the 
flow stop and start? 
When you passed urine, how 
often did the flow stop and 
start? 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 









As a result of expert clinical opinion, an additional straining item was included in version 12 to ascertain if 
the patient strains to maintain the flow while passing urine. Following additional cognitive interview 
testing, each straining question (to start, maintain, or finish) was considered mutually exclusive by most of 
the interviewed patients and were answered as separate items. The new item was interpreted as expected 
by all patients in the additional cognitive interviews. All three questions relating to straining were included 
in version 13. 
Version 11b Version 12 Version 13 
Item 12 Item 12 Item 12 
How often did you strain to 
start your urinations? 
How often did you strain to 
start passing urine? 
Retained 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 




Version 11b Version 12 Version 13 
No corresponding item Item 13 Item 13 
When passing urine, how often 
did you strain to maintain your 
flow? 
Retained 
 Not at all 
occasionally 
about half the time 




Version 11b Version 12 Version 13 
Item 13 Item 14 Item 14 
How often did you strain 
towards the end of your 
urinations to try and empty 
your bladder? 
 
How often did you strain 
towards the end of passing 




Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 









There was an even distribution of responses for each option for this item apart from the highest category. 
No changes were made to this item.  
Version 11b Version 12 Version 13 
Item 14 Item 15 Item 15 
On average, would you say that 
the strength of flow of your 
urinary stream was… 
 
Retained Retained  
Normal (not reduced) 








There was a floor effect (50% in groups 0 or 1) for this item. There was some discussion that the highest 
response option ‘every time’ should be rephrased or is not required due to this being very unlikely to occur 
in this patient population. However, the decision was made to keep the item unchanged as theoretically 
this is possible, and therefore an option for ‘every time’ should be included. 
Version 11b Version 12 Version 13 
Item 15 Item 16 Item 16 
How often did you experience a 
sudden or strong need to pass 
urine which you were unable to 
ignore, and had to rush to the 
bathroom? 
Retained Retained 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 









Following discussion with the development team, version 11b was retained because it was deemed 
clinically more useful to measure nocturnal voids (rather than actual nocturia i.e ‘to awake and get up’). 
This symptom is known to have complex aetiologies 47 so there was some doubt that it would show 
responsiveness to change for a DU specific intervention. However, it is considered important for inclusion 
as is highly bothersome to many patients and often mentioned spontaneously in the CE study.  
Version 11b (1 week version) Version 12 Version 13 
Item 16 Item 17 Item 17 
During the night, how many 
times did you have to get up to 
urinate, on average? 
During the night, how many 
times did you have to get up to 
pass urine? 
Retained 




Four or more times 
Retained Retained 
 
Daytime urinary frequency 
 
The scoring of this item was under scrutiny by the development team due to discussion around what may 
be considered a ‘normal’ urinary frequency. Although context dependent, it was considered that ‘4-8 times’ 
would provide a sufficiently broad response option to capture natural variation for non-symptomatic 
individuals. This was implemented in version 13 following testing with patients in the additional cognitive 
interviews. The response option ‘1-3 times’ is a relatively low daytime urinary frequency so may be 
considered symptomatic. For this reason, treatment may cause patients to improve in either direction. This 
is reflected in the alternative proposed scoring of these response options, although this will require full 
statistical evaluation to establish its appropriateness. 
Version 11b Version 12 Version 13 Scoring 
Item 17 Item 18 Item 18 
During the day, how 
many times did you 
urinate, on average? 
During the day, how 
many times did you 
pass urine, on average? 
During the day, how 























Reduced sensation of the fullness of the bladder 
 
A slight change in wording was proposed by the development team in order to aid clarity of interpretation. 
A comparison of the difference in wording between version 11b and version 12 by patients in the additional 
cognitive interviews appeared to result in very little or no difference in interpretation. However, there was 
  
 
a slight preference for the wording of version 12 by patients so this was retained. In addition, the response 
options were changed to measure frequency following confirmation that these were interpreted as 
intended in the additional cognitive interviews. 
Version 11b Version 12 Version 13 
Item 18 Item 19 Item 19 
Did you find it difficult to tell 
how full your bladder was? 
Did you find it difficult to tell 
when your bladder was full? 
Retained 
Not difficult 




Not at all 
occasionally 
about half the time 
most of the time 
all of the time 
Retained 
 
Waiting in bathroom after voiding 
 
Following discussion at the development team meeting slight changes to the wording were suggested to 
aid clarity of the item.  Due to patient preference in the additional cognitive interviews, the wording was 
changed from ‘wait’ to ‘stay’, and ‘a bit longer’ was retained in version 13.  
Version 11b Version 12 Version 13 
Item 19 Item 20 Item 20 
How often did you wait a bit 
longer in the bathroom after 
urinating, to make sure your 
bladder was as empty as 
possible? 
How often did you wait in the 
bathroom after passing urine, 
to make sure your bladder was 
as empty as possible? 
How often did you stay a bit 
longer in the bathroom after 
passing urine, to make sure 
your bladder was as empty as 
possible? 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 
most of the time 






Length of time in bathroom 
 
A revision to the wording to aid clarity was suggested following discussion at the development team 
meeting. This was well received by the patients in the cognitive interviews. The change in response options 
were also thought to better reflect the time in which patients tended to spend in the bathroom, and would 
allow more honest answers.  
 
Version 11b Version 12 Version 13 
Item 20 Item 21 Item 21 
What was the longest time that 
you needed to spend in the 
bathroom to finish urinating? 
What was the longest time that 
you needed to spend in the 
bathroom trying to empty your 
bladder? 
Retained 









more than 15 minutes 
Retained 
 
Temporarily unable to pass urine 
 
There was a large floor effect observed in the pilot study for this item (61%) and the highest two scores 
were not recorded by any of the patients. All patients in the additional cognitive interviews confirmed this 
symptom as infrequent, if it occurred at all, so were likely only to answer ‘occasionally’, even if the recall 
period was 1 week. However, the average bother score for those who had these symptoms in the pilot 
study was relatively high (6).  It was considered to have potentially important clinical relevance and no 
further suggestions were made for the wording or response options. This item may be considered for 
removal or further amendment following the responsiveness to change data.  
Version 11b Version 12 Version 13 
Item 21 Item 22 Item 22 
How often did you go to the 
toilet to pass urine but were 
unable to urinate at all, so had 
to return to the bathroom to 
try again later? 
Retained Retained 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
Not at all 
occasionally 
about half the time 









Seventy percent of participants reported no problems with their bowels, and for the patients who have 
problems, the severity was low. In addition, associations with bowel problems were not deemed of 
sufficient clinical relevance. This item was removed for version 12. 
Version 11b Version 12 Version 13 
Item 22 Removed 
Did you have problems with 
your bowels? (yes/no) 
If so, were your urinary 
symptoms made worse by this? 
Not at all 
occasionally 
sometimes 
most of the time 
every time 
 
Clustering of symptoms 
 
No subjects ticked multiple boxes here and this was the only item with missing data >5%. In addition, it was 
deemed to have limited clinical importance. This item was removed for version 12.  
Version 11b Version 12 Version 13 
Item 23 Removed 
Were your urinary symptoms 
worse at particular times? 
Please tick those that apply… 
No 
In the morning 
In the afternoon 








The impact items were all observed to have a high floor effect in the pilot study (30-50%). In order to 
improve the capacity for responsiveness to change a number of changes were made to the impact items as 
detailed below. 
Planning life around toilet visits 
 
Following discussion at the development team meeting it was felt that examples should be given to aid 
clarity on the intention of the question. These were confirmed by the cognitive interview patients to be 
helpful so were retained in version 13. ‘Plan your activities’ was also tested versus ‘make plans’ and the 
latter was thought to allow greater flexibility in answering, so was retained. 
Version 11b Version 12 Version 13 
Item 24 Item 23 Item 23 
How often did you plan your 
life around the location of 
toilets? 
How often did you make plans 
around the location of toilets 
(e.g. shopping, social outings, 
travelling, holidays)? 
Retained 
Not at all 
occasionally 
sometimes 






This question was reworded to include social life and work as part of ‘day to day life’ following discussion 
with the development team. There was some concern from patients in the additional cognitive interviews 
that this question overlapped with the ‘planning life around toilet visits’ item. ‘Daily activities’ was 
marginally preferred to ‘day to day life’ by patients so was changed for v13. 
Version 11b Version 12 Version 13 
Item 25 Item 24 Item 24 
How often did you feel that 
your urinary symptoms 
interfered with your social life? 
How often did you feel that 
your urinary symptoms 
interfered with your day to day 
life (including social life and 
work outside the home)? 
How often did you feel that 
your urinary symptoms 
interfered with your normal 
daily activities (e.g. social life, 
work outside the home)? 
Not at all 
occasionally 
sometimes 







Impact of nocturia and/or nocturnal voids 
 
Patients in the additional cognitive interviews expressed a preference to be asked specifically about sleep 
or tiredness. This was seen as ‘cutting to the chase’ rather than asking indirectly if getting up at night 
affected day to day life. ‘Daytime activities’ was tested as an alternative to ‘day to day life’ but there was no 
preference expressed for either option. ‘Day to day life’ was retained and both items were included in 
version 13 as separate impact items. Their responsiveness to change will provide further information on 
whether both items will be retained in the final instrument. 
Version 11b Version 12 Version 13 
Item 26 Item 25 Item 25 
How often did you feel getting 
up at night to pass urine 
affected your day to day life? 
Retained Retained 
Not at all 
occasionally 
sometimes 




Version 11b Version 12 Version 13 
No corresponding item No corresponding item Item 26 
How often did you urinary 
symptoms prevent you from 
getting the amount of sleep 
you needed? 
Not at all 
occasionally 
sometimes 







Physical activity  
 
Despite a floor effect of 46%, no changes were made to this item as this was felt to be a separate concept 
to the other impact items. Further information on its responsiveness to change will determine whether it 
will be retained in the final instrument. 
Version 11b Version 12 Version 13 
Item 27 Item 26 Item 27 
How often did you feel that your 
urinary symptoms affected your 
physical activities 
(e.g. walking, swimming, sport)? 
Retained Retained 
Not at all 
occasionally 
sometimes 




Way feel about self 
 
The examples given in version 12 were agreed by most of the patients in the additional cognitive interviews 
as improving the clarity of the question. However, the specificity of the question was also limited to the 
examples given. For example, one patient highlighted concern that the examples do not capture her sense 
of frustration and irritation which she may associate with this question. Due to no previous specific 
evidence of frustration or irritation in previous CE/cognitive interviews the examples were retained in 
version 13. 
Version 11b Version 12 Version 13 
Item 28 Item 27 Item 28 
Did your urinary problem affect 
the way you feel about 
yourself? 
Did your urinary symptoms 
affect the way you feel about 
yourself (e.g. embarrassment, 
self-confidence, self-esteem)? 
Retained 
Not at all 
occasionally 
sometimes 









This item was removed in version 12. The emotion ‘embarrassment’ was included as one of the examples in 
item 28, and inclusion was therefore considered duplication. 
Version 11b Version 12 Version 13 
Item 29 Removed 
Did your urinary problem cause 
you to feel embarrassed? 
No 
In the morning 
In the afternoon 
In the evening 
At night 
 
Fluid intake  
 
This item showed the lowest average bother score of the impact items although still relatively high (5.75). 
The item was left unchanged awaiting further responsiveness to change data. 
Version 11b Version 12 Version 13 
Item 29 Item 28 Item 29 
Did your urinary symptoms 
cause you to be careful about 
how much or the type of fluid 
you drink? 
Retained Retained 
Not at all 
occasionally 
sometimes 






No changes were made to this item as it was answered well, and an overall item for assessing quality of life 
was considered clinically useful. 
Version 11b Version 12 Version 13 
Item 30 Item 29 Item 30 
Overall, how much would you 
say your urinary symptoms 









Appendix 8 Revisions and rationale for changes to the draft ICIQ-UAB following 




Concept elicitation interviews were conducted in the United States and Japan, detailed in chapter 7. The 
implications for the instrument of a number of findings were discussed by the development team in 
September, 2017. When making decisions surrounding the modification, inclusion or removal of items, 
consideration was given to the clinical utility, frequency, bother, and the spontaneity by which a concept 
was reported.  
 Although coded as ‘lower urinary tract pain’ in the UK interviews, pain or discomfort, perhaps as a 
result of a post void residual or full bladder was a concept that was reported relatively frequently in 
the US and Japanese interviews. However, the location or underlying aetiology of bladder pain may 
be complicated. When related items were explored in the original cognitive interviews, this 
uncertainty in the origin or characterisation of bladder pain was the rationale for not including an 
item relating to this concept. However, due to the prominence of pain or discomfort in the US and 
Japanese findings, an item relating to this concept which was removed during the original cognitive 
interviews was proposed to be adapted and re-instated. 
 A long urination time and impacts of hygiene and on clothing appearance in the Japanese sample 
were reported by one patient so were not considered sufficient to include separate items to 
capture these concepts. 
 The increased prominence of the reporting of impact on sex-lives in the US sample could reflect 
cultural openness of talking about sex-related issues. However, it was recognised that side-effects 
of urological surgery or medication which can affect sex-drive and/or erectile dysfunction in men 217 
could complicate the measurement of this concept. It was also only reported by a minority of 
patients. An additional impact item to measure this concept was deemed not warranted by the 
development team. 
 Additional items or modification to the existing items in the ICIQ-UAB which measure the 
emotional impact (e.g. frustration, anxiety, effects on self-esteem and confidence) were 
considered. The development team considered that these concepts were captured sufficiently by 
the current impact items in the instrument. 
 The financial impact of UAB reported in the US was not considered for the inclusion of an 
associated item, as this concept is applicable to any disease requiring healthcare, dependent on 







Following the development team meeting in September 2017, some proposed minor modifications to some 
items resulted in version 14. These changes were tested in further confirmatory cognitive interviews, 
conducted over the telephone. The following summarises the rationale for changes made to ICIQ-UAB 
version 13 and version 14, resulting in the final ‘developmental’ version 15. For most items there was no 
change, so details are only given for the aspects of the instrument where changes were made. 
Confirmatory cognitive interview sample 
 
Four individual confirmatory interviews were conducted to test the modifications (Table 2). The 
participants also participated in the additional cognitive interviews. Informed consent was taken over the 
phone and all were audio recorded. Participants were emailed the draft questionnaire in advance of the 
call. Notes were taken during the interviews using an interview schedule.  


















05 CD P5 DU M 69 Yes 
Yes, every 
day 
03 02 CD P6 DU+ BOO + DO M 81 Yes No 
04 03 CD P4 DU + DO + BOO M 67 Yes No 
 
Abbreviations: Detrusor underactivity (DU), detrusor overactivity (DO), stress urinary incontinence (SUI), bladder 
outlet obstruction (BOO), bladder outlet obstruction in the equivocal range (BOO-E), Post void residual (PVR), 








The development team meeting suggested a minor rephrasing of the initial introductory instructions to the 
questionnaire. The patients in the confirmatory interviews agreed with the changes but suggested to add 
‘or all of the time’ in the first sentence to reflect their experience. The words ‘aims to’ were also removed 
for clarity. 
Version 13 Version 14 Version 15 
Many people experience 
urinary symptoms some of the 
time. This questionnaire aims 
to find out whether you 
experience symptoms 
associated with underactive 
bladder, and whether or not 
these symptoms have an 
impact on your everyday life.  
Many people experience 
urinary symptoms some of the 
time. This questionnaire aims 
to ask you about symptoms 
that are associated with 
underactive bladder, and 
whether or not these 
symptoms have an impact on 
your everyday life. 
Many people experience 
urinary symptoms, some or all 
of the time. This questionnaire 
asks you about symptoms that 
are associated with underactive 
bladder, and whether or not 
these symptoms have an 




At the development meeting there was clinical value placed in capturing historical self-catheterisation. The 
item was therefore tested in two parts to capture this information which was accepted well by patients in 
the confirmatory interviews. This format was slightly changed in version 15 to include the initial ‘yes/no’ 
question as a separate item to improve clarity. However, item 3 in version 15 is to be considered for 
removal from the tool at a later stage, with the possible inclusion in a baseline questionnaire or case report 
form (CRF) as part of a study, or separately in clinical use. 
Version 13 Version 14 Version 15 
Item 3 Item 3 Item 3 and item 4 
Over the last week, how often 
did you self-catheterise? 
Have you ever self-
catheterised? (yes/no) 
If so, how often did you self-
catheterise over the last week? 
Item 3: Have you ever self-
catheterised? (yes/no) 
Item 4: Over the last week, how 
often did you self-catheterise? 
Not at all 
less than once a day (1-6 times 
per week) 
1-2 times a day 
3-4 times a day 





Daytime urinary frequency 
 
The second response option was changed from ‘4-8’ to ‘4-7’ and the remaining options adjusted 
accordingly. This was to corroborate with clinically accepted parameters for what constitutes ‘normal’ 
number of micturitions per day. This was checked by the confirmatory interviews and was interpreted as 
intended. 
Version 13 Version 14 Version 15 Scoring 
Item 18 Item 19 Item 20 
During the day, how 
many times did you 
pass urine? 
During the day, how 





















It was agreed by the development team that there was clinical utility in capturing different types of 
incontinence. The incontinence item in version 13 was split into two items to capture urgency, and stress 
urinary incontinence as separate items. These were understood and accepted well by the patients in the 
confirmatory interviews. One patient explained that ‘physical activity, coughing or sneezing’ may not be 
applicable to the last 24 hours. However, on discussion with the team it was accepted that although this 
may have the effect of exacerbating any floor effect associated with this item, it is preferable to await 
further evidence of the responsiveness of these items. Both items were retained. 
Version 13 Version 14 Version 15 
Item 8 Item 8 and item 9 Item 9 and item 10 
How often did you leak urine 
(e.g. before you could get to 
the toilet, when physically 
active, or when you coughed or 
sneezed)? 
Item 8: How often did you leak 
urine before you could get to 
the toilet? 
Item 9: How often did you leak 
urine when physically active, or 
when you coughed or sneezed? 
Retained 
Not at all 
occasionally 
about half the time 







Bladder pain or discomfort 
 
This item was adapted and re-instated as a result of the additional evidence obtained from the interviews 
in the US and Japan. The wording was based on previously tested versions of items in the original cognitive 
interviews, relating to bladder pain or discomfort. The patients in the confirmatory interviews had no 
difficulty answering the item. However, their interpretation could be normal discomfort when experiencing 
a full bladder, or bladder pain/discomfort in other circumstances. The words pain and discomfort also 
appeared to be interchangeable in meaning, although discomfort perhaps was perceived as being less 
severe. The item was retained with these caveats, with the knowledge that it is likely to be considered for 
removal from the tool at a later stage, following responsiveness to change data. 
Version 13 Version 14 Version 15 
 Item 24 Item 25 
No item How often did you feel pain or 
discomfort in your bladder as it 
filled? 
Retained 
 Not at all 
occasionally 
about half the time 








The pilot study provided information on the measurement properties of the ICIQ-UAB. The proposed 
changes to the questionnaire as a result of this evidence were subjected to additional cognitive interviews 
which provided feedback on their facility of interpretation and understanding. Following a development 
team meeting and evidence from the concept elicitation interviews in US and Japan, additional proposed 
modifications were checked by confirmatory cognitive interviews. This resulted in a final ‘developmental 
version’ of the ICIQ-UAB (version 15). The 33-item instrument is now ready for further psychometric 











Initial number             CONFIDENTIAL                DAY           MONTH         YEAR   




Many people experience urinary symptoms, some or all of the time. This questionnaire asks you 
about symptoms that are associated with underactive bladder, and whether or not these symptoms 
have an impact on your everyday life.  
 
Please write in your date of birth:   
  
                                                                         DAY          MONTH         YEAR 
 
Are you (tick one):                                Female       Male  
 
 
1a. Have you ever been unable to pass urine at all and had to go to hospital to have a 
catheter tube inserted to drain the bladder? 
no  0 
   
once  1 
   
twice  2 
   
three or more times  3 
   
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 









2a. Over the last 12 months, have you had a urinary infection for which you took 
medication?  
 
no  0 
   
unsure  1 
  
 
once  2 
   
twice  3 
   
three or more times  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 







3. Have you ever self-catheterised? 
no  0 
   
yes  1 
   
   
 
4a. Over the last week, how often did you self-catheterise?   
not at all  0 
   
less than once a day (1-6 times)   1 
   
1-2 times a day    2 
   
3-4 times a day  3 
   
5 or more times a day   4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
Please answer the following questions thinking about how your symptoms 




  Over the LAST 24 HOURS… 
 
5a. When ready to pass urine, was there a delay before the urine flow started? 
 
not at all  0 
   
occasionally  1 
  
 
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 





  Over the LAST 24 HOURS… 
  
  
7a. How often were you only able to pass a small volume of urine? 
 
  
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 





  Over the LAST 24 HOURS… 
 
6a. When ready to pass urine, did you feel you had to concentrate in order to start passing 
urine? 
 
not at all  0 
   
occasionally  1 
  
 
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
8a. How often did a few drops leak out into your underwear shortly after you had finished 
passing urine and had dressed yourself? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  
 
  Over the LAST 24 HOURS… 
 
9a. How often did you leak urine before you could get to the toilet?  
  
not at all  0 
   
occasionally  1 
   
about half the time   2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
  Over the LAST 24 HOURS… 
 
10a. How often did you leak urine when physically active, or when you coughed or sneezed? 
  
not at all  0 
   
occasionally  1 
   
about half the time   2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
  Over the LAST 24 HOURS… 
 
11a. After passing urine, how often did you have to return to the bathroom to pass urine 
again, within a short space of time (e.g. within 15 minutes)? 
 
not at all  0 
   
occasionally  1 
   
 about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 







  Over the LAST 24 HOURS… 
 
12a. Soon after passing urine, how often did you have a sensation that your bladder was not 
completely empty? 
not at all  0 
   
occasionally  1 
   
 about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
13a. When passing urine, how often did the flow stop and start? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
14a. How often did you strain to start passing urine? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time   4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 







  Over the LAST 24 HOURS… 
 
17a. On average, would you say that the strength of flow of your urinary stream was… 
 
normal (not reduced)  0 
   
a little reduced   1 
   
 reduced  2 
   
very reduced  3 
   
extremely reduced  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
15a. How often did you strain to maintain your flow when passing urine? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time   4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
16a. How often did you strain towards the end of passing urine, to try and empty your 
bladder? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time   4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 








  Over the LAST 24 HOURS… 
 
18a. How often did you experience a sudden or strong need to pass urine which you were 
unable to ignore, and had to rush to the bathroom? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time   4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
19a. During the night, how many times did you have to get up to pass urine? 
not at all  0 
   
once  1 
   
twice  2 
   
three times  3 
   
four or more times  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
  Over the LAST 24 HOURS… 
 
20a. During the day, how many times did you pass urine? 
1-3 times  1 
   
4-7 times  0 
   
8-9 times  1 
   
10-11 times  2 
   
12 or more times  3 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 






  Over the LAST 24 HOURS… 
 
21a. Did you find it difficult to tell when your bladder was full? 
not at all   0 
   
occasionally   1 
   
 about half the time  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
  Over the LAST 24 HOURS… 
 
22a. How often did you stay a bit longer in the bathroom after passing urine, to make sure 
your bladder was as empty as possible? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 





  Over the LAST 24 HOURS… 
 
23a. What was the longest time that you needed to spend in the bathroom trying to empty 
your bladder? 
1-2 minutes  0 
   
3-5 minutes  1 
   
 6-10 minutes  2 
   
11-15 minutes  3 
   
more than 15 minutes  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
   
 
 
  Over the LAST 24 HOURS… 
 
  
24a. How often did you go to the toilet to pass urine but were unable to urinate at all,  
so had to return to the bathroom to try again later? 
  
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




  Over the LAST 24 HOURS… 
 
25a. How often did you feel pain or discomfort in your bladder as it filled? 
not at all  0 
   
occasionally  1 
   
about half the time  2 
   
most of the time  3 
   
every time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 








The following questions relate to how these symptoms may have affected your everyday life. 





  Over the LAST WEEK… 
 
  
26a. How often did you make plans around the location of toilets (e.g. shopping, 
social outings, travelling, holidays)? 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 





  Over the LAST WEEK… 
 
  
27a. How often did you feel that your urinary symptoms interfered with your normal daily 
activities (e.g. social life, work outside the home)? 
  
not at all   0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 






  Over the LAST WEEK… 
  
  
28a. How often did you feel getting up at night to pass urine affected your day to day life? 
 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




  Over the LAST WEEK… 
  
  
29a. How often did your urinary symptoms prevent you from getting the amount of sleep 
you needed? 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
  Over the LAST WEEK… 
  
  
30a. How often did you feel that your urinary symptoms affected your physical activities 
(e.g. walking, swimming, sport)? 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 







  Over the LAST WEEK… 
  
  
31a. Did your urinary symptoms affect the way you feel about yourself (e.g. embarrassment, 
 self-confidence, self-esteem)? 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
   
    
 
Over the LAST WEEK… 
 
  
32a. Did your urinary symptoms cause you to be careful about how much or the type of fluid 
you drink? 
  
not at all  0 
   
occasionally  1 
   
sometimes  2 
   
most of the time  3 
   
all of the time  4 
 b. How much does this bother you? 
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 




Over the LAST WEEK… 
 
  




   
 Please circle a number between 0 (not at all) and 10 (a great deal) 
 
0      1      2      3      4      5      6      7      8      9      10 
not at all  a great deal 
 
 
Thank you very much for answering these questions. 
 
 
